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Abstract 
The aim of the work reported in this thesis was to develop a scoring algorithm that converts 
ratings from a validated disease-specific quality of life questionnaire called the Utility-Based 
Questionnaire-Cancer (UBQ-C) into a utility index that is designed for evaluating clinical 
trials to inform clinical decisions about cancer treatments. 
The UBQ-C includes a scale for global health status (1 item); and subscales for physical 
function (3 items), social/usual activities (4 items), self-care (1 item), and distresses due to 
physical and psychological symptoms (21 items). Data from three studies was used. A 
valuation survey consisted of patients with advanced cancer (n=204) who completed the 
UBQ-C and assigned time-trade-off utilities about their own health state. Clinical trials were 
of chemotherapy for advanced (n=325) and early (n=126) breast cancer. A scoring algorithm 
was derived to convert the subscales into a subset index, and combine it with the global scale 
into an overall quality of life index, which was converted to a utility index with a power 
transformation. Optimal weights were assigned to the subscales that reflected their 
correlations with a global scale in each study. The derived utilities were validated by 
comparison with other patient characteristics. Each trial was evaluated in terms of 
differences in utility between treatment groups. 
In the valuation survey, the weights (range 0 to 1) for the subset index were: physical 
function 0.28, social/usual activities 0.06, self-care 0.01, and distresses 0.64. Weights for the 
overall quality of life index were health status 0.65 and subset index 0.35. The mean of the 
utility index scores was similar to the mean of the time trade-off utilities (0.92 vs. 0.91, 
p=0.6). The weights were adjusted in each clinical trial. The utility index was substantially 
correlated with other measures of quality of life, discriminated between breast cancer that 
was advanced rather than early (means 0.88 vs 0.94, p<0.0001), and was responsive to toxic 
effects of chemotherapy in early breast cancer (mean change 0.07, p<0.0001). There were 
trends to better mean scores on the utility index for patients allocated to standard-dose versus 
high-dose chemotherapy in the early cancer trial (p=0.1), and oral versus intravenous 
chemotherapy in the advanced cancer trial (p=0.2). 
In conclusion, data from a simple, self-rated, disease-specific questionnaire can be converted 
into a utility index based on cancer patients’ preferences. The index can be optimised in 
different clinical contexts to reflect the relative importance of different aspects of quality of 
life to the patients in a trial. The index can be used to generate utility scores and quality-
adjusted life-years in clinical trials. It enables the evaluation of the net effect of treatments 
on health-related quality of life (accounting for trade-offs between disparate aspects); the 
evaluation of the net benefit of treatments (accounting for trade-offs between quality of life 
and survival); and an alternate perspective for comparing the incremental cost-effectiveness 
of treatments (accounting for trade-offs between net benefit and costs). 
The practical significance of this work is to facilitate the integration of data about health-
related quality of life with traditional trial endpoints such as survival and tumour response. 
This will better inform clinical decision-making, and provide an alternate viewpoint for 
economic decision-making. Broadly, it will help patients, clinicians and health funders make 
better decisions about cancer treatments, by considering potential trade-offs between effects 
on survival and health-related quality of life. 
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1.  Introduction 
1.1 Rationale and origins of the thesis 
The choice of treatments for cancer is growing rapidly. Cancer treatments may 
extend life, relieve cancer symptoms or improve physical and psychological 
function. On the other hand, cancer treatments can also cause significant toxicity, 
inconvenience and other costs. Patients, clinicians and health funders need to know if 
the benefits are sufficient to outweigh the harms. 
 
An index of net clinical benefit that explicitly weighs up these trade-offs is helpful 
for making these decisions. Such an index can be used to evaluate and compare 
treatments on a common scale that incorporates disparate treatment effects like gains 
in survival duration, improvements in health status and health-related quality of life 
(HRQL) due to relief of cancer symptoms on the one hand, and deteriorations in 
HRQL due to treatment-related side effects on the other. 
 
The quality-adjusted life year (QALY) is one such index of net clinical benefit. The 
QALY approach combines effects on survival duration, expressed in life years, with 
net effects on HRQL, expressed as a ‘utility’ (defined in the next paragraph). This 
approach enables cancer treatments to be compared on a common scale. Analyses of 
cancer treatments in terms of utilities and QALYs are commonly used to inform 
economic decisions by funders and policy-makers, but can also be used to inform 
clinical decisions by patients and clinicians. 
 
A utility is a single number expressing the net impact of a health condition and its 
treatment on HRQL. It represents a unified assessment about the desirability of a 
health state relative to full health (one) and death (zero). A utility can be directly 
elicited from a respondent using a standard gamble or time trade-off interview. This 
task is complex and resource-intensive. An alternative approach is to derive a utility 
index from an individual’s responses to a simple self-rated questionnaire. 
 
The work presented in this thesis was motivated by the desire to evaluate a series of 
randomised clinical trials conducted by the NHMRC Clinical Trials Centre at the 
University of Sydney, Australia using the QALY approach. For each trial, data about 
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the effects of treatments on survival duration and other time-to-event outcomes were 
obtained. Data about HRQL were obtained using a cancer-specific HRQL 
questionnaire called the Utility-Based Questionnaire-Cancer. This questionnaire was 
developed and validated at the NHMRC Clinical Trials Centre, and provided 
descriptive information about effects of treatments across a range of aspects of 
HRQL. The purpose of the work reported in this thesis was to further develop the 
questionnaire as a feasible method of obtaining valid and reliable utility scores. The 
utility scores could be used to inform analyses of the clinical trials using the QALY 
approach. This could aid in interpretation of clinical trial results, and ultimately 
could help to inform clinical decisions by patients and clinicians about cancer 
treatments.. 
1.2 Aim 
The aim of the work reported in this thesis was to develop a scoring algorithm that 
converts the responses to a cancer-specific questionnaire into an optimally weighted 
utility index. The index is intended to: 
 
i) reflect the perspective of patients with cancer; 
ii) be optimally weighted for comparisons in specific clinical contexts, and 
iii) be feasible for use in cancer clinical trials. 
 
The utility index can be used to describe the net effect of cancer treatments on 
quality of life, and to evaluate trade-offs between quality and quantity of life using 
quality-adjusted survival analyses. 
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1.3 Main approaches 
Source of data 
Ambulatory patients with advanced cancer (n=204) assigned utilities for their current 
state of health in a face-to-face interview, and completed the Utility-Based 
Questionnaire-Cancer. 
 
Participants in two randomised controlled trials of chemotherapy for breast cancer 
(n=421) also completed the Utility-Based Questionnaire-Cancer at baseline and 
during treatment. The first trial compared oral versus intravenous chemotherapy for 
advanced breast cancer. The second trial compared high-dose chemotherapy with 
stem cell support to standard adjuvant chemotherapy for high risk early breast 
cancer. 
Algorithm development 
A scoring algorithm was derived that converted the 30 items of the Utility-Based 
Questionnaire-Cancer into an optimally weighted index of overall HRQL using data 
from the cross-sectional study. The approach incorporated the views and preferences 
of trial patients for rating changes in aspects of health-related quality of life and 
weighing their importance. 
 
A second equation was derived that converted the index of overall health-related 
quality of life to a utility index using data from the cross-sectional study. The best 
transformation was selected in terms of its predictive ability.  
Validation and application 
The utility index was validated using data from the two randomised controlled trials. 
 
The system was extended so that it could be applied to longitudinal data, and then 
applied to evaluate the net benefit of treatments in terms of overall health-related 
quality of life and utility in the randomised controlled trial of chemotherapy for 
advanced breast cancer. The differences in overall HRQL and utility between 
treatment groups were determined, and utility weights were calculated to be 
integrated with survival data for quality-adjusted survival analyses. 
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1.4 Outline of chapters 
Chapter 2 provides a general introduction to the research area that is built upon in 
later chapters. The first section introduces the concept of HRQL as an outcome in 
health care, and describes the relevance of quality of life data for informing both 
clinical decisions and economic decisions about cancer treatments. The middle 
sections describe the different approaches for measuring health-related quality of 
life: standard value-based health-related quality of life instruments, direct utility-
based scaling methods, and utility-based instruments that incorporate elements of 
both. The third section reviews methods that have been used to construct scoring 
algorithms for utility-based instruments. 
 
Chapter 3 describes the study materials used for the work presented in later chapters. 
The content and development of the Utility-Based Questionnaire-Cancer, and other 
questionnaires used for validation, are described. The study designs of the 
component studies used to develop, validate and apply the algorithm are also 
presented. 
 
Chapter 4 gives an overview of all the methods used, and the background relating to 
the methodological approach taken. By necessity, some information in chapters 3 and 
4 is repeated in the studies reported in chapters 5, 6 and 7. 
 
Chapter 5 describes how a scoring algorithm was derived to convert the responses on 
the Utility-Based Questionnaire-Cancer into a utility index. 
 
Chapter 6 describes the optimisation of the scoring algorithm in the setting of clinical 
trials for early breast cancer and advanced breast cancer, validation of the resultant 
utility index by comparison with related measures, and its application to evaluate the 
net effects of treatments tested in a randomised controlled trial of adjuvant 
chemotherapy for early breast cancer. 
 
Chapter 7 describes the further development of the scoring algorithm for use with 
longitudinal data, and its application to evaluate the net effects of treatments tested in 
a randomised controlled trial of palliative chemotherapy for advanced breast cancer.  
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Chapter 8 revisits the rationale for, aims of, and approach taken to the thesis, and 
summarises the principal findings. The strengths and limitations of the work 
undertaken are discussed, the implications of the findings for clinical practice and 
future research are considered, and priorities for future research are identified. 
Finally, the contribution to knowledge and practical significance of the work are 
stated.
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2.  Background 
2.1 Overview 
This chapter provides a descriptive overview of methods used to assess health-related 
quality of life. Measures that focus on specific aspects of quality of life are compared 
to measures that focus on global quality of life, in terms of their differing 
measurement properties and applications. The chapter is focussed on methods to 
produce summary data from quality of life measures that can be applied to evaluate 
treatments in clinical trials, and more broadly to inform decision-making about 
treatments. 
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2.2 Health-related quality of life 
2.2.1 Definition 
Quality of life is a subjective and abstract concept that reflects an individual’s 
perception of and response to their unique circumstances. It is a broad and multi-
dimensional concept which can be separated into ‘health-related’ and ‘non-health’ 
related aspects. Health-related quality of life (HRQL) focuses on the potential effects 
of a disease and its treatment on quality of life. Non-health aspects of quality of life 
include the quality of the environment, an individual’s standard of living, and 
political freedom. Health researchers tend to focus on HRQL, because non-health 
aspects are unlikely to be affected by disease or treatment [1-3]. 
 
No universally accepted definition of HRQL exists, but there is broad agreement that 
an assessment of HRQL should include physical, psychological and emotional, and 
social dimensions. Many researchers recommend that other dimensions be included, 
for example symptoms of disease and side effects of treatment, such as pain, nausea, 
sleep disturbance, cognitive impairment, or sexual dysfunction; and broader aspects 
of quality of life such as spirituality or patient satisfaction [2-7]. 
 
In this thesis, the symptoms of disease and side effects of treatment are included as 
dimensions of HRQL. This is commonly done by researchers, but there are 
theoretical problems with this approach. Physical, psychological, emotional and 
social dimensions can be considered as indicator items that indicate (or reflect) the 
effects of HRQL impairment [8]. Symptoms and side effects can be considered as 
causal items that cause impairment in a patient’s HRQL. Measuring both indicator 
and causal items can lead to ‘double-counting’ of effects of HRQL. However it is 
intuitively felt that their inclusion is important in a questionnaire used to measure 
treatment effects in clinical trials. This approach is used by many researchers [2]. 
2.2.2 Relevance of HRQL to the evaluation of cancer treatments 
Assessing HRQL is increasingly recognised as an important component of the 
evaluation of treatments for cancer and other conditions. HRQL information is used 
to guide individual patient care, to evaluate cancer treatments tested in groups of 
patients in clinical trials, and to inform decisions for populations by health funders 
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and policy makers. At the individual patient level, improvements (or deteriorations) 
in HRQL can be used to determine the net benefit of a treatment in a particular 
patient. At a clinical trial level, HRQL assessment helps to evaluate and compare 
average effects of treatments on specific aspects of HRQL, and the trade-offs of 
beneficial and harmful effects on different aspects of HRQL. HRQL assessment can 
also evaluate and compare treatments in terms of the trade-offs between quantity and 
quality of life by integrating HRQL data with survival data into a single common 
metric called quality-adjusted life years (QALYs). At a population level, health 
economists use QALY data about the effectiveness of treatments together with data 
about the costs of treatments in cost-effectiveness analysis to inform funding and 
policy decisions [2, 5, 9-10]. 
2.2.3 Overview of approaches for measuring HRQL  
A diverse range of approaches for measuring HRQL exist, because no single 
approach is suitable for all situations. This reflects the broad and complex nature of 
the concept of HRQL, the variety of backgrounds of analysts, and the multiple 
purposes for HRQL assessment described above [11]. This section addresses the 
distinction between measures that are ‘global’ or ‘specific’, and measures that are 
derived by a ‘value-based’ or ‘utility-based’ scaling method. 
 
One way of classifying HRQL measures is by whether the content of its questions 
are ‘global’ or ‘specific’. A global question asks respondents for a unified assessment 
of HRQL or health status. Examples include rating scales such as the health status 
thermometer of the Utility-Based Questionnaire-Cancer [12-13] (appendix 1), and 
the Spitzer-Uniscale [14-15] (appendix 2); and direct utility-based scaling techniques 
such as the standard gamble and time trade-off. In contrast, a specific question 
focuses on a specific aspect of HRQL such as an element of physical function, 
psychological well-being, or social function; or a specific symptom of disease or side 
effect of treatment such as pain or hair loss. Specific questions are often grouped 
together by domains in a HRQL instrument, providing a comprehensive profile-
based assessment across physical, psychological and social dimensions. Examples of 
these instruments are described in section 2.3.3 below. Global and specific questions 
have different uses. A global question can provide an estimate of overall HRQL at 
one point in time, changes in overall HRQL over time, and the difference in overall 
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HRQL between groups such as those allocated to differing treatments in a clinical 
trial. A profile of specific questions can provide descriptive data about the specific 
aspects in which the impairment of deterioration occurred [1]. 
 
Another way of classifying HRQL measures is by whether the scaling method used 
to assign numbers to the responses on the question is value-based or utility-based. A 
value-based scaling method is one that expresses a respondent’s perceptions about 
the presence, intensity or severity of a symptom, function or disability. In contrast, a 
utility-based scaling method is one that expresses a respondent’s strength of 
preference for a particular outcome or health state [5]. The value-based and utility-
based scaling methods have different uses. Value-based scaling methods are 
commonly used to evaluate and compare the effects of diseases and treatments on 
various dimensions of HRQL in clinical trials and surveys. Utility-based scaling 
methods are commonly used to inform choices between alternate therapies by 
decision-makers. This is because utility-based scaling methods capture both the 
person’s preference, and their attitude towards risk for future outcomes that are 
uncertain; and express it in a standardised way that can be integrated with other data 
about the probabilities and values of outcomes using econometric techniques and 
metrics such as quality-adjusted life-years [5, 9, 16-17]. This is discussed in more 
detail in section 2.4. 
 
The next section discusses methods for evaluating the effects of diseases and 
treatments on HRQL with value-based scaling methods. 
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2.3 Measurement of HRQL with value-based scaling methods 
2.3.1 Conceptual framework 
A value-based scaling method is one that expresses a respondent’s perceptions about 
the presence, and intensity or severity of a symptom, function or disability [5]. 
Unlike utility-based scaling methods discussed in the next section, the focus of 
value-based scaling methods is on current health rather than future outcomes. The 
value-based scaling method is sometimes referred to as the psychometric scaling 
method because the way that numerical scores are assigned to the subjective 
responses comes from the psychometric tradition. Psychometric techniques enable 
perceptions such as the statement ‘I feel severe pain’, which is not inherently 
quantitative, to be converted to a level on a response scale. Examples of response 
scales are binary scales: for example pain ‘present’ or ‘absent’; ordinal scales 
representing increasing severity: for example 3 for ‘mild’ pain, 4 for ‘moderate’, 5 
for ‘severe’; or a visual analogue scale where a respondent marks a point on a line 
anchored from ‘no pain’ on the left and ‘the most severe pain’ on the right [5]. 
 
Value-based scaling methods can express a respondent’s perceptions about global 
HRQL or health status with a single-item global scale, or express a respondent’s 
perceptions about specific aspects of HRQL. The merits of each approach are 
discussed in sections 2.3.2 and 2.3.3 below. 
2.3.2 Single-item global scales 
A single-item global scale is one that asks respondents for a unified assessment of 
their global health status or HRQL. The main strength of a single-item global scale is 
that it is easier to interpret than a profile of multiple items about specific aspects of 
HRQL. A single rating can help to determine the net difference in overall HRQL 
between groups or changes over time. Another advantage is that a single-item global 
scale is quick and easy to elicit, which reduces the burden on patients and staff. It 
also reduces the burden on statisticians and readers by providing data that is simpler 
to analyse and report [18]. 
 
The main limitation of a single-item global scale is that it is less reliable and 
informative than a profile of multiple items. Single-item global scales elicit 
11  
responses that are open to interpretation by each respondent and, when used alone, 
do not provide information about what aspects of quality of life are important to each 
respondent. This is beneficial, in that it allows each respondent to focus on what is 
most important to them in rating global quality of life, even if their conceptualisation 
of quality of life is different to that of other patients. It does however pose additional 
problems because global ratings are more vulnerable to certain types of bias and 
measurement error that make them less reliable than a profile of multiple items. 
Response shift refers to respondents changing their conceptualisation of quality of 
life over time and therefore effectively answering a different question on each 
occasion. For example, as subjects deteriorate, their expectations may also decrease, 
and their responses do not differ as much as would be expected. Another type of bias 
is called context bias. Subjects who are older or with worse disease may assign 
similar responses to that of subjects who are younger or with less advanced disease. 
End-aversion bias means that subjects rarely assign responses at the higher or lower 
extreme of a scale. Ceiling and floor effects occur where subjects assign a similar 
response despite different HRQL, because the scale has a restricted range of options 
[5, 18-19]. Single-item global scales compared to indices derived from a profile of 
multiple items are more susceptible to these types of bias, because the random error 
in multiple items tends to cancel out (see section 2.5.2) [18]. 
 
Another problem with single-item global scales is that respondents may find that the 
elicitation task is conceptually difficult, which may lead to imprecise responses. For 
a subject to rate their HRQL with a global scale, they must consider all aspects of 
their HRQL, implicitly adding additional weight to the specific aspects of HRQL that 
are most important to them, and ignoring irrelevant aspects. The biases and 
imprecision of single-item global scales reduce their power to detect small but 
meaningful differences in HRQL between treatment groups [5, 20-22]. Instruments 
containing items about specific aspects of HRQL are often used either to substitute 
for, or to complement a single-item global scale, in an attempt to overcome some of 
these problems [18]. 
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2.3.3 Profile-based instruments 
Multiple items about specific aspects of HRQL are often grouped together in an 
instrument that provides a profile across a range of HRQL dimensions. These 
instruments are sometimes referred to as ‘profile-based instruments’ or ‘Health status 
assessments’. They are designed to compare levels of functioning in specific 
dimensions of HRQL between groups, and changes in their function over time [2, 5, 
17]. 
 
Profile-based instruments vary according to the type of questions that they contain. 
They can be classified as generic, disease-specific or domain-specific. Generic 
instruments assess aspects of HRQL that are applicable to a wide range of 
populations and interventions. Disease-specific instruments cover all dimensions of 
HRQL but focus on particular aspects that are relevant to a specific population: for 
example patients with advanced cancer or diabetes. Domain-specific instruments do 
not cover all dimensions of HRQL, but instead focus on a particular dimension of 
HRQL such as emotional function, or a specific symptom or side effect of a disease 
or treatment [2, 5].  
 
The multiple items contained in a generic profile-based instrument will typically 
address key dimensions of HRQL such as physical function, psychological and 
emotional well-being, and social function. These dimensions are applicable to 
patients with a range of diseases and treatments, and to the general population. The 
advantage of generic instruments over disease-specific instruments is that they allow 
straightforward comparisons between different populations. They are useful for 
monitoring patients with multiple diseases, for comparing the health status of 
patients with different diseases, and for comparing patients with members of the 
general population [5].  
 
The items contained in a disease-specific profile-based instrument are more pertinent 
to a specific disease or treatment. They include questions about specific symptoms 
and side effects that are likely to be encountered by patients with a particular disease 
as well as questions about general aspects of HRQL. For example, nausea and 
vomiting are commonly experienced by patients with cancer, due to the effects of 
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cancer and chemotherapy. A generic instrument may lack any items about nausea 
and vomiting, but they will be included in most disease-specific instruments for 
cancer. The inclusion of disease-specific items in a disease-specific instrument 
should improve its responsiveness to detect changes in disease-specific aspects of 
quality of life that are not addressed by a generic instrument. The major limitation of 
disease-specific instruments is that they may hamper comparisons between 
populations with different diseases because of differences in the items that are 
included [2, 5]. 
 
Examples of a generic and three commonly used disease-specific instruments for 
cancer are shown in table 2.1. The Medical Outcomes Study 36-item Short-Form 
Survey (SF-36) include 35 questions about generic aspects of HRQL that are 
grouped into 8 dimensions, as well as a transition question that asks how the 
respondents health has changed compared to one year ago [23]. The disease-specific 
instruments in table 2.1 include some questions about generic aspects of HRQL, in 
addition to the specific symptoms that are relevant to cancer patients. 
 
The purpose of a study will determine the most suitable profile-based instrument. In 
a clinical trial, a disease-specific instrument will often be used because it is more 
likely to detect differences between treatment groups and changes in HRQL over 
time. A generic instrument may be used in combination with a disease-specific 
instrument if the researcher wishes to study broader aspects of HRQL, but care must 
be taken not to unreasonably increase patient burden [2, 11]. 
 
Both types of profile-based instruments often contain a large number of items, and 
generate a large number of responses. The next section describes methods for 
reducing the multidimensionality of the data to aid analysis and interpretation. 
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Table 2.1 Generic and cancer-specific profile-based HRQL instruments 
Instrument Type Number 
of items 
Dimensions 
(Number of items) 
Region of 
development 
SF-36 Generic 36 Physical functioning (10) 
Role limitations due to physical 
health problems (4) 
Bodily pain (2) 
Social functioning (2) 
General mental health (5) 
Role limitations due to emotional 
problems (3) 
Vitality, energy or fatigue (4) 
General health perceptions (5) 
Transition question (1) 
USA 
EORTC QLQ-
C30 
Cancer-
specific 
30 Physical function (5) 
Role function (2) 
Cognitive function (2) 
Emotional function (4) 
Social function (2) 
Fatigue (3) 
Nausea (2) 
Pain (2) 
Symptom scales (6) 
Global quality of life (2) 
Europe 
FACT-G Cancer-
specific 
27 Physical well-being (7) 
Social/family well-being (7) 
Emotional well-being (6) 
Functional well-being (7) 
USA 
UBQ-C Cancer-
specific 
31 Physical function (3) 
Distresses due to physical and 
psychological symptoms (21) 
Social/usual activities (4) 
Self-care (1) 
General health (1) 
Global health status (1) 
Australia 
  
SF-36, Medical Outcomes Study 36-item Short-Form [23]. EORTC QLQ-C30, European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Cancer [24-25]. 
FACT-G, Functional Assessment of Cancer Therapy – General [26]. UBQ-C, Utility-Based 
Questionnaire-Cancer [12-13]. 
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2.3.4 Scoring of profile-based instruments 
Profile-based instruments typically include multiple items across several dimensions 
of HRQL. Analysing data about multiple items can pose methodological problems 
concerning multiple testing and is difficult to interpret. To overcome these problems, 
some instruments use a scoring system to aggregate the individual items into a 
smaller number of subscales that represent each dimension [17, 27]. In this section, 
scoring systems that derive subscales from multiple items are discussed. In section 
2.5, scoring systems that derive a utility index from multiple items are discussed. 
Both approaches are relevant to the work presented in this thesis. 
 
The standard approach to deriving subscales from individual items is referred to as 
the ‘equally-weighted’ approach. It derives a subscale by combining the simple 
average of the responses on each related item. Related items may be selected by 
expert opinion, or by psychometric techniques such as factor analysis [28]. The result 
is expressed in a standardised form, such as a percentage of the maximum score 
achievable for that dimension [2, 4-5, 29]. For example, the generic SF-36 
instrument (referred to in the previous section) consists of 36 items. Its scoring 
algorithm produces a profile of subscales across eight dimensions about physical 
functioning, physical role, bodily pain, general health, vitality, social functioning, 
emotional role and mental health; by applying equal weight to each component item. 
The first four dimensions contribute greatest weight to a Physical Component 
summary score, and the remaining four contribute greatest weight to a Mental 
Component Summary score. However the weights were generated by factor analysis 
[23]. The cancer-specific EORTC QLQ-C30 instrument consists of 30 items. The 
scoring algorithm produces a profile of subscales across 8 dimensions about physical 
function, role function, cognitive function, emotional function, social function, 
fatigue, nausea, pain, and global quality of life [25]. For both instruments, the 
subscales are the simple averages of the items. The result is linearly transformed to a 
scale from 0 to 100 with a higher score representing a higher level of function [5]. 
 
Aggregating multiple items within one dimension into a subscale using the equally-
weighted approach is often used because it aids interpretation, is straightforward, and 
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gives similar results to more complex methods that assign different weights to each 
item based on their importance [27, 29-30]. 
Aggregating multiple items across dimensions into a single index of overall HRQL 
using the equally-weighted approach is appealing but can be problematic. It is 
intended to express a unified assessment of the impact of a disease and its treatment 
on daily life that is more precise and informative than a single-item global scale 
because of its better psychometric properties [31] (discussed in sections 2.3.2 and 
2.3.3). However, the problem with assigning equal weights to unrelated dimensions 
of HRQL is that it assumes that each dimension is equally important to patients, and 
that questions are included about all important aspects of HRQL. Some studies have 
shown that indices calculated with equal weightings can give results that are 
inconsistent with patients’ views as reflected in a global measurement, particularly if 
the index is calculated from less than 40 items [28, 32]. Biased results could lead to 
incorrect conclusions in analysis of treatment effects [11, 32-33]. 
 
Indices of overall HRQL derived by assigning equal weights to items across 
dimensions have been developed for cancer-specific instruments including the 
Functional Living Index-Cancer (FLIC) (referred to as the ‘overall FLIC score’)[34], 
and the Functional Assessment of Cancer Therapy (FACT) (referred to as the 
‘FACT-G total score’)[26]. However this approach is generally not recommended 
[32, 35], especially for primary analysis, because of the potential for biased results 
that was discussed in the previous paragraph [29]. Better approaches that derive an 
index of overall HRQL by giving weights to each item or subscale that reflects their 
relative importance are described in section 2.5. 
2.3.5 Applications and limitations 
Value-based scaling methods provide useful descriptive information about the effects 
of diseases and treatments on specific aspects of HRQL and of global HRQL. 
However they do not express the overall desirability of health states in a way that can 
be directly integrated with other data about the probabilities and values of outcomes 
to inform decision-making. The next section discusses direct utility-based scaling 
methods that go beyond the descriptive information obtained with value-based 
scaling methods. 
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2.4 Measurement of HRQL with direct utility-based scaling methods 
The utility-based scaling method, sometimes referred to as the preference-based 
method, is one that provides an estimate of the overall desirability of a health state 
expressed on a scale from zero, representing death, to one, representing perfect 
health. The utility-based scaling method arose from the econometric tradition. A 
utility is a quantitative expression of an individual’s preference for a particular health 
state under conditions of uncertainty. Utilities have special properties that allow their 
integration with other information about the probabilities and value of outcomes 
using the econometric techniques of decision analysis and cost-utility analysis based 
on the quality-adjusted life-year (QALY) approach [5, 9, 16, 36]. This facilitates 
their use to inform decision-making. 
2.4.1 Conceptual framework 
The conceptual framework of the utility-based scaling method is best understood by 
contrasting the differences between utilities and values. The traditional interpretation 
of von Neumann-Morgenstern utility theory states that utilities and values are related 
concepts that differ mainly in the conditions under which the judgments are made. 
Utilities are numbers that represent the strength of an individual’s preferences for 
different health states under conditions of uncertainty, while values are the numbers 
that people assign to different health states that are certain. In other words, the 
utility-based scaling method expresses preference for outcomes that are uncertain, 
whereas the value-based scaling method reflects preference for outcomes that are 
certain. Utilities and values both reflect an individual’s level of satisfaction, distress 
or desirability for a particular health state. In this interpretation, the main difference 
between utilities and values is that utilities incorporate a respondent’s attitude to risk 
[17, 37-39]. 
 
The conceptual framework underlying utilities has been used in health economic 
applications since the 1940s. The von Neumann-Morgenstern utility theory, also 
known as the theory of rational decision making under uncertainty, is an extension of 
the utility theory of economics. It was developed as a model of how a rational 
individual ought to make decisions when faced with uncertain outcomes [40]. 
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Fundamental axioms of choice underlie the von Neumann-Morgenstern utility 
theory, as described by Torrance et al [40]. The first axiom states that respondents 
will have preferences for one outcome compared to another, and that these 
preferences are transitive. This means that if two potential outcomes exist, o and o’; 
either o will be preferred to o’, or o’ to o, or the subject will be indifferent between o 
and o’. The preferences are transitive because if o is preferred to o’ and o’ is 
preferred to o’’, then o is preferred to o’’. The second axiom states that a rational 
individual will be indifferent between a one-stage and a two-stage gamble. This will 
be illustrated by description of the standard gamble method of eliciting utilities in the 
next section. The third axiom is of continuity of preferences. This implies that if an 
individual prefers an outcome o to o’, and o’ to o’’; then there is a probability p at 
which the individual is indifferent between the certain outcome of o’, and a gamble 
between o with probability p, and o’’ with probability (1-p) [40]. These axioms of 
utility theory determine how utility-based scaling methods such as the standard 
gamble are used to express the preferences of respondents for differing health states, 
and how utilities about the desirability of outcomes are combined with information 
about the probabilities of outcomes using econometric techniques such as decision 
analysis. 
 
Alternate interpretations of utility theory exist. Richardson states that decision 
making under uncertainty is not essential to obtain utilities [41]. He also argues that 
utility-based scaling methods based on decisions under certainty (as discussed in the 
next section) have both theoretical and empirical advantages for generating QALYs 
[41]. 
2.4.2 Direct utility-based scaling methods 
There are two main approaches for eliciting utilities for health states, which are 
‘direct’ and ‘indirect’. The direct approach uses a utility-based scaling method, and is 
discussed in this section. The indirect approach converts responses elicited with a 
value-based scaling method into a utility index by applying a scoring algorithm, and 
is described in section 2.5. 
 
The scaling method is the specific task required of a respondent to assign their 
strength of preference to a health state. There are several direct utility-based scaling 
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methods and controversy exists as to which method is best. The most common 
methods are the standard gamble and time trade-off. The rating scale is related but 
uses a value-based scaling method rather than a utility-based scaling method [9, 16, 
42]. This section describes the specific task required of respondents for each method, 
and discusses the relative merits of each approach. 
Standard gamble 
The standard gamble method requires respondents to choose between uncertain 
outcomes that may occur in the future, as described by Drummond [9], Torrance [40] 
and Froberg [42]. The respondent is given a choice between accepting a defined 
health state with certainty; or taking a gamble between a treatment that may give a 
better outcome (such as perfect health) with a probability p, or a worse outcome 
(such as immediate death) with a probability of (1-p). The probability p is varied 
until the respondent is equally willing to accept (ie. indifferent to) the defined health 
state with a certain outcome and the gamble. This value of p represents the utility of 
the health state. For example, a respondent is asked to consider the desirability of a 
defined health state relative to perfect health or death. The respondent may prefer a 
gamble with a 99% chance of returning to perfect health and a 1% chance of 
immediate death, rather than remaining within that defined health state for a fixed 
period of time. However they would prefer the defined health state to a gamble with 
a 50% chance of returning to perfect health and 50% chance of immediate death. 
They are indifferent to a gamble with an 80% chance of returning to perfect health 
and a 20% chance of immediate death versus remaining in the defined health state. 
The utility of the defined health state is then 80% or 0.8. The method can be varied 
as to the duration of the health state (such as 5 years), and the outcome of the gamble 
alternative (usually perfect health and death) [9, 43]. The standard gamble is 
generally administered by a trained interviewer [9, 40, 42]. 
Time trade-off 
Like the standard gamble, the time trade-off requires respondents to choose between 
outcomes that occur in the future, however the outcomes occur with certainty rather 
than uncertainty. The time trade-off was developed by Torrance et al for use in health 
research as an easier alternative to the standard gamble [44]. As described by 
Drummond, Froberg and Feeny [9, 42, 45], the time trade-off method involves 
respondents being given a choice between a longer period of time (t) in a defined 
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health state with less than perfect health, or a shorter period of time (x) with perfect 
health. The period of time with perfect health (x) is varied until the point of 
indifference between the two health states: this reflects how much time a respondent 
is willing to trade-off in order to have better health. The utility of the health state is 
x/t. For example, a respondent is asked to consider the desirability of a defined health 
state. The respondent may prefer to live for 4.5 years in perfect health rather than 5 
years in the defined health state. However they would prefer 5 years in the defined 
health state rather than 1 year with perfect health. They are indifferent to 4 years with 
perfect health versus 5 years in the defined health state. The utility of the defined 
health state is then 4/5 or 0.8. The method can be varied as to the duration of the 
health state t (such as 5 years), and the outcome of the health state alternative 
(usually perfect health) [9, 43]. Like the standard gamble, the time trade-off is 
usually administered by a trained interviewer [9, 42, 45]. 
Rating scale 
The rating scale, also referred to as the visual analogue scale, involves respondents 
rating the desirability of a defined health state by placing it at some point on a line, 
anchored by clearly defined endpoints which are conventionally ‘death’ and ‘perfect 
health’. If respondents are asked to rate more than one health state, then they are 
asked to place the health states so that they reflect the rank order of the states, and 
the intervals between the placements reflect the perceived differences between the 
health states. The line may vary in length, be vertical or horizontal, and may have 
intervals marked out with different values. The rating scale is usually self-
administered [9, 16, 42]. 
Comparison of methods 
A number of reviews with differing conclusions highlight the controversy regarding 
the optimal direct utility-based scaling method. Different authors favour the standard 
gamble, time trade-off, or rating scale, because of their underlying theory, reliability, 
validity, or ease of use [16, 42, 46-50].  
 
From the theoretical perspective, the standard gamble is the criterion method for 
eliciting utilities. It is directly founded in von Neumann-Morgenstern utility theory 
because it measures preferences for outcomes under uncertainty. Unlike the standard 
gamble, the time trade-off does not measures preferences for outcomes under 
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uncertainty, because there are no probabilities in the time trade-off question. It does 
however take into account a respondents’ attitude to choice, and also tests preference 
for immediate versus delayed outcomes (ie. time preference). It is commonly used as 
a substitute for the standard gamble because it was designed to give comparable 
scores. The rating scale does not measure preferences for outcomes under 
uncertainty, because the responses are assigned by a value-based scaling method. 
Therefore the scores elicited with a rating scale are values rather than true utilities [9, 
16, 51-52]. 
 
Both the standard gamble and the time trade-off have been shown to have acceptable 
validity, reliability and responsiveness in a wide variety of contexts [16]. The main 
limitation of these methods is the difficult cognitive task required of respondents, 
leading to a larger number of refusals, missing values and inconsistent responses than 
other methods [45]. Utilities derived from the standard gamble are susceptible to risk 
aversion, leading to inflated values [42]. The time trade-off was developed to 
overcome the difficulties of explaining probabilities to patients in the standard 
gamble. It is easier to administer than the standard gamble, but is still cognitively 
demanding [16]. Utilities derived from the time trade-off tend to be lower than those 
derived from the standard gamble [49]. Greater inconsistencies in rating of patient 
preferences have been identified with the time trade-off than with other scaling 
methods – for example rating all health states as equal or illogical ordering of 
utilities - have been identified, particularly in older and less educated individuals, as 
well as those with cognitive impairment or poorer health status [47]. Another 
limitation of the standard gamble and time trade-off is that some respondents are 
unwilling to trade-off or risk any of their remaining life-expectancy to improve their 
health state, which leads to suboptimal health states having the same utility as perfect 
health [16]. 
 
The rating scale has a high rate of completion and reliability, given the easier 
cognitive task demanded of respondents, and is less costly to administer [16]. One 
limitation of the rating scale is ‘end-of-scale aversion’, where respondents avoid 
putting states very close to the most and least desirable ends of the scale [45]. The 
greater problem is that the responses on the rating scale are expressed with a value-
based rather than utility-based scaling method, so do not provide utilities. This is 
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problematic, because they do not measure HRQL in a way that can be combined with 
quantity of life to generate QALYs. However unlike profile-based instruments, 
global scales require respondents to implicitly add additional weight to specific 
aspects of HRQL that are more important (section 2.3.2). This is why methods exist 
to map the obtained value to a utility using a transformation function [16], at least at 
a population level (see chapter 5, section 5.6 for more discussion). In this sense, a 
global rating scale is a hybrid between a value-based and a utility-based scale. 
 
In summary, there is no single direct utility-based scaling method that is optimal for 
all situations. When selecting the scaling method for a particular study, it is 
important to assess the purpose of the study and the importance of deriving a true 
utility estimate, the characteristics of the respondents who will have to perform the 
scaling method, the framing of assessment, and the resources available. Regardless 
of the scaling method, great care must be taken when eliciting utilities from 
respondents, to elicit valid and reliable results [40]. 
2.4.3 Perspectives for utilities 
Utilities can be elicited from lay people, health care professionals, relatives or 
patients. Lay people can only assign utilities about their preference or desire for 
hypothetical health states. This is referred to as ‘decision utility’, and is based on the 
concept of ‘wantability’. Patients can assign utilities about hypothetical health states, 
health states they have previously experienced, or their current experience of a health 
state. This is referred to as ‘experienced utility’ and is based on the concept of 
‘hedonic’ experience [53]. The distinction is important because marked differences 
in valuations between different groups have been reported [54-58]. This difference in 
perspectives may have significant implications for clinical and economic decisions 
that incorporate utilities and QALYs [56-58]. Because utilities assigned by patients 
are typically higher than utilities assigned by lay people, their use is likely to redirect 
priorities away from treatments that improve HRQL and towards treatments that 
extend life [59]. For example, in the extreme situation where a patient has complete 
adaptation to a health state and assigns a utility of 1, there is no gain from a treatment 
that improves HRQL. These effects are described in detail in the discussion chapter 
of this thesis (Section 8.5.1). 
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For example, a patient typically assigns a higher utility to a health state than a lay 
person [55-58]. This may reflect partly the lay person’s difficulty appreciating what a 
hypothetical health state is really like, and partly the patient’s adaptation to their own 
health state [16, 58, 60-62]. Dolan notes that lay people overestimate the losses 
associated with transition to health states because of focus on the immediate impact 
which may lessen over time, and focus on a specific health domain rather than 
unaffected health domains. Dolan also notes that patients’ adaptation to health states 
is common but not universal [53]. It has been recognised that the preferences and 
attitudes of patients in different clinical contexts may differ, because patients with 
different diagnoses, stages of disease and treatments may assign different importance 
to different aspects of HRQL [32, 63-65]. It has also been recognised that the 
preferences and attitudes of lay people in different countries may differ, because of 
differences in demographic background, social and cultural values, and political and 
economic systems [66-67]. 
 
Controversy exists about the suitability of utilities that are valued from the 
perspective of lay people versus patients [58-59, 68]. The choice of perspective for 
eliciting utilities should reflect the viewpoint from which the results will be 
interpreted [16, 61]. Health economic guidelines generally recommend the use of 
generic utility-based instruments based on the perspective of lay people [69-71]. The 
main argument for using the perspective of lay people for informing funding and 
policy decisions is that the primary objective in a publicly funded health system is to 
maximise health for society [9]. A limitation of using general population samples is 
that their assessments are less well informed, and limited to the supplied descriptions 
[72]. It is generally recommended that the perspective of patients is used to inform 
clinical decision making [62, 73]. The main argument for using the perspective of 
patients for clinical decisions is that the primary objective is to maximise health for 
the individual patient experiencing that condition. Some also argue that the 
perspective of patients should be used to inform funding and policy decisions, 
because patients better understand what it is like to live with a particular disease [56, 
59], but this argument is controversial because it runs counter to prevailing health 
economic theory and guidelines [69-71]. 
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In summary, it is important to recognise that: utilities are dependent on the 
experiences, attitudes and beliefs of the respondents; and a judging population should 
be chosen to be appropriate for the research or policy question that is being answered 
[16, 54]. 
2.4.4 Applications and limitations 
Utilities elicited by direct utility-based scaling methods are available for a wide 
range of diseases [74]. Utilities and the QALYs that are generated from them are a 
useful way to compare treatments for cancer and other diseases, because they can be 
evaluated on a common metric that incorporates disparate treatment effects. The 
utility combines the improvements in HRQL due to relief of disease symptoms, and 
the deteriorations in HRQL due to treatment-related side effects [9, 75]. The QALY 
approach combines the net effects of treatments on HRQL with the effects on 
survival. Analyses of cancer trials in terms of utilities and QALYs are increasingly 
used to inform economic decisions about cancer treatments [76-83], but can also be 
used to inform clinical decisions [60, 84-89]. 
 
Although direct utility-based scaling methods are a standard way of eliciting utilities 
from respondents, they have several limitations. One is that the task is complex, 
resource-intensive, and can be distressing or burdensome if patients are required to 
assign utilities for their own health state [16, 32]. Another limitation is that the 
resultant utility scores do not provide descriptive information about the dimensions 
of HRQL that influence the utility [38]. For example, in the interpretation of a 
clinical trial, a treatment may improve overall HRQL as reflected by a greater utility, 
however this improvement could reflect large positive improvements in some aspects 
of HRQL, at a cost of detriments in other aspects. Therefore the single direct utility-
based scaling method may obscure important trade-offs. 
 
Because of these limitations, a more practical approach for obtaining utility scores in 
clinical trials is to derive them indirectly from a utility-based instrument. This 
approach is discussed in the next section. 
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2.5 Measurement of HRQL with utility-based instruments 
An alternative and practical approach to obtain utilities for health states is to use a 
utility-based instrument. A utility-based instrument uses a scoring algorithm to 
convert the responses from a questionnaire that elicits ratings about various 
dimensions of HRQL, into a single index that is expressed with a utility-based 
scaling method. The scoring algorithms are valued in surveys, where a sample of 
respondents is asked to assign utilities to the health states defined by the 
questionnaire. Patients then complete the questionnaire during a clinical trial or 
survey, and based on their ratings are assigned to a discrete health state category. The 
health state category is then mapped to a pre-existing utility score by applying the 
scoring algorithm. Utility-based instruments vary in the type of items contained 
within the questionnaire (single-item global scale, multiple generic items, or multiple 
disease-specific items), and the perspective from which they are valued (typically of 
lay people or patients) [9, 38, 42, 90]. 
2.5.1 Conceptual framework 
The broad conceptual framework for a utility-based instrument is that an individual’s 
utility for a given health state can be determined by their perceived health status and 
quality of life in that health state. There are two distinct but related approaches and 
conceptual frameworks which will be referred to as the ‘global health preference’ 
approach and the ‘multi-attribute health preference’ approach [9, 91] (figures 2.1 and 
2.2). 
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Figure 2.1 Deriving a utility index with the global health preference approach 
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HRQL, health-related quality of life. 
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Figure 2.2 Deriving a utility index with the multi-attribute health preference 
approach 
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A utility-based instrument based on the global health preference approach comprises 
a single-item global scale such as a rating scale about global quality of life or health 
status. It is important that the scale has the anchors of full health and death to 
correspond with the anchors of a utility scale. The utility scores are derived by 
applying a scoring algorithm to the global scale such as a mathematical power 
transformation [92] (figure 2.1). 
 
The underlying conceptual framework for the global health preference approach is 
that a value-based scaling method, such as a global rating scale, measures 
preferences under certainty, and a utility-based scaling method measures preferences 
under uncertainty. The link between the value and utility is an individual’s attitude to 
trading length and quality of life and to risk, which is estimated by the mathematical 
transformation [37, 92-95]. 
  
Other utility-based instruments are based on the multi-attribute health preference 
approach. They are comprised of multiple items about various dimensions of HRQL. 
The utility scores are derived by applying a scoring algorithm that applies weights to 
the responses on each item that reflects its relative importance. For example, greater 
weight may be applied to alterations in physical function compared to alterations in 
appearance. The underlying conceptual framework is that an individual’s utility for a 
given health state can be determined by their perceived status in multiple dimensions 
of health and quality of life, such as physical, emotional, and social dimensions [9, 
39, 90]. 
 
The merits of a utility-based instrument comprised of a single-item global scale and 
based on the global health preference framework, versus one comprised of multiple 
items and based on the multi-attribute health preference framework, is discussed in 
the next section. 
2.5.2 Utility-based instruments comprised of a global scale or multiple 
items 
There are strengths and weaknesses of utility-based instruments that are comprised of 
a single-item global scale, or of multiple items about specific aspects of HRQL. As 
discussed in section 2.3.2, the major strengths of single-item global scales are that 
29  
they are simpler to elicit and analyse compared to a set of multiple items, and allow 
respondents to assign a unified assessment of their global HRQL. The major 
limitation is that they are less reliable and informative than an index derived from 
multiple items. 
 
A utility-based instrument comprised of multiple items has several advantages over a 
utility-based instrument comprised of a single-item global scale. The multi-
dimensionality of the data gives more descriptive information about HRQL than a 
single-item global scale. An instrument based on multiple items also has better 
measurement properties than one based on a single-item. This finding is explained by 
classical test theory. An index derived from multiple items will provide a more 
reliable estimate than a single-item scale, because of reductions in random error and 
bias afforded by averaging. An index is therefore more stable and reliable than one 
based on a single-item scale [22, 31, 96]. 
 
One potential limitation of a utility-based instrument comprised of multiple items is 
its dependence on the inclusion of all important aspects of HRQL. To be valid, the 
instrument should include scales about all important aspects of HRQL, including 
symptoms due to disease and side effects of treatment. If important items are 
omitted, then the instrument may miss important differences in HRQL between 
groups [32, 97-98]. 
 
One complexity of a utility-based instrument comprised of multiple items is its 
reliance on the scoring algorithm. The scoring algorithm should optimally weight the 
items to reflect the relative importance of each aspect to the population that the 
researcher is trying to reflect in the decision-making [9, 16, 99]. Evidence suggests 
that different populations assign very different weights to different aspects [64]. The 
preferences and attitudes of lay people in different countries differ, perhaps because 
of differences in demographic background, social and cultural values, and political 
and economic systems [66-67]. It has also been shown that the preferences and 
attitudes of cancer patients in different clinical contexts differ, perhaps because 
patients with different cancer diagnoses, stages of disease and treatments assign 
different importance to different aspects of HRQL [32, 63-65]. If an instrument lacks 
important aspects (as stated above), or is inappropriately weighted, then it may give a 
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biased estimate of a treatment effect. Once a standard instrument comprised of 
multiple items and its scoring algorithm is developed and validated, modification by 
adding relevant items, dropping unnecessary items, or altering weights for a 
particular purpose, all necessitate repetition of the development and validation 
process [32]. For example, significant work has been required to generate new 
country-specific scoring algorithms for utility-based instruments, where the attitudes 
of lay people in different countries are thought to differ [66, 100-102]. 
 
In summary, utility-based instruments comprised of only a single-item global scale 
are more transparent, and are simpler to administer, analyse and interpret, because 
there is only one scale. But they are less reliable and informative than multi-item 
scales. Utility-based instruments comprised of multiple items have better 
measurement properties, but are less transparent, and are only valid if all relevant 
aspects of HRQL are included and are appropriately weighted. In the next section, 
the merits of multi-item utility-based instruments comprised of generic or disease-
specific items are discussed. 
2.5.3 Multi-item instruments containing generic or disease-specific items 
Utility-based instruments comprised of multiple items can be generic, in that they 
only contain items about generic aspects of HRQL, or disease-specific, in that they 
contain items about aspects of HRQL that are particularly relevant to a specific 
disease. Generic instruments like the EuroQol EQ-5D [103-105], Health Utilities 
Index (HUI3) [106] or SF-6D [107] ask about core aspects of HRQL that are of 
interest in a wide range of settings. The main argument for using a generic utility-
based instrument is that it allows comparisons across a wide range of diseases and 
healthy populations [68, 108-109]. However a generic instrument is likely to provide 
an inadequate description of many diseases, so the utility scores that it generates may 
be insensitive to differences between individuals with that disease [108, 110-112]. 
More recently, disease-specific utility-based instruments have been developed that 
ask about specific aspects of HRQL relevant to that disease or condition [97-98, 110, 
113]. The main advantage of a disease-specific instrument over a generic instrument 
for generating utility scores is that it should be more sensitive to differences in 
HRQL between individuals with a particular condition, such as cancer [95, 98, 110] 
or a range of other diseases [97, 111, 113-114]. Another advantage of using a 
disease-specific utility-based instrument is that it provides data on specific aspects of 
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HRQL, overall HRQL, and utility with a single questionnaire and increases the 
availability of utility data for comparisons of treatment from randomized clinical 
trials [98]. 
 
The major limitation of using disease-specific, utility-based instruments is that the 
utility scores they provide may not be comparable to those derived from other 
instruments, particularly generic instruments, because the dimensions of health status 
and HRQL that they cover are different [68, 108-109]. For this reason, disease-
specific instruments are best suited to treatment comparisons within a particular 
disease used to inform clinical decisions. In this context comparisons across other 
diseases and healthy populations are less important, but coverage of aspects relevant 
to the patients under study is crucial. Others have argued that disease-specific 
instruments may also be suitable for treatment comparisons across all diseases to 
inform health funding and policy decisions if the scoring algorithm is derived using a 
valuation technique and population sample that is similar to a generic instrument, and 
the utility scores are shown to be comparable [97]. 
2.5.4 Perspectives 
Utility-based instruments also vary by the perspective from which they are valued. 
The perspective is determined by the characteristics of the judges who assigned 
utilities to the health states that were used to derive the scoring algorithm. Most 
utility-based instruments are based on the perspective of lay people, but utility-based 
instruments have also been developed that are based on the perspective of patients 
[94, 97-98]. In section 2.4.3 it was noted that the appropriate perspective is 
determined by the context in which the utilities are to be applied. The perspective of 
lay people is best suited to informing economic decisions, and the perspective of 
patients is best suited to informing clinical decisions. 
2.5.5 Applications and limitations 
Utility-based instruments are commonly used in clinical trials for cancer and a range 
of other conditions [9, 115]. They provide descriptive information about the effects 
of disease and treatment on HRQL, and also provide utility scores that can be used to 
generate QALYs. The main potential limitations of utility-based instruments are that 
they may be comprised of inappropriate items, or use a scoring algorithm that is 
based on an inappropriate population. The next section describes standard 
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approaches for selecting appropriate items, and deriving appropriate scoring 
algorithms for utility-based instruments. 
2.6 Deriving scoring algorithms for utility-based instruments 
A key component of utility-based instruments is the scoring algorithm that converts 
ratings on the questionnaire into a utility index. In this section, considerable detail 
will be given to the approaches for deriving a scoring algorithm, because this is the 
focus of the work presented in this thesis. The task of deriving the scoring algorithm 
takes place in three stages. The first stage is to determine the items and response 
options that will comprise the questionnaire of the utility-based instrument. 
Instrument developers refer to this process as developing a ‘health state classification 
system’ that describes a series of health states in terms of levels of impairment on 
one or ‘attributes’. The second stage is to perform a ‘valuation survey’, where the 
health states described by the health state classification system (ie. all the health 
states described by all the conceivable combinations of responses on each item of the 
questionnaire) are valued. The third stage is to produce a scoring algorithm that 
assigns a utility to every conceivable health state described by the health state 
classification system. Once the scoring algorithm is produced, the utility-based 
instrument can be used in a clinical trial or other situation. Respondents complete the 
questionnaire of the utility-based instrument that describes their level of impairment 
on each attribute in the health state classification system. The scoring algorithm is 
then applied to map the respondent’s health state, as represented by the ratings to 
each item on the questionnaire, to a utility between zero and one that represents the 
desirability of their health state [9, 39, 90]. 
2.6.1 Determining the items and response options 
The first stage in deriving a scoring algorithm is to determine the items and response 
options that will describe a series of health states in terms of level of impairment on 
each item. Each item can have two or more levels ranging from best to worst, such as 
‘No impairment’, ‘Moderate impairment’ and ‘Severe impairment’; or less 
commonly a numerical scale which could range from 0 to 10. The simplest 
instrument has only a single-item global scale, and is based on the global health 
preference framework referred to in section 2.5.1. A multi-attribute instrument has 
multiple items relating to relevant dimensions of HRQL such as physical, 
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psychological and social function, and is based on the multi-attribute health 
preference framework referred to above. 
 
Most utility-based instruments limit the number of items and their levels to reduce 
the size and complexity of the instrument. One reason for limiting the number of 
items is that a judge rating health states in a valuation survey (as discussed in the 
next section) may be unable to reliably process information on more than five to nine 
attributes. Another reason is that producing a scoring algorithm from a large number 
of items is mathematically complex because of the large number of possible 
interactions between items [39, 116]. 
 
Items and response options for commonly used utility-based instruments are shown 
in table 2.2. For example, the Disability and Distress Scale is one of the earliest and 
simplest multi-attribute utility-based instruments. Its health state classification 
system consists of two items: distress (4 levels) and disability (8 levels), describing 
32 health states (4*8). 29 of the health states are plausible and 3 are implausible (eg. 
chair-bound but no distress) [117-118]. The EQ-5D utility-based instrument has five 
items, each with three levels, and describes 243 health states [103-105]. The SF-6D 
utility-based instrument has 6 items, each with 4-8 levels, and describes 18000 health 
states [107]. 
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Table 2.2 Comparison of scoring algorithms for utility-based instruments 
 Subjective health 
estimation scale 
Disability and 
Distress scale 
EQ-5D HUI3 SF-6D 
Items and response options    
Number of items 
 
1 2 5 8 6 
Item description (and 
number of response 
options) 
 
Health status (100) Disability (8) 
Distress (4) 
Mobility (3) 
Self-care (3) 
Usual activities (3) 
Pain (3) 
Anxiety/depression (3) 
Vision (6) 
Hearing (6) 
Speech (5) 
Ambulation (6) 
Dexterity (6) 
Emotion (5) 
Cognition (6) 
Pain (5) 
Physical functioning (6) 
Role limitation (4) 
Social functioning (5) 
Mental health (5) 
Bodily pain (6) 
Vitality (5) 
Potential number 
of health states 
1*100 
=100 
4*8 – 3 
= 29 
35 = 243 6*6*5*6*6*5*6*5 
= 972000 
6*4*5*5*6*5 
= 18000 
Valuation survey     
Scaling method TTO Magnitude estimation TTO Rating scale/  
Standard gamble 
Standard gamble 
Population Patients Health care workers Lay people (UK) Lay people (Hamilton, 
Canada) 
Lay people (UK) 
Modelling      
Modelling approach 
 
 
Statistical inference Holistic Statistical inference Multi-attribute 
utility function 
Statistical inference 
Scoring algorithm 1-(1-TTO)1.6 Holistic 1 + C1 + C2 + 
W1*Mobility + … 
+ W5*Anxiety/depression 
(1+C1)*(W1*Vision)*… 
*(W8*Pain) – C 
1 + C1 + 
W1*Physical functioning 
+ … +W6*Vitality 
Subjective health estimation scale [94]. Disability and Distress Scale [117-118]. EQ-5D, EuroQol EQ-5D [103-105]. HUI3, Health Utilities Index version 3 
[106]. SF-6D, Short Form Survey-6D [116]. W1 -8 are the weights for each item. C1 and C2 are constants. 
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The items for a health state classification system can be either designed explicitly for 
a utility-based instrument, or taken from a questionnaire for an existing profile-based 
instrument. The attributes for the Disability and Distress Scale, EQ-5D and HUI3 
were designed explicitly with utility-based methods in mind. The number of items 
and their levels were deliberately restricted to limit the size and complexity of the 
instrument [2]. In contrast, the items for the SF-6D were taken from an existing 36-
item generic profile-based instrument called the SF-36 [23]. The attributes for most 
disease-specific utility-based instruments are taken from existing disease-specific 
profile-based instruments [95, 97-98, 113]. 
 
Taking items from an existing instrument rather than designing a new instrument has 
a number of advantages. One is that the items often have established evidence of 
feasibility, reliability and validity. Another is that ratings already collected with the 
existing instrument in clinical trials and other studies can be converted to utility data, 
and future studies can provide both profile data and utility data with a single 
instrument to reduce respondent burden. A disadvantage of using an existing profile-
based instrument is that it may contain large number of items that make the potential 
number of health states vert large, and the task of deriving the scoring algorithm very 
complex, as discussed above. 
 
One way of limiting the complexity of a utility-based instrument that is derived from 
an existing profile-based instrument is to select a limited number of its items. For 
example, the SF-6D referred to above contains only six of the 36 items from the SF-
36. The items can be selected by expert opinion, or psychometric methods that select 
items on the basis of criteria such as feasibility, discriminative ability, construct 
validity, and correlation with utilities [28, 97, 116]. Another way to reduce 
complexity is to use subscales derived from multiple items rather than individual 
items. The use of subscales may limit the ability of judges to understand individual 
health states, so the use of subscales is best restricted to situations where patients are 
judging the utility of their own health states and do not rely on the description of 
attributes to interpret it. 
 
This section described methods to determine the items and response options of a 
utility-based instrument. The next section describes the valuation survey. 
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2.6.2 The valuation survey 
The valuation survey involves valuing the health states that are described by the 
utility-based instrument, and takes place in three steps. This section adopts a classic 
description by Froberg and Kane [39]. The first step is to select an appropriate 
sample of ‘judges’ who will assign utilities to the health states. Typically this is a 
sample of the general population or patients. The second step is to present a set of 
health states to the judges, where each health state is described by its level of 
impairment on each attribute of the health classification system. The third step is for 
the judges to assign utilities to the health states presented to them using a direct 
utility-based scaling method such as the standard gamble or time trade-off. The three 
steps are now described in more detail. 
Step 1 – Who to involve in the valuation task 
The first step in performing the valuation survey is to select an appropriate sample of 
‘judges’ who will assign utilities to the health states. As was discussed in section 
2.5.4, the characteristics of the sample of judges who assign utilities to the health 
states in the valuation survey will determine the perspective of the utility-based 
instrument. Typically a sample of the general population or patients is used, but 
experts such as health-care professionals were used for early utility-based 
instruments [117]. It is important that a representative sample from the appropriate 
population is obtained. This is because the valuations depend on the experience, 
attitudes and beliefs of the judges [54]. Valuations often differ between patients and 
the general population, and even within each group because of differences in 
demographic background, social and cultural values, and political and economic 
systems; as was discussed in section 2.4.3. The sources of valuations for five 
commonly used utility-based instruments are shown in table 2.2. Three of the 
instruments source valuations from lay people in the United Kingdom or Canada, one 
from health care workers and one from patients. 
Step 2 – Presentation of health states to judges 
Once the sample of judges has been selected, the second step in the valuation survey 
is to present a set of health states to them. Each of the health states are described in 
terms of the level of impairment on each item of the instrument. The number of 
health states that are presented and their characteristics depends on the number of 
health states described by the instrument (table 2.2). For example, for a simple 
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instrument such as the Disability and Distress Scale, it is feasible to present all 29 
health states. In contrast, for the SF-6D it is not feasible to present all 18000 health 
states. The approach used to produce the scoring algorithm (described in the next 
section) will determine which health states are presented. If the holistic approach is 
used to produce the scoring algorithm then all health states are valued. If statistical 
modelling is used, then only a limited number of health states are presented. The 
characteristics of the sample of judges perspective will also determine which health 
states are presented. If the general population is used, or patients are rating 
hypothetical health states, then the judges can assign a utility to any health state. If a 
sample of patients is used who are asked to assign a utility to their own health state, 
then those respondents can only consider that one health state. In this situation, it is 
important that the health states experienced by the sample of patients are diverse. 
Step 3 – Scaling method 
Once the set of health states have been presented to the judges, the third step in the 
valuation survey is for the judges to assign utilities to those health states. 
Respondents consider each health state that is presented, and assign a utility score 
between zero (death) and one (perfect health) using a direct utility-based scaling 
method. The standard gamble or time trade-off is typically used (table 2.2). The 
advantages and disadvantages of each scaling method were discussed previously in 
section 2.4.2. 
 
The valuation survey results in utilities being assigned by one or more judges to a 
series of health states that are defined by levels of impairment on one or more items. 
2.6.3 Modelling approaches to produce the scoring algorithm 
The third stage is to produce a scoring algorithm that assigns a utility to every 
plausible health state described by the instrument. The three main modelling 
approaches to producing a scoring algorithm are described below. 
 
The three modelling approaches for producing a scoring algorithm can be referred to 
as the ‘holistic’ approach, the ‘multi-attribute utility function’ approach, and the 
‘statistical inference’ approach. The holistic approach requires all possible health 
states to be valued, and is only feasible for very simple health state classification 
systems. The other approaches require only a limited number of possible health states 
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to be valued, and are more feasible for more complex instruments that result in large 
numbers of potential health states. The latter approaches use statistical methods to 
examine the relationship between the utility of each health state and the level of 
impairment on each attribute. A statistical function is then derived that predicts the 
utility of any potential health state from all conceivable combinations of responses 
on each item [9, 39]. The modelling approaches for five utility-based instruments are 
shown in table 2.2, with the majority using the statistical inference approach. The 
process and merits of each approach are described in the next three sections. 
Modelling by the holistic approach 
The holistic approach was used in the earliest work on health utilities. It requires 
judges to value every health state derived by all conceivable combinations of 
different levels of each attribute. For example, the scoring algorithm for the Distress 
and Disability Scale, referred to previously, is called the Rosser Index and produced 
by establishing utilities for all 29 conceivable health states [117]. The advantage of 
the holistic approach is that it does not require any statistical modelling to produce a 
scoring algorithm. The major limitation of the holistic approach is the potential 
burden on judges if a large number of health states must be valued [39]. For example, 
establishing utilities for all 18000 health states described by the health state 
classification system of the SF-6D would be impractical. Statistical approaches have 
been developed to deal with valuations of large numbers of potential health states. 
Modelling by the multi-attribute utility function approach 
One approach that avoids having to value every health state is the multi-attribute 
utility function approach, also known as the explicitly decomposed approach. The 
evaluation process is broken up into a series of simpler subtasks. Subjects value 
health states with differing levels of impairment on each level of a single attribute, 
assuming the level of impairment on all other items are held constant. Few 
judgements where there is impairment on more than one item are required. These 
relate to corner states: for example, where one attribute is at its worst and all other 
attributes are at their best; and a limited number of multi-attribute states. The utility 
for a health state is estimated as a function of the underlying single items [39, 93, 
106, 119]. 
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The foundation of the multi-attribute utility function approach is multiattribute utility 
theory, which is an extension of von Neumann-Morgenstern utility theory that was 
discussed in section 2.4.1. Multiattribute utility theory states that there is no 
interaction between utilities among levels on any one attribute and the fixed levels 
for the other attributes. This assumption of multiattribute utility theory is called first-
order utility independence. For example, worst impairment in physical function may 
have a utility of 0.6 on the physical function attribute regardless of the levels of 
impairment on the other attributes. Multiattribute utility theory allows utilities for 
each health state to be estimated as a function of the utilities of the underlying single 
attributes. The form of the mathematical function is dependent on the degree of 
independence between the attributes. It is often a multiplicative function, but may 
have a more complex additive or multi-linear function [39-40, 93, 106, 119-120]. 
Multi-attribute utility functions based on multiattribute utility theory have been 
produced for the Health Utilities Index (table 2.2) and Assessment of Quality of Life 
(AQoL) instruments [9, 106, 119, 121]. 
 
A strength of the multi-attribute utility function approach compared to the alternate 
statistical inference approach described in the next section is that it has a strong 
theoretical foundation in multi-attribute utility theory. Another strength over the 
statistical inference approach is that less health states need to be valued by judges in 
the valuation survey, because the focus of valuation is on a limited number of health 
states where there is impairment in only one attribute, and other attributes are not 
impaired [106, 119]. A potential limitation of the multi-attribute utility function 
approach compared with the statistical inference approach is that the type of health 
states presented to judges may not be credible. For example, a health state with one 
attribute at its worst and all other attributes at their best is unlikely to occur [116]. A 
more serious limitation is that the ability of a multi-attribute utility function to 
accurately predict utilities for health states may be inferior to that of the statistical 
inference approach discussed in the next section [119]. 
Modelling by the statistical inference approach 
The third approach to produce a scoring algorithm is the statistical inference 
approach, also known as the econometric approach. Judgement is restricted to a 
limited number of health states, with differing levels of impairment on item. Utilities 
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of other health states are predicted using a statistical model. The model is derived by 
regression using data from the valuation survey. The utility is the dependent variable 
and the items are the independent variables. Models vary in which items from the 
instrument are included, and in whether the response levels for each item are 
combined. Each item can be represented as a continuous variable, or the shifts 
between response levels of an item can be represented by dummy variables [39, 116, 
119]. The primary criterion for selecting one model over another is its ability to 
accurately predict a utility for a health state [116, 119]. 
 
The major advantage of the statistical inference approach over the multi-attribute 
utility function approach is that the resultant scoring algorithm may better predict 
utilities for health states, but a limitation is that there is no theoretical basis for the 
selected statistical model The selection of an appropriate statistical model is based 
purely on empirical findings, without reference to multi-attribute utility theory [119].  
 
The statistical inference approach has been used to produce scoring algorithms for a 
number of multi-attribute instruments including the generic EuroQol EQ-5D [103] 
(table 2.2), Quality of Well Being scale [45], and Health Utilities Index-2 [119]; and 
several disease-specific instruments [97-98, 122]. The statistical inference approach 
can also be used to produce a scoring algorithm for an instrument derived from one 
or more single-item global scales [37, 91-92] (table 2.2). 
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2.7 Summary 
This chapter has provided an overview of methods used to assess HRQL. It has 
focussed on the differences in measurement properties and applications of value-
based and utility-based scaling methods, and the merits of instruments that focus on 
global HRQL or specific aspects. Methods to produce summary data from 
instruments were described that can be applied to evaluate treatments in clinical 
trials, and more broadly to inform decision-making about treatments. A utility-based 
instrument is one approach to producing summary data that combines aspects of both 
value-based and utility-based scaling methods, and uses both global and specific 
measures. A utility-based instrument is a practical way to determine the overall 
desirability of health states. To be valid and responsive, it is essential that a utility-
based instrument asks about appropriate and relevant aspects of HRQL, and derives a 
utility index that provides an appropriate valuation of the desirability of a health 
state. Methods for developing a utility-based instrument to fulfil these requirements 
have been discussed. 
 
The next chapter describes the study materials for the work developed in this thesis. 
The cancer-specific HRQL questionnaire is described from which a scoring 
algorithm will be derived that converts its responses to a utility index. The valuation 
survey used to produce the scoring algorithm, and clinical trials used to optimise, 
validate and apply the scoring algorithm are also described. 
42  
3.  Study materials 
3.1 Overview 
This chapter describes the study materials and general methods used in this thesis. 
Section 3.2 describes a questionnaire about health-related quality of life called the 
Utility-Based Questionnaire-Cancer (UBQ-C), which is the focus of this thesis. The 
description outlines its purpose and conceptual basis, the history of its development, 
its composite items and their scoring, and its psychometric properties. Section 3.3 
describes other questionnaires that were used to validate the indices derived from the 
UBQ-C. Section 3.4 describes the interview procedure used to directly elicit utilities 
from subjects. Sections 3.5 to 3.7 describe the designs, profiles, and patient 
characteristics of the three included studies used in this thesis. Sections 3.8 and 3.9 
present the elicited ratings on the UBQ-C and other questionnaires, and utilities. The 
chapter concludes with a brief summary in section 3.10. 
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3.2 The Utility-Based Questionnaire-Cancer (UBQ-C) 
This section describes the cancer-specific HRQL questionnaire from which a scoring 
algorithm is derived, optimised, applied and validated. The UBQ-C was completed 
by subjects in the valuation survey and trial datasets (section 3.5 below). As stated in 
section 1.1, the rationale for using this instrument was to facilitate the evaluation of a 
series of randomised controlled trials that have collected comprehensive HRQL data 
with this instrument. Content for this section is taken from published work by Martin 
et al [12-13]. 
3.2.1 Purpose 
The UBQ-C is a disease-specific HRQL questionnaire that was designed to be an 
outcome measure for clinical trials in the field of cancer. Within this context, it was 
intended to serve two purposes. First, the UBQ-C was intended to be a cancer-
specific profile-based questionnaire that can measure the effects of cancer and its 
treatment on a broad range of HRQL dimensions. This has been achieved in a range 
of cancer trials [123-127]. Second, the UBQ-C was intended to be a cancer-specific 
utility-based instrument that can derive utilities in clinical trials. This requires a 
scoring algorithm that converts the responses on the questionnaire to a utility index. 
The work presented in this thesis aims to derive such a scoring algorithm for the 
UBQ-C. 
3.2.2 Conceptual basis 
The UBQ-C was designed for use in clinical trials of cancer therapy, so it needed to 
be relevant to cancer patients, relatively brief, and easy to self-complete. It contains 
items that measure a cancer patient’s experience of illness across all key dimensions 
of HRQL including general health, physical functioning, physical and psychological 
symptoms, role functioning, and social well-being. Additional items focus on the 
symptoms of cancer and the toxicity of treatment. Aspects of HRQL that are less 
likely to be influenced by cancer or its treatment such as deafness, blindness, or 
incontinence are not included; as is discussed in the next section. 
3.2.3 History of development 
The questionnaire was developed at the NHMRC Clinical Trials Centre, University 
of Sydney, Australia in parallel with a cardiovascular questionnaire called the 
Utility-Based Questionnaire-Heart (UBQ-H) [128-129]. The form and content of the 
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questionnaire builds on the conceptual framework for health status assessment 
developed by Gudex et al for an existing generic utility-based instrument called the 
Health Measurement Questionnaire [118]. 
 
The Health Measurement Questionnaire includes 36 items covering 5 key 
dimensions of HRQL (general mobility, usual activities, self-care activities, social 
and personal relationships, and psychological distresses). A generic core set of items 
from the Health Measurement Questionnaire was taken for the UBQ-C. Items less 
relevant for cancer patients (eg hearing, vision, writing, speaking and incontinence) 
were discarded, and the response formats of some items were modified. 
 
Cancer-specific items were selected for addition by a review of existing literature on 
HRQL instruments used in cancer patients [130-131]. 
 
Two measures of global health status were also added. The health status thermometer 
is similar to the graduated, vertical, visual analog scale that accompanies the 
EuroQol EQ-5D questionnaire [103-105], but with the anchors of ‘best imaginable 
health state’ and ‘worst imaginable health state’ replaced by ‘full health’ and ‘death’, 
to conform with the requirements of a utility scale. The UBQ-C also includes the 
general health item from the Short-Form-36 health survey (SF-36) [132], which is a 
widely used and extensively validated measure of generic health status [5]. This item 
asks respondents to ‘describe their general health’ as excellent, very good, good, fair 
or poor. 
3.2.4 Description 
The UBQ-C includes 29 items about specific aspects of HRQL and two global scales 
(table 3.1). A sample of the questionnaire is reproduced in appendix 1. 
 
The 29 items about specific aspects of HRQL are grouped into four subscales 
according to the HRQL dimensions that they are hypothesised to sample: physical 
function (3 items), social/usual activities (4 items), self-care (1 item), and distresses 
(21 items) due to physical and psychological symptoms associated with cancer and 
its treatment. 
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Table 3.1 Grouping of UBQ-C items within subscales 
Subscale Items 
Physical function Walking several blocks 
Climbing stairs 
Vigorous activities 
Social/usual activities Usual daily activities 
Social life 
Hobbies or leisure activities 
Sex-life 
Self-care Self-care 
Distresses Shortness of breath 
Difficulty sleeping 
Feeling sick (nausea/vomiting) 
Lack of energy 
Aches or pains 
Feeling sad or depressed 
Feeling anxious or worried 
Loss of appetite 
Dissatisfaction with your weight or appearance 
Uncertainty about the future 
Numbness or pins & needles 
Anger or resentment 
Loneliness 
Loss of hair 
Diarrhoea 
Constipation 
Loss of self confidence 
Feeling dependent on others 
Thought of chemotherapy 
Inability to concentrate 
Any other problems 
Global scales Health status thermometer 
General health 
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 The items within the subscales for physical function, social/usual activities, and self-
care each have four response categories: ‘not at all’, ‘slightly affected’, ‘severely 
affected’ and ‘unable to do activities at all’. The items within the distresses subscale 
have 11 response categories for amount of distress ranging from ‘0 (None)’ to ‘10 
(Extreme)’ (appendix 1). 
 
The two global scales are single items that ask respondents for a unified assessment 
of their health status and general health. The health status thermometer is a 
graduated, vertical, visual analog scale ranging from ‘100 (Full health)’ to ‘0 
(death)’. The general health scale has five response categories: Excellent’, ‘Very 
good’, ‘Good’, ‘Fair’ and ‘Poor’. 
3.2.5  Scoring 
The scores for the subscales about physical function, social/usual activities, self-care 
and distresses are the simple average of the non-missing items, linearly transformed 
to a scale from 0 (worst) to 1 (best). More details are given in chapter 4 (section 4.5). 
Responses to the items labelled ‘Sex life’ and ‘Other problems’ are not included 
when calculating the scores for the subscales, because they are commonly omitted by 
respondents [12-13]. 
3.2.6 Psychometric properties 
The psychometric properties of the UBQ-C in a cancer population have been 
reported previously. These include good feasibility (high completion rate with little 
missing data), internal consistency of subscales (Cronbach’s alphas > 0.75 and 
confirmatory factor analysis), test-retest reliability (intraclass correlation 
coefficients: median 0.85, lower quartile 0.81, upper quartile 0.90), convergent 
validity (substantial correlations with related instruments: GLQ-8 and GLQ-Uniscale 
[130], Priestman and Baum LASA scales [131], and Life Satisfaction Index-A 
[133]), discriminative ability (between groups with different disease severity) and 
responsiveness to change within individuals [12-13]. 
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3.3 Other questionnaires about HRQL and health status 
This section describes additional questionnaires that were completed by subjects and 
their clinicians. The ratings on these questionnaires are used to validate the utility 
index (chapters 5 and 6), and to inform treatment comparisons (chapters 6 and 7). A 
sample of each questionnaire is reproduced in appendix 2. 
 
Three additional questionnaires were completed by subjects. The Spitzer-Uniscale of 
global life quality and the Priestman and Baum Linear Analog Self Assessment 
Scales (LASAS) were completed by subjects in the valuation survey and advanced 
cancer trial (section 3.5 below). The Chemotherapy Acceptability Questionnaire was 
completed by subjects in the advanced cancer trial only. The Spitzer-Uniscale is a 
validated, single-item visual analog scale that asks the respondent to indicate their 
‘overall life quality’ [14-15]. The anchors of ‘highest quality’ and ‘lowest quality’ 
were replaced by ‘best possible’ and ‘worst possible’. The LASAS is a validated 
measure of cancer-specific HRQL that is comprised of five visual analog scales 
comprised of horizontal lines about physical well-being, mood, pain, nausea and 
vomiting, and appetite [131, 134]. The Chemotherapy Acceptability Questionnaire is 
a study-specific scale for the advanced cancer trial that was designed to supplement 
the UBQ-C. It includes 15 items about the inconvenience and additional side effects 
that were expected to occur with the trial chemotherapy regimens but were not 
assessed by existing questionnaires. 
 
Clinicians completed the Eastern Cooperative Oncology Group (ECOG) 
performance status scale in the advanced cancer trial. This validated scale rates 
patients’ physical functional status as ‘0’, fully active; ‘1’, restricted in physical 
activity but able to do light work; ‘2’, confined to a bed or chair for less than 50% of 
waking hours and capable of all self-care but unable to do any work; ‘3’, confined to 
a bed or chair for more than 50% of waking hours but capable of limited self-care; 
and ‘4’, totally confined to bed or chair, completely disabled, incapable of any self-
care [135]. 
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3.4 Interview procedure for utility elicitation 
This section describes the interview procedure used to elicit utilities directly from 
subjects. Utilities were elicited in the valuation survey (section 3.5 below). The 
utilities are used to derive a scoring algorithm for the utility index (chapter 5). 
 
Utilities were elicited directly from subjects about their current HRQL using the time 
trade-off technique with a hypothetical survival time of two years. The time trade-off 
technique was selected because it is practical, reliable, and has empirical validity 
(section 2.4.2). In particular, ease of administration is an important consideration for 
patients with advanced cancer. A two-year survival time was used because it is 
consistent with the expected median survival of the group. Face-to-face interviews 
were conducted by one trained researcher and took about 30 minutes to complete. A 
script was used to standardise the administration of each interview, and a series of 
cards were used as visual aids to accompany each question. The subjects were 
presented with pairs of hypothetical situations and asked to indicate which was 
preferable (figure 3.1). The time spent in full health was changed (ping-ponged) until 
a point of indifference was reached. Subjects were reassured that the hypothetical 
choices were not meant to reflect their present circumstances and that their answers 
would have no effect on their future medical care. 
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Figure 3.1 Time trade-off interview: script and visual aid 
  
 2 years  1 year  
  
 Present 
symptoms 
 Full health  
  
“The situation on the left involves living for 2 
years with symptoms identical to the ones you 
are presently experiencing. The symptoms are 
stable - they don't get any worse or any better. 
The other situation involves living less time, 1 
year in full health. Think about these two 
situations and tell me which one you feel is most 
[sic] preferable” 
     
50  
3.5 Included studies 
This section describes the three studies that provide data for the work presented in 
this thesis. The ‘valuation survey’ was a cross-sectional study of patients with 
advanced cancer. Participants completed the UBQ-C and other questionnaires, and 
assigned utilities in a face-to-face interview. This data is used to derive the scoring 
algorithm (chapters 4 and 5). The ‘advanced cancer trial’ and ‘early cancer trial’ 
were two randomised clinical trials of chemotherapy for breast cancer. Participants 
completed the UBQ-C and other questionnaires at various time points during the 
trials. This data is used to optimise, validate and apply the scoring algorithm 
(chapters 6 and 7). Details of each study are given in the following section. 
3.5.1 Valuation survey 
The valuation survey was a cross-sectional study of ambulatory patients who were 
recruited from two tertiary-referral oncology outpatient units. Eligible patients had 
advanced cancer, impaired HRQL, and were willing and able to complete both a self-
administered HRQL questionnaire and a one hour interview in English [13]. 
 
Potential subjects were given a patient information sheet (appendix 3). Consenting 
subjects were registered and scheduled for an interview, usually on the day of their 
next appointment at the oncology clinic. Utilities were elicited directly from subjects 
about their current HRQL by one trained researcher using a standardised, face-to-
face, time trade-off interview with a hypothetical survival time of two years (section 
3.4). The time trade-off was expressed on the standard continuum where 1 represents 
full health and 0 represents dead [16]. Patients were mailed the UBQ-C (section 3.2 
and appendix 1), Spitzer-Uniscale and LASAS (section 3.3 and appendix 2), and 
asked to complete them 3 to 7 days before the planned interview [13].  
3.5.2 Advanced cancer trial 
The advanced cancer trial was conducted by the Australian New Zealand Breast 
Cancer Trials Group and included patients with advanced breast cancer who were 
randomly allocated to receive either daily oral capecitabine or standard 
cyclophosphamide, methotrexate and 5-fluouracil (CMF) as first-line chemotherapy 
until disease progression. The primary outcome measure of the trial was quality-
adjusted time to progression. Secondary outcome measures were time to progression, 
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response rates, HRQL, overall survival, safety and cost-effectiveness. Eligible 
subjects were 18 years or older, and were about to start first-line chemotherapy for 
histologically confirmed advanced breast cancer. Subjects were excluded if they 
were totally confined to bed and completely disabled (ECOG performance status 4, 
as described in section 3.3). Enrolment was from June 2001 to July 2005 at 34 
centres in Australia and New Zealand [124]. 
 
Potential subjects were given a patient information sheet (appendix 4). Consenting 
subjects completed the UBQ-C (section 3.2 and appendix 1), and the Spitzer-
Uniscale, LASAS and Chemotherapy Acceptability Questionnaire (section 3.3 and 
appendix 2) unless they could not read English. Clinicians completed the ECOG 
performance status scale (section 3.3 and appendix 2). Questionnaire were completed 
at baseline (prior to randomisation), then every three to four weeks during treatment 
and until disease progression. Questionnaires were not completed after disease 
progression. For the analyses reported in chapter 7, ‘during treatment’ was defined as 
from the time of randomisation until 30 days after disease progression.  
 
The data from baseline questionnaires competed prior to randomisation was used to 
optimise, apply and validate the scoring algorithm (chapter 6), and the data during 
treatment was used to apply the scoring algorithm to a treatment comparison (chapter 
7). 
3.5.3 Early cancer trial 
The early cancer trial was conducted by the Australian New Zealand Breast Cancer 
Trials Group in collaboration with the International Breast Cancer Study Group. It 
included patients with high-risk early stage breast cancer who were randomly 
allocated to receive either high-dose chemotherapy with stem cell support over 12 
weeks or standard-dose chemotherapy over 24 weeks. The primary outcome measure 
of the trial was overall survival. Secondary outcome measures were quality-adjusted 
survival, disease-free survival, toxicity, HRQL and cost-effectiveness. Eligible 
subjects were aged 16 to 65 years, and were about to start adjuvant chemotherapy for 
histologically confirmed early-stage primary breast cancer with 5 or more involved 
axillary lymph nodes. Subjects were excluded if they were capable of only limited 
self-care and/or were confined to a bed or chair for more than 50% of waking hours 
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(ECOG performance status 3 or 4). Enrolment was from March 1997 until March 
2000 at multiple centres in Australia, New Zealand, Europe and Asia [136]. 
 
Potential subjects were given a patient information sheet (appendix 5). Consenting 
subjects living in Australia and New Zealand were eligible to participate in a 
substudy about HRQL and resource usage. Substudy participants were required to 
complete the UBQ-C prior to starting chemotherapy (baseline), 12 weeks after 
randomisation (during chemotherapy), and a few months after completing 
chemotherapy. 
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3.6 Study profiles 
This section describes the study profiles for the three studies. For the valuation 
survey, 204 of the 323 patients that were approached to take part in the study were 
eligible (figure 3.2). Compliance was excellent, with planned interviews and 
questionnaires completed by 98% of participants. For the advanced cancer trial, 
compliance was excellent with questionnaires completed by over 95% of subjects 
who were expected to complete them (figure 3.3). For the early cancer trial, 
compliance was not as good with questionnaires completed by 72% prior to 
chemotherapy, 40% during chemotherapy, and 88% after completing it (figure 3.4). 
Good compliance is important in HRQL assessment, because patients who do not 
comply with assessment tend to have worse HRQL [137]. The resultant missing data 
can bias results of HRQL analyses in favour of patients with better HRQL. 
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Figure 3.2 Valuation survey: study profile 
323 patients screened at clinic
204 consented and
sent questionnaires
119 patients ineligible
28 declined
30 too unwell
20 non-English speaking background
21 ineligible for logistic reasons
15 ineligible for other reasons
5 patients subsequently dropped
out or became too unwell
200 questionnaires received
199 patients completed interview
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Figure 3.3 Advanced cancer trial: study profile 
325 patients in a randomised trial of 
first-line chemotherapy for advanced 
breast cancer
Questionnaires expected from
311 patients
14 patients unable to
read English
Questionnaires received
from 295 patients at baseline
Questionnaires received
from 299 patients during treatment
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Figure 3.4 Early cancer trial: study profile 
344 patients in a randomised trial of
adjuvant chemotherapy for high-risk
early-stage breast cancer
136 patients eligible to participate in Australia-
New Zealand substudy about HRQL
208 patients not eligible as recruited outside 
Australia and New Zealand
126 patients agreed to participate 10 patients did not participate 
91 completed questionnaires
prior to chemotherapy
51 completed questionnaires
during chemotherapy
111 completed questionnaires
after completing chemotherapy
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3.7 Patient characteristics 
This section describes the characteristics of the 655 subjects in each of the three 
studies (see table 3.2). 
 
The valuation survey consisted of 204 patients with advanced cancer, mostly arising 
from the breast or bowel. The other cancer types were lung (2), ovarian (5), sarcoma 
(5), melanoma (4), prostate (3), and non-Hodgkins lymphoma (3). Male and female 
patients were included and most age groups were represented (range 22 to 81 years, 
mean 56 years). The different levels of self-reported general health status were well-
represented. Most modes of treatment were represented: chemotherapy, supportive 
care and observation. 
 
The trial datasets consisted of 451 patients with breast cancer of both early and 
advanced stages. All subjects were female and most age groups were represented 
(range 25 to 84 years). For the advanced cancer trial, most had good performance 
status (ECOG 0 in 34% and ECOG 1 in 54%), and fewer had poor performance 
status (ECOG 2 in 11% and ECOG 3 in 2%). The different levels of self-reported 
general health status were well-represented. 
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Table 3.2 Included studies: patient characteristics 
Dataset  Valuation survey 
(n=204) 
 Advanced cancer trial 
(n=325) 
 Early cancer trial 
(n=126) 
Cancer stage  Advanced  Advanced  High-risk early-stage 
Cancer type (%) 
  Breast 
  Bowel 
  Other 
  
50 
29 
21 
  
100 
- 
- 
  
100 
- 
- 
Gender (%) 
  Male 
  Female 
  
32 
68 
  
- 
100 
  
- 
100 
Age (Years) (%) 
  < 40 
  40-49 
  50-59 
  60-69 
  ≥ 70 
  
12 
21 
25 
28 
14 
  
2 
12 
29 
36 
21 
  
14 
47 
35 
3 
- 
General health 
at baseline (%) 
  Excellent 
  Very good* 
  Good 
  Fair 
  Poor 
  
 
10 
- 
48 
35 
7 
  
 
6 
18 
30 
32 
13 
  
 
22 
- 
54 
19 
4 
 
* Response category ‘Very good’ not included in some versions of ‘General health’ item of UBQ-C 
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3.8 Ratings on the UBQ-C 
This section describes and compares the ratings on the UBQ-C for each of the three 
included studies. 
 
All items on the UBQ-C except ‘Sex life’ and ‘Other problems’ were completed by 
over 90% of patients in all studies. Ratings on the health status thermometer and 
subscales are summarised in table 3.3. Patients in each study consistently reported 
worst impairment for physical function and least impairment for self-care.  
 
The ratings from the two trial datasets were compared. At baseline, patients with 
advanced cancer reported worse health status than patients with early cancer, as 
expected (means of 0.69 vs 0.81, difference 0.13 [with rounding], 95% CI 0.08 to 
0.17, p<0.0001). Patients with early cancer reported worse health status during 
chemotherapy than before starting it (means 0.68 vs 0.81, mean deterioration 0.13, 
95% CI 0.08 to 0.19, p<0.0001); or after finishing it (means 0.68 vs 0.84, mean 
improvement 0.15 [with rounding], 95% CI 0.10 to 0.21, p<0.0001). Similar 
differences were reported for ratings on UBQ-C subscales (table 3.3). Ratings during 
treatment for the advanced cancer trial are not reported here, but are reported in 
chapter 7. 
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Table 3.3 Included studies: ratings on UBQ-C 
Dataset 
 
Valuation 
survey 
 Advanced 
cancer trial 
 Early cancer 
trial 
Cancer stage Advanced  Advanced  High-risk early-stage 
Treatment phase 
 
n 
Various 
 
204 
 Before 
treatment 
295 
 Before 
treatment 
91 
During 
treatment 
51 
After 
treatment 
111 
 Mean SD  Mean SD  Mean SD Mean SD Mean SD 
Health status 
thermometer 
0.74 0.16  0.69 0.20  0.81 0.15 0.68 0.21 0.84 0.13 
UBQ-C subscales  
Physical function 
Social/usual activities 
Self-care 
Distresses 
 
0.65 
0.77 
0.95 
0.80 
 
0.23 
0.22 
0.14 
0.15 
  
0.53 
0.66 
0.89 
0.78 
 
0.32 
0.29 
0.20 
0.15 
  
0.77 
0.74 
0.89 
0.77 
 
0.21 
0.23 
0.15 
0.15 
 
0.63 
0.69 
0.97 
0.69 
 
0.24 
0.22 
0.10 
0.18 
 
0.80 
0.88 
0.99 
0.83 
 
0.20 
0.17 
0.06 
0.13 
SD, standard deviation. UBQ-C, Utility-Based Questionnaire-Cancer. HRQL, health-related quality of life. 
All ratings on scale from best (one) to worst (zero). 
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3.9 Elicited time trade-off utilities 
This section describes the time trade-off utilities that were assigned by subjects in the 
valuation survey. 
 
The mean (SD) time trade-off utility assigned by subjects in the valuation survey 
about their own health state was 0.91 (0.17), and the 95% confidence intervals were 
0.89 to 0.94. The median of the time trade-off utilities was 0.995. The time trade-off 
utility was tied at 1.000 for 100 of 200 subjects, despite their significant impairments 
in HRQL as self-reported on the UBQ-C. Because of the skewed distribution and the 
spike at 1.000, the mean value of the time trade-off utility was lower than its median 
value (figure 3.5). The implications of skewed and spiked data are discussed in 
chapter 4. 
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Figure 3.5 Valuation survey: histogram of time trade-off utilities 
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3.10 Summary 
This chapter described the study materials used in this thesis. The 
comprehensiveness, conceptual basis and psychometric properties of the Utility-
Based Questionnaire-Cancer (UBQ-C) were presented along with a description of 
other questionnaires used in this thesis. The three included studies used in this thesis 
were described in detail, together with the characteristics of the participants and their 
ratings on the UBQ-C, other questionnaires, and time trade-off utilities. The next 
chapter outlines the general approach used for the work presented in this thesis. 
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4.  Statistical methods 
4.1 Overview 
This chapter describes the general methods used in this thesis to develop a scoring 
algorithm that converts the responses to the UBQ-C cancer-specific questionnaire 
(described in section 3.2 of chapter 3), into an optimally-weighted utility index. 
Section 4.2 provides the rationale for the methodological approach taken. Section 4.3 
describes the general approach. This involved deriving, optimising, validating and 
applying the scoring algorithm. Sections 4.4 to 4.9 describe the methods for 
statistical analysis. The chapter concludes with a brief summary. 
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4.2 Background 
The methodological approach taken in this thesis is novel in that the utility index was 
derived from both a single-item global scale, and multiple subscales about specific 
aspects of HRQL. In contrast, most utility indices are derived from either multiple 
subscales, or a single-item global scale, but not both. The conceptual and empirical 
arguments supporting each approach were described in chapter 2 (sections 2.3.2 and 
2.5.2). The rationale for deriving a utility index from both multiple subscales and a 
single-item global scale is to incorporate the strengths of each approach, and is 
advocated by Lumley et al [32]. The single-item global scale provides a unified 
assessment of global HRQL. It may capture additional aspects contributing to global 
HRQL that are important but not detected by specific subscales. The inclusion of 
multiple subscales may improve the precision of the index, because it is derived from 
multiple items, and explicitly assesses specific aspects of HRQL. Lumley presented 
evidence that the resultant index has better reliability than a single-item global scale 
without meaningfully altering validity [32]. Lumley has also developed a novel 
method to produce the scoring algorithm for such an index, which is described 
below. 
 
The scoring algorithm was produced using what others have referred to as the 
statistical inference approach, whereby valuation is restricted to a limited number of 
health states with differing levels of impairment on each scale, and utility scores for 
other health states are predicted using a statistical model. This approach was the most 
feasible for the data obtained from the valuation survey, because of the diversity of 
health states that were represented. The strengths and weaknesses of alternatives 
were outlined in chapter 2 (section 2.6.3). Lumley’s approach is a novel variant of 
the statistical inference approach that is designed to optimally combine a single-item 
global scale and multiple subscales [32]. The three steps of Lumley’s approach are 
outlined in figure 4.1, and described in the following paragraphs. 
 
 66
Figure 4.1 Deriving a utility index with Lumley’s combined approach 
Overall
HRQL index
1-W
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W1-4:
Weights for each subscale
determined by strength of association of
subscale with single-item global scale
Global scale
Subcale 1
Single-item global scale
Subset
Index
W
1-W & W:
Weights for single-item global scale
and subset index are proportional
to their statistical precision
Subcale 2
Subcale 3
Subcale 4
W2
W4
Utility index
Transformation
Multiple subscales about
specific aspects of HRQL
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The first step of Lumley’s approach calculates a ‘subset index’ (referred to by 
Lumley as the subset estimate) by combining multiple scales about specific aspects 
of HRQL according to weights based on their correlations with the single-item global 
scale. The weights are proportional to the coefficients from a multivariable linear 
regression of the single-item global scale on the specific subscales. 
 
The second step calculates an ‘overall HRQL index’ (referred to by Lumley as the 
global estimate) by combining the subset index with the single-item global scale. 
Extra weight is given to the component with less measurement error. The 
measurement error of the subset index is taken to be the error mean square of the 
linear regression of the global scale on the subscales. The measurement error of the 
global scale is taken to be the variance of the global scale multiplied by (1- its intra-
class correlation coefficient). The intra-class correlation coefficient is a measure of 
test-retest reliability. It is a generalisation of Pearson’s correlation that measures 
absolute agreement amongst two or more ratings [138]. A more reliable scale has a 
higher intra-class correlation and less measurement error. The weight for the subset 
index is derived by dividing the measurement error of the subset index by the 
measurement error of the global scale. The weight for the global scale is 1 – the 
weight for the subset index. 
 
The third step calculates a utility index from the overall HRQL index that is 
expressed with a utility-based scaling method. Lumley recommends a transformation 
function of the form used to convert single-item global scales such as a visual 
analogue scale to a utility index [32]. Potential models that include power 
transformations, linear, quadratic and cubic models [37] are discussed in more detail 
in the next chapter. The transformation function is derived in a valuation survey, as 
described in chapter 2 (section 2.6.2). Respondents rate health states by assigning 
utilities with a direct utility-based scaling method (eg. time trade-off), and by 
assigning responses to the single-item global scale and the multiple subscales. 
 
One novel aspect of Lumley’s approach described above is in its combination of a 
single-item global scale with multiple subscales for specific aspects of HRQL. 
Another is that the scoring algorithm can be optimised in different clinical contexts 
by adjusting the weights for the multi-item subscales. The purpose of optimising the 
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algorithm is to reflect the differences in importance that patients with different types 
and stages of disease and treatment assign to various dimensions of HRQL [32, 63-
64, 139]. In contrast, standard utility-based instruments rely on fixed weights that are 
derived from populations that may be very different [64]. 
 
The next section describes how Lumley’s approach was adapted to develop a scoring 
algorithm for the UBQ-C. 
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4.3  General approach 
This section describes the general approach taken in this thesis to develop the UBQ-
C as a cancer-specific utility-based instrument. This involved deriving, optimising, 
validating and applying a scoring algorithm that converts ratings from the UBQ-C to 
indices of overall HRQL and utility. 
 
The scoring algorithm was derived by adapting Lumley’s approach and applying it to 
the UBQ-C. The first step determined the scales from which the utility index would 
be derived. This is analogous to developing a health state classification system for a 
utility-based instrument, as described in chapter 2 (section 2.6). The health status 
thermometer was the single-item global scale. The multi-item subscales for physical 
function, social/usual activities, self-care and distresses were the multiple subscales. 
The general health item of the UBQ-C was not included, because it is strongly 
correlated with the health status thermometer and is unlikely to contribute additional 
information [12]. The four multi-item subscales were used rather than the individual 
items of the UBQ-C to minimise problems of collinearity. 
 
The second step calculated a subset index, overall HRQL index and utility index 
from a weighted combination of the health status thermometer and multi-item 
subscales. This process is analogous to valuing a subset of the health states described 
by a health state classification system, as described in chapter 2 (section 2.6). Data 
was used from the valuation survey of patients with advanced cancer referred to in 
chapter 3 (section 3.5.1). The weights were derived by applying Lumley’s approach, 
as above. The method is illustrated in figure 4.2, and detail of the methods and 
results are presented in chapter 5.  
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Figure 4.2 Deriving a utility index for the UBQ-C with Lumley’s combined 
approach 
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UBQ-C, Utility-Based Questionnaire-Cancer. HRQL, health-related quality of life. 
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The third step optimised the scoring algorithm for two clinical contexts by adjusting 
the weights assigned for the health status thermometer and the multi-item subscales. 
The contexts were adjuvant chemotherapy for early breast cancer, and palliative 
chemotherapy for advanced breast cancer. Data from the early trial and advanced 
trial (referred to in sections 3.5.2 and 3.5.3 of chapter 3) were used to adjust the 
weights. The utility index was then validated by applying the scoring algorithm to 
the questionnaire data from these trials, and comparing the scores with responses to 
other questionnaires and patient characteristics. Details of the methods and results 
are presented in chapter 6. 
 
The fourth step applied the scoring algorithm to evaluate the differences in utility 
between chemotherapy regimens in these clinical contexts. The regimens were high-
dose versus standard adjuvant chemotherapy for early breast cancer, and single-agent 
oral versus multi-agent intravenous chemotherapy for advanced cancer. The analyses 
used cross-sectional data from the early breast cancer trial (during the intense phase 
of treatment), and longitudinal data from the advanced breast cancer trial (during the 
entire period from randomisation to disease progression). The latter required the 
scoring algorithm to be adapted to the analysis of longitudinal data, and extended by 
incorporating additional information about HRQL. Detail of the methods and results 
are presented in chapters 6 and 7. 
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4.4 Missing and censored data 
There was a limited amount of missing data within the datasets analysed in this 
thesis. Some questionnaires were not submitted, some interviews were not 
completed, and some items within submitted questionnaires were left blank. Details 
were reported in the study profiles in chapter 3 (section 3.6 and 3.8, figure 3.2). 
 
Missing data within questionnaires was considered missing at random. The scores on 
the UBQ-C subscales were imputed as the average of the non-missing items, when 
some (but not all) items from a subscale were missing. Analyses involving multiple 
subscales and the health status thermometer only included individuals with complete 
data. Individuals without complete data were excluded. 
 
Some of the subjects in the advanced cancer trial had missing HRQL data prior to 
progression. These were assumed to be missing at random. No specific adjustments 
were made to account for these missing values. In effect, this means that the missing 
values were assumed to be similar to the average of the same patient’s non-missing 
values. 
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4.5 Data transformations 
Responses to the questionnaires were transformed for the analyses reported in 
chapters 5 to 7. The methods for each questionnaire are described below. 
UBQ-C 
For the UBQ-C, the responses to the items were converted to an interval scale 
ranging from 0 (worst) to 1 (best) as follows: 
 
The responses to the items within the subscales for physical function, social/usual 
activities and self-care were converted from four ordinal response levels of ‘Not 
affected’, ‘Slightly affected’, ‘Severely affected’ and ‘Unable to do activities at all’ 
to 0, 1/3, 2/3, and 1 respectively. The responses to the items within the distresses 
subscale were converted from an 11-point scale (0 to 10) by dividing by 10. The 
score for each of the four multi-item subscales was the simple average of the non-
missing component items, but the responses to the items labelled ‘sex life’ and ‘other 
problems’ were excluded because they are commonly left blank by respondents 
(table 3.1, section 3.2.5 of chapter 3). 
 
The responses to the health status thermometer were converted from an interval scale 
ranging from 0 (worst) to 100 (best), by dividing by 100. 
 
The format of the general health item differed in each study. For the valuation 
survey, the responses to the general health item were converted from four ordinal 
response levels of ‘Excellent, ‘Good’, ‘Fair’ and ‘Poor’ to 0, 1/3, 2/3, and 1 
respectively. For the early and advanced cancer trials, the responses were converted 
from five ordinal response levels of ‘Excellent, ‘Very good’, ‘Good’, ‘Fair’ and 
‘Poor’ to 0, 1/5, 2/5, 3/5, 4/5 and 1 respectively. 
 
The transformed health status thermometer, general health item, and 4 multi-item 
subscales were assumed to have interval properties. This is common practice, but 
was not empirically tested 
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Spitzer-Uniscale, and Priestman and Baum Linear Analog Self Assessment 
Scales 
The responses to the Spitzer-Uniscale and the Priestman and Baum Linear Analog 
Self Assessment Scales (LASAS) were converted from an interval scale ranging 
between 0 (best) and 100 (worst) to a scale from 0 (worst) to 1 (best) by subtracting 
each score from 100, and dividing the result by 100. 
Performance status scale 
The responses to the Eastern Cooperative Oncology Group (ECOG) performance 
status scales were converted from five ordinal response levels of ‘0’ to ‘4’ to 
dichotomous response levels of ‘good’ for response levels 0 and 1, and ‘poor’ for 
response levels 2, 3 and 4. 
Time trade-off interview 
The responses to the time trade-off interview were converted from a number 
representing the number of years in full health that was equivalent to two years with 
present symptoms, to a utility value ranging between ‘0’ (death) and ‘1’ (full health), 
by dividing each response by two. 
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4.6 Measures of central tendency 
The responses to the utility interviews, and to a lesser extent the questionnaires, 
suffered from a ceiling effect with many responses at the upper end of the scale (full 
health), as reported in chapter 3 (sections 3.8 and 3.9). 50% of the respondents to the 
utility interviews assigned a utility of 1.0. The effect of this skewed distribution was 
that the median was higher than the mean. This raised questions about whether to use 
the median or mean as the measure of central tendency for reporting on groups, and 
for regression analyses. 
 
Statistical arguments favour use of the median, but the mean is generally 
recommended for applications based on economic methods [116]. The statistical 
argument for using the median for a skewed distribution is that the mean is unduly 
affected by the outlying observations [138]. The philosophical argument for using 
the mean is that all responses are ‘acceptable’ and should contribute equally 
including extreme values, whereas using the median filters outlying values which are 
implied to be ‘unacceptable’ [140]. This argument is based on the principles of 
utilitarianism [140] and is founded in welfare economic theory [141]. For this reason, 
health economists generally recommend that applications based on economic 
methods such as utilities should be aggregated using the mean, irrespective of the 
skewness of that distribution [141]. This was the approach used in this thesis, but 
arguments advocating use of the median are acknowledged [141-143]. 
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4.7 Statistical tests 
Parametric tests were used to assess the statistical significance of differences in mean 
scores, despite the lack of normality of distributions for responses to the utility 
interviews and questionnaires. This was done in accordance with the 
recommendations of economists to use the mean in preference to the median, as 
described in the previous paragraph. The alternative would have been to compare 
distributions using non-parametric tests, but the results and conclusions were similar. 
 
The statistical significance of differences in scores between groups were assessed 
with unpaired t-tests [138]. The statistical significance of differences in scores within 
groups from one timepoint to another were compared with paired t-tests [138]. The 
statistical significance of differences in scores within groups over multiple 
timepoints were calculated with generalised estimating equations that took into 
account the correlation between successive observations for each subject. For these 
analyses, the ‘PROC GENMOD’ statement of SAS was invoked, and a normal 
distribution was specified with the identity link function. Reported p-values for all 
statistical tests were two-sided. 
 
The strengths of associations between related measures on scales were calculated 
using Spearman’s rank-order correlation [138]. 
 
The relative precision of related measures was compared with the relative efficiency 
statistic [138, 144]. The reciprocal of the relative efficiency statistic is the factor by 
which the sample size can be reduced when a more precise and therefore more 
efficient scale is used. The relative efficiency statistic was calculated as the squared 
ratio of the t-score from the comparison of the groups using the measure under 
evaluation divided by the t-score from the comparison of the groups using the 
reference measure. 
 
The statistical significance of differences in survivals between groups were 
compared with the logrank test, and the survival curves for each group were derived 
using the Kaplan-Meier method [138]. 
 77
4.8 Regression models 
Standard linear regression models based on minimising the differences between the 
observed and predicted values using ordinary least-squares regression were used in 
chapters 5 to 7 to derive the scoring algorithm. First, multivariable linear regression 
was used to calculate scores on the subset index from a weighted combination of the 
UBQ-C subscales according to their correlations with scores on the health status 
thermometer. Second, information from that regression was used to combine the 
subset index with the health status thermometer. Third, a disutility power 
transformation was selected amongst other candidates to map the relationship 
between the overall HRQL index and the time trade-off utility interviews. Fourth, 
this power transformation was used to convert the overall HRQL index to the utility 
index (figure 4.2). 
4.9 Statistical software 
All analyses were performed using SAS for Windows Release 8.02 [145]. 
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4.10 Summary 
This chapter has described the statistical methods used to develop a utility index for 
the UBQ-C. The background described the method, rationale and merits of Lumley’s 
approach. This approach combines a global scale and multiple specific subscales, and 
optimises the combination in specific clinical contexts. Next, the general approach 
taken to the work reported in this thesis was described. This involved deriving, 
optimising and validating the scoring algorithm for the utility index. The remainder 
of the chapter outlined the methods for statistical analysis. 
 
The next chapter reports the results of the approach taken to derive the scoring 
algorithm for the utility index. 
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5.  Deriving a patient-based cancer utility index from a 
cancer-specific quality of life questionnaire 
5.1 Overview 
This chapter is a published work. The entire manuscript is quoted verbatim, and 
amendments are presented in italics. The supplementary online appendix for the 
manuscript is quoted verbatim in the supplementary section to this chapter (section 
5.6). This supplementary section describes additional analyses that support the work 
reported in the manuscript. 
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Abstract 
Objectives: The aim of this study was to derive a scoring algorithm for a validated 
disease-specific quality of life instrument called the Utility-Based Questionnaire-
Cancer (UBQ-C) that provided a utility index designed to inform clinical decisions 
about cancer treatments. 
 
Methods: The UBQ-C includes a scale for global health status (1 item); and 
subscales for physical function (3 items), social/usual activities (4 items), self-care (1 
item), and distresses due to physical and psychological symptoms (21 items). A 
scoring algorithm was derived to convert the subscales into a subset index, and 
combine it with the global scale into an overall HRQL index, which was converted to 
a utility index with a power transformation. The valuation survey consisted of 204 
advanced cancer patients who completed the UBQ-C and assigned time-trade-off 
(TTO) utilities about their own health state. Preliminary validation involved 
comparing these derived utilities with other measures of HRQL. 
 
Results: Weights for the subset index were: physical function 0.28, social/usual 
activities 0.06, self-care 0.01, and distresses 0.64. Weights for the overall HRQL 
index were health status 0.65 and subset index 0.35. The mean of the utility index 
scores was similar to the mean of the TTO utilities (0.92 vs 0.91, p=0.6). The utility 
index was substantially correlated with other measures of HRQL. 
 
Conclusions: Data from a simple, self-rated, disease-specific questionnaire can be 
converted into a utility index suitable for comparing the net effect of cancer 
treatments on quality of life, and to evaluate trade-offs between quality and quantity 
of life in quality-adjusted survival analyses. 
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5.2 Introduction 
Utility-based instruments are a common means of generating utility scores for 
calculating quality-adjusted life-years (QALYs) [9]. A utility-based instrument 
generally consists of a questionnaire which elicits responses about multiple 
dimensions of health status and health-related quality of life (HRQL), and a scoring 
algorithm that is used to convert the ratings on the questionnaire into a single utility-
based index [9, 90]. The scoring algorithms for utility-based instruments are valued 
in surveys, where subjects are asked to assign utilities to the health states defined by 
the questionnaire [9, 90]. For example, the valuation survey for the EQ-5D 
instrument involved lay people assigning utilities with the time trade-off method to a 
number of hypothetical health states defined in five generic dimensions (mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression)[100, 103]. Utility-
based instruments may vary in the type of questions they contain (generic or disease-
specific), and the perspective from which the scoring algorithm is valued (lay people 
or patient) [9, 36, 97]. 
 
Controversy exists about the suitability of generic versus disease-specific utility-
based instruments for generating utility scores. Generic instruments like the EuroQol 
EQ-5D [103], Health Utilities Index (HUI3) [106] or SF-6D [107] ask about core 
aspects of HRQL that are of interest in a wide range of settings. The main argument 
for using a generic utility-based instrument is that it allows comparisons across a 
wide range of diseased and healthy populations [68, 108-109]. However a generic 
instrument is likely to provide an inadequate description of many diseases, so the 
utility scores that it generates may be insensitive to differences between individuals 
with that disease [108, 110-112]. Disease-specific, utility-based instruments were 
designed to address this lack of sensitivity by asking about specific aspects of HRQL 
relevant to that disease or condition [97-98, 110, 113].  
 
Controversy also exists about the suitability of utilities that are valued from the 
perspective of lay people versus patients [58-59, 68]. The distinction is important 
because a patient typically assigns a higher utility to a health state than a lay person 
[56-58]. Economic guidelines generally recommend the use of generic utility-based 
instruments based on the perspective of lay people [69-71]. The main argument for 
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using the perspective of lay people for informing funding and policy decisions is that 
the primary objective in a publicly funded health system is to maximise health for 
society [9]. It is generally recommended that the perspective of patients is used to 
inform clinical decision making [9, 16, 36, 61]. The main argument for using the 
perspective of patients for clinical decisions is that the primary objective is to 
maximise health for the individual patient experiencing that condition [62, 73]. 
 
We posit that disease-specific instruments valued by patients are preferable for 
informing clinical decisions, whereas generic instruments valued by lay people may 
be preferable for decisions about health policy. 
 
The aim of this study was to derive a scoring algorithm for a disease-specific, utility-
based, HRQL instrument that is designed to inform clinical decisions about cancer 
treatments. The algorithm converts ratings from a cancer-specific HRQL 
questionnaire into a utility-based index designed to reflect the perspective of cancer 
patients. This paper describes the development and preliminary validation of the 
algorithm. A companion paper describes the application of the algorithm to trial 
datasets, and illustrates how it can be optimised in different treatment contexts [146] 
(Chapter 6). 
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5.3 Methods 
5.3.1 Source of data 
The valuation survey used to derive the scoring algorithm involved ambulatory 
patients with advanced cancer and impaired HRQL who were recruited from two 
tertiary-referral oncology outpatient units (as described in section 3.5.1 of chapter 3) 
[13]. Eligible patients had advanced cancer, impaired HRQL and were willing and 
able to complete a self-administered HRQL questionnaire and participate in a one 
hour interview in English. All patients provided written informed consent. The study 
was approved by the human research ethics committees at all participating 
institutions. 
 
Consenting patients were registered and scheduled for an interview, usually on the 
day of their next appointment at the oncology clinic. Utilities were elicited directly 
from subjects about their current HRQL by one trained researcher using a 
standardised, face-to-face, time trade-off (TTO) interview with a hypothetical 
survival time of two years (as described in section 3.2 of chapter 3). The TTO was 
expressed on the standard continuum where 1 represents full health and 0 represents 
dead [16]. Patients were mailed the questionnaire and asked to complete it 3 to 7 
days before the planned interview.  
 
5.3.2 The Utility-Based Questionnaire-Cancer (UBQ-C) 
The Utility-Based Questionnaire (UBQ) is a validated, disease-specific HRQL 
questionnaire that was designed to be an outcome measure for clinical trials in cancer 
and cardiovascular disease [12-13, 129]. The cancer version (the Utility-Based 
Questionnaire-Cancer, UBQ-C) includes 29 items about specific aspects of HRQL, 
and a global scale called the health status thermometer, which is a single item that 
asks respondents for a unified assessment of their health status. The 29 items about 
specific aspects of HRQL are grouped into subscales for physical function (3 items), 
social/usual activities (4 items), self-care (1 item), and distresses (21 items) due to 
physical and psychological symptoms associated with cancer and its treatment 
(Reproduced in appendix 1). 
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The UBQ-C was designed for use in clinical trials of cancer therapy, so it needed to 
be relevant to cancer patients, relatively brief and easy to self-complete. The form 
and content of the questionnaire builds on the conceptual framework for health status 
assessment developed by Gudex et al for an existing generic utility-based instrument 
called the Health Measurement Questionnaire (HMQ) [118]. The HMQ includes 36 
items covering 5 key dimensions of HRQL (general mobility, usual activities, self-
care activities, social and personal relationships, and psychological distresses). A 
generic core set of items from the HMQ was taken for the UBQ-C. Items less 
relevant for cancer patients (eg hearing, vision, writing, speaking and incontinence) 
were discarded, and the response formats of some items were modified. Cancer-
specific items were selected for addition by a review of existing literature on HRQL 
instruments used in cancer patients [130-131]. Two measures of global health status 
were also added. The health status thermometer is similar to the graduated, vertical, 
visual analog scale that accompanies the EuroQol EQ-5D questionnaire [104-105], 
but with the anchors of ‘best imaginable health state’ and ‘worst imaginable health 
state’ replaced by ‘full health’ and ‘death’, to conform with the requirements of a 
utility scale. The UBQ-C also includes the general health item from the Short-Form-
36 health survey (SF-36) [132], which is a widely used and extensively validated 
measure of generic health status [5]. This item asks respondents to ‘describe their 
general health’ as excellent, very good, good, fair or poor. 
 
The psychometric properties of the UBQ-C in a cancer population have been 
reported previously [12-13]. These include good feasibility (high completion rate 
with little missing data), internal consistency of subscales (Cronbach’s alphas > 0.75 
and confirmatory factor analysis), test-retest reliability (intraclass correlation 
coefficients: median 0.85, lower quartile 0.81, upper quartile 0.90), convergent 
validity (substantial correlations with related instruments: GLQ-8, GLQ-Uniscale 
[130], Priestman and Baum LASA scales [131], and Life Satisfaction Index-A 
[133]), discriminative ability (between groups with different disease severity) and 
responsiveness to change within individuals. 
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5.3.3 Statistical methods 
The scoring algorithm was produced by modelling the valuation survey data using 
the multi-step approach developed by Lumley et al [32]. A ‘subset index’ is 
calculated by combining the questionnaire subscales into a subset index according to 
weights based on their correlations with a global scale. Here we define a global scale 
as a single item asking respondents directly for a unified assessment of their HRQL 
[31]. An ‘overall HRQL index’ is then calculated by combining the subset index with 
this global scale using weights based on their statistical precision. Finally, a ‘utility 
index’ is calculated by transforming the overall HRQL index. A novel feature of 
Lumley’s approach that is not incorporated in other approaches to deriving scoring 
algorithms [9, 39, 90] is that it combines a single-item global scale with multi-item 
subscales for specific aspects of HRQL. The purpose of including the global scale in 
the index is to incorporate information about any additional aspects of HRQL that are 
important but not captured by the subset index [32]. 
 
The scoring algorithm for the UBQ-C was derived in four steps (figure 4.2 of chapter 
4). First, subscale scores for physical function, social/usual activities, self-care and 
distresses were calculated from the ratings on the relevant UBQ-C items. Second, a 
subset index was calculated by weighted combination of the subscale scores. Third, 
an overall HRQL index was calculated by weighted combination of the subset index 
and the health status thermometer. Fourth, the overall HRQL index was converted to 
a utility-based index with a suitable transformation. The following paragraphs 
describe each step in detail. 
 
The subscale scores for physical function, social/usual activities, self-care and 
distresses are the simple averages of the relevant, non-missing items, linearly 
transformed to a scale from 0 (worst) to 1 (best). Responses to the items about ‘Sex 
life’ and ‘Other problems’ are not included when calculating the scores for the 
subscales because they are commonly omitted by respondents. 
 
The subset index was calculated by weighted combination of the subscales for 
physical function, social/usual activities, self-care and distresses. Weights for the 
subscales (W1-4 in figure 4.2 of chapter 4) were derived from, and proportional to, 
the coefficients obtained from multivariable ordinary least squares linear regression 
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of the health status thermometer on the subscales. The weights are designed to reflect 
the relative contribution of each subscale to overall HRQL. The scores for the subset 
index for each subject were calculated by applying the weights to the subscale scores 
as follows: 
[1] Subset index = [W1 * PF] + [W2 * SA] + [W3 * SC] + [W4 * DI] 
W1-4 are the weights for the subscales: PF is physical function, SA 
is social/usual activities, SC is self-care, DI is distresses. 
The score for the subset index was recorded as missing if any of its component 
scores were missing. 
  
The overall HRQL index was calculated by weighted combination of the subset 
index with the health status thermometer. Greater weight was given to the component 
with least measurement error. The weights were calculated using Lumley’s formulae, 
as follows: 
[2] W = Var(T) * [ 1 – r(T) ] / MSE(R) 
W is the weight allocated to the subset index, so 1 – W is the 
weight allocated to the health status thermometer (figure 4.2 of 
chapter 4). Var(T) is the variance of the health status thermometer 
obtained from the dataset. r(T) is the intraclass correlation 
coefficient of the health status thermometer, and was calculated 
with test-retest data from a previous validation study [13]. MSE(R) 
is the mean square for error from the linear regression of the health 
status thermometer on the four subscales, and was obtained from 
the dataset. 
The scores for the overall HRQL index for each subject were calculated as follows: 
[3] Overall HRQL index = [ W * Subset index ] + [ (1 – W ) * HST ] 
HST is the health status thermometer. The scores for the overall 
HRQL index were recorded as missing if the score for the subset 
index or health status thermometer was missing. 
A suitable transformation function was sought to convert the overall HRQL index to 
the utility index. We considered a range of functional forms used to transform 
measures of HRQL to measures of utility in previous studies [92]. We selected the 
 87
function that best mapped the relationship between the overall HRQL index and TTO 
utility in the development dataset. The details are described in the supplement to this 
chapter (section 5.6). The scores for the utility index for each subject were calculated 
by applying the chosen transformation function to the scores for the overall HRQL 
index. 
 
Preliminary validation of the algorithm was done by comparing the scores on the 
utility index to those from other measures of HRQL, health status and utility. We 
assessed how closely the utility index was related to the TTO utility using 
Spearman’s rank-order correlation (rs) and paired t-tests. Associations between the 
utility index and two independent global measures of HRQL, the general health item 
from the SF-36 (referred to above) and the Spitzer-Uniscale of global life quality 
(described in section 3.3 of chapter 3 and appendix 2) [14-15], were also assessed 
with Spearman’s rank-order correlation. We tested the hypothesis that compared with 
related global measures, the derived indices would give estimates of differences in 
mean scores between subjects that were grouped by their response to the general 
health item that were more precise (narrower confidence intervals) but unbiased 
(similar point estimate). The overall HRQL index was compared with the health 
status thermometer, and the utility index was compared with the TTO utility. 
Differences in mean scores between groups were calculated using unpaired t-tests. 
The relative precisions of the related measures were compared using the relative 
efficiency statistic [138, 144]. The reciprocal of the relative efficiency statistic is the 
factor by which the sample size can be reduced when a more precise and therefore 
more efficient scale is used. The relative efficiency statistic was calculated as the 
squared ratio of the t-score from the comparison of the groups using the derived 
index divided by the t-score from the comparison of the groups using the related 
global measure. 
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5.4 Results 
The study profile describing the subjects and data used to generate the scoring 
algorithm is shown in figure 3.2 of chapter 3. Of the 323 patients that were 
approached to take part in the study, 204 were eligible. Compliance was excellent, 
with planned interviews and questionnaires completed by 98% of participants. All 
items on the UBQ-C except ‘Sex life’ and ‘Other problems’ were completed by over 
90% of patients. Characteristics of eligible subjects are summarised in table 5.1. All 
patients had advanced cancer, mostly arising from the breast or bowel. The mean age 
was 56 and most age groups were represented. The different levels of general health 
status were also well-represented. Most modes of treatment were represented: 
chemotherapy, supportive care and observation. 
 
UBQ-C ratings on the health status thermometer and subscales are summarised in 
table 5.2. Patients reported worst impairment for physical function and least 
impairment for self-care.  
 
The derived weights for the subscales (W1-4) health status thermometer (1-W), and 
subset index (W) are shown in table 5.3. The health status thermometer accounted for 
about two-thirds of the index for overall HRQL. Of the subscales, greatest weight 
was given to distresses and least to self-care. 
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Table 5.1 Valuation survey: patient characteristics 
 (n=204) 
% 
 
Cancer type 
  Breast 
  Bowel 
  Other 
 
50 
29 
21 
 
Age (Years) 
  < 40 
  40-49 
  50-59 
  60-69 
  ≥ 70 
 
12 
21 
25 
28 
14 
 
Gender  
  Male 
  Female 
 
32 
68 
 
Marital status  
  Partner 
  No partner 
 (single, divorced, widowed) 
 
65 
35 
 
Education  
  Primary school 
  Some high school 
  Completed high school 
  Higher education 
 
4 
22 
35 
39 
 
Country of origin  
  Australia 
  Other 
 
80 
20 
 
General health  
  Excellent 
  Good 
  Fair 
  Poor 
 
10 
48 
35 
7 
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Table 5.2 Valuation survey: ratings on UBQ-C 
 Mean SD 
Health status thermometer 0.74 0.16 
Physical function 
Social/usual activities 
Self-care 
Distresses 
0.65 
0.77 
0.95 
0.80 
0.23 
0.22 
0.14 
0.15 
SD, standard deviation. UBQ-C, Utility-Based Questionnaire-Cancer. All ratings on scale from best 
(one) to worst (zero). 
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Table 5.3 Valuation survey: weights for scoring algorithm 
  Weight 
W 
1-W 
Health status thermometer 
Subset index 
0.65 
0.35 
W1 
W2 
W3 
W4 
Physical function 
Social/usual activities 
Self-care 
Distresses 
0.28 
0.06 
0.01 
0.64 
W is the weight allocated to the subset index. 1 – W is the weight allocated to the health status 
thermometer. W1-4 are the weights for the subscales. 
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The overall HRQL index was calculated by applying these weights to the subjects’ 
ratings on the UBQ-C using formulae [1] and [3]. The transformation that best 
reflected the relationship between the overall HRQL index and TTO utility was a 
disutility power transformation (supplementary section 5.6), viz: 
[4] Utility index = 1 – (1 – overall HRQL index)2.03 
This transformation was used to convert the overall HRQL index 
into the utility index. 
 
Scores for the overall HRQL index, utility index and TTO utility are compared in 
table 5.4. The TTO utility was 1.0 for about half the subjects, despite significant 
impairments in HRQL. Because of this skewed distribution, the mean value of the 
TTO utility was lower than its median value. There were no associations between the 
TTO utility and the patient characteristics listed in table 5.1 above (data not shown). 
The overall HRQL index gave substantially lower scores than the TTO utility (means 
0.74 vs 0.92, difference 0.17, 95% CI 0.14 to 0.19). Scores were similar for the 
utility index and the TTO utility (means 0.92 vs 0.91, difference 0.01, 95% CI -0.02 
to 0.03). 
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Table 5.4 Valuation survey: comparison of scores for overall HRQL index, utility 
index and time trade-off utility 
Statistic Time trade-off utility Overall HRQL index Utility index 
Mean 
Standard deviation 
95% confidence intervals 
0.91 
0.17 
(0.89, 0.94) 
0.74 
0.14 
(0.72, 0.76) 
0.92 
0.08 
(0.90, 0.93) 
Median 
Inter-quartile range 
% with score of 1.0 
1.00 
(0.88, 1.00) 
50 
0.77 
(0.63, 0.86) 
0.5 
0.95 
(0.87, 0.98) 
0.5 
Mean difference compared 
to time trade-off utility 
(p-value) 
0 
 
N/A 
0.17 
 
< 0.0001 
0.01 
 
0.6 
HRQL, health-related quality of life. All ratings on scale from worst (0) to best (1). 
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Comparisons of the utility index with other measures of HRQL, utility and health 
status provide preliminary evidence of its validity. The utility index was moderately 
correlated with the TTO utility (rs 0.38), the general health status item from the SF-
36 (rs 0.63), and the Spitzer-Uniscale of global life quality (rs 0.68). The estimated 
differences in mean scores between subjects grouped by general health in the 
development dataset were more precisely estimated by the derived indices than by 
the health status thermometer or the TTO utility (figure 5.1). The relative efficiency 
statistics in figure 5.1 correspond with reductions in sample size needed to detect a 
significant difference by using the indices of 33% for the overall HRQL index 
compared with the health status thermometer, and of 75% for the utility index 
compared with the TTO utility. 
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Figure 5.1 Valuation survey: comparison of precision of (i) overall HRQL index and 
health status thermometer, (ii) utility index and time trade-off utility, in 
distinguishing subjects grouped by their general health status (excellent or good 
versus fair or poor) 
 
Utility index
(t=8.5)
UTILITY MEASURES
Health status 
thermometer
(t=7.7)
Overall HRQL index
(t=9.4)
MEASURES OF 
GLOBAL HEALTH 
STATUS AND OVERALL 
HRQL
TTO utility
(t=4.3)
-0.10 -0.05 0.00 0.05 0.10 0.15 0.20 0.25
Relative
efficiency
of overall
HRQL
index
= 1.5 
Relative
efficiency
of utility
index
= 3.9
 
 Difference in HRQL (and 95% confidence intervals) 
<- Favours fair or poor health                Favours excellent or good health -> 
 
HRQL, Health-related quality of life. Relative efficiency, reciprocal of factor by which sample size 
can be reduced when more efficient index is used (see text). t, t-score for difference between groups. 
All ratings on scale from 0 to 1. 
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5.5 Discussion 
We have derived a scoring algorithm for a disease-specific utility-based instrument 
that is designed to inform clinical decisions about cancer treatments. The algorithm 
converts ratings from a cancer-specific HRQL questionnaire called the UBQ-C into a 
utility-based index. Firstly, the algorithm calculates a subset index from a weighted 
combination of the UBQ-C subscales for physical function, social/usual activities, 
self-care and distresses. Secondly, an overall HRQL index is calculated from a 
weighted combination of the health status thermometer and the subset index. Thirdly, 
the algorithm calculates a utility index by applying a power transformation to the 
overall HRQL index. The scoring algorithm was developed using TTO utilities and 
UBQ-C ratings elicited from patients with advanced cancer who rated their current 
health status and HRQL. The utilities can be used to generate QALYs to compare 
cancer treatments. 
 
Utilities and QALYs are a useful way to compare cancer treatments because they can 
be evaluated on a common scale that incorporates disparate treatment effects like 
gains in survival duration, improvements in HRQL due to relief of cancer symptoms, 
and deteriorations in HRQL due to treatment-related side effects [9, 75]. Analyses of 
cancer trials in terms of utilities and QALYs are increasingly used to inform 
economic decisions about cancer treatments [76-83], but can also be used to inform 
clinical decisions [60, 84-88]. Despite the advantages of utilities and QALYs, there is 
no standardised approach for eliciting utilities [9, 16, 147-148]. One way to obtain 
utilities is to elicit them directly from respondents using a standard gamble or time 
trade-off (TTO) interview, but this task is complex, resource intensive, and can be 
distressing if cancer patients are required to assign utilities for their own health state 
[16]. A more practical approach is to derive utility scores from a utility-based 
instrument. We posit that deriving utility scores from a utility-based instrument that 
is disease-specific and based on the perspective of patients is the best approach for 
informing clinical decisions. 
 
The UBQ-C is a disease-specific instrument that is designed for the evaluation of 
cancer treatments. It asks about important consequences of cancer and its treatment 
not covered by generic instruments such as such as the EQ-5D [103], HUI3 [106] or 
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SF-6D [107] including fatigue, nausea, shortness of breath, and hair loss. The main 
advantage of a disease-specific instrument such as the UBQ-C over a generic 
instrument for generating utility scores is that it should be more sensitive to detect 
differences in health-related quality of life between individuals with cancer. This 
requires empirical testing, as has been done for other disease-specific instruments 
that generate utility scores for cancer [95, 98, 110] and a range of other diseases 
including bladder disorders [97, 113], hearing impairment [114] and asthma [111]. 
Another advantage of using a disease-specific utility-based instrument is that it 
provides data on specific aspects of HRQL, overall HRQL, and utility with a single 
questionnaire and increases the availability of utility data for comparisons of 
treatment from randomized clinical trials [98]. This approach enables utilities to be 
derived from previous studies where the UBQ-C was used, and reduces questionnaire 
burden for future trial participants by having a single questionnaire and approach that 
provides these 3 kinds of information. 
 
The major limitation of using disease-specific, utility-based instruments is that the 
utility scores they provide may not be comparable to those derived from other 
instruments, particularly generic instruments, because the dimensions of health status 
and HRQL that they cover are different [68, 108-109]. Whether this is a problem 
depends on the decision for which the utilities are being applied. We argue that 
disease-specific instruments are best suited to treatment comparisons within a 
particular disease used to inform clinical decisions. In this context comparisons 
across other diseases and healthy populations are less important, but coverage of 
aspects relevant to the patients under study is crucial. Others have argued that 
disease-specific instruments may also be suitable for treatment comparisons across 
all diseases to inform health funding and policy decisions if the scoring algorithm is 
derived using a valuation technique and population sample that is similar to a generic 
instrument, and the utility scores are shown to be comparable [97]. 
 
The algorithm described in this study was based on the perspective of cancer patients 
who were currently experiencing those health states. The perspective differs in two 
important ways from scoring algorithms used for most of the generic and cancer-
specific utility-based instruments reported previously. First, it is the perspective of 
patients rather than lay people. Second, it reflects views about a health state that is 
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real and current rather than hypothetical and in the future [149]. The perspective 
from which a utility is elicited may have significant implications for clinical and 
economic decisions that incorporate utilities and QALYs, because patients typically 
assign higher utilities to a given health state than lay people [56-58]. This may reflect 
partly the lay person’s difficulty appreciating what a hypothetical health state is 
really like, and partly the patient’s adaptation to their own health state [16, 58, 60-
62]. The choice of perspective should reflect the viewpoint from which the results 
will be interpreted [16, 61]. As discussed in the introduction, it is generally agreed 
that the perspective of patients is more appropriate for informing clinical decisions 
about specific treatments, while the perspective of lay people is more appropriate for 
informing decisions about health policy and funding. Some also argue that the 
perspective of patients should be used to inform funding and policy decisions, 
because patients better understand what it is like to live with a particular disease [56, 
59], but this argument is controversial because it runs counter to prevailing health 
economic guidelines [69-71]. 
 
This study also provides preliminary evidence supporting the validity of the utility 
index. It was substantially correlated with independent measures of general health, 
overall life quality, and TTO utilities. Mean scores for groups from the utility index 
and TTO utility were almost identical. This supports the validity of using the utility 
index to generate mean utilities for comparing patient groups. However, as expected 
we found that the utility index did not accurately predict utilities for individual 
patients. The mean absolute difference between the utility index and TTO utility for 
each subject was relatively large at 0.10. This finding argues against using the utility 
index to predict utilities for individuals. This is exactly as expected [98], because 
utilities are influenced by factors apart from HRQL such as individuals’ attitudes to 
risk and uncertainty (for the standard gamble), discount rate (for the time trade-off), 
and idiosyncratic preferences) [16, 148].  
 
The derived indices for HRQL and utility gave more precise estimates of differences 
between groups than the health status thermometer or TTO utility. We expected more 
precise estimates because any score aggregated from multiple items will produce a 
more precise estimate of differences between groups than a single-item scale [22, 
32]. This finding does not strengthen or weaken the validity of the indices but is an 
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expected measurement property which enhances the sensitivity and responsiveness of 
the indices. 
 
Ongoing work is needed to support the validity of the utility index. A companion 
paper describes the application of the scoring algorithm to independent trial datasets 
in breast cancer, and provides further evidence to support its validity by comparison 
with clinical data [146] (Chapter 6). We have also reported on a comparison of the 
value and sensitivity of utility scores generated by the index to those generated by 
the EQ-5D in colorectal cancer [150]. Independent testing in other datasets will 
further establish validity. 
 
The study population and valuation survey used to develop the scoring algorithm has 
several strengths. The patient characteristics were diverse including men and women 
with a broad range of ages, levels of performance status, and levels of health status. 
Compliance was excellent with both UBQ-C completion and utility interviews. We 
used the TTO method to elicit utilities for health states. The TTO is practical, reliable 
and has empirical validity [16, 49, 151]. A limitation of our valuation survey was that 
its sample size was too small to allow division of the group into a ‘training’ set, 
where the algorithm was developed, and a ‘validation’ dataset where its validity and 
accuracy was independently tested. The dataset was confined to patients with 
advanced cancer, mostly with breast or colorectal primaries, and attending 
ambulatory clinics. This may raise questions about the generalisability of the 
algorithm and approach to patients with cancers that are of earlier-stage, in 
remission, or from other primary sites. 
 
The novelty of our statistical approach is in its combination of a single-item global 
scale with multi-item subscales for specific aspects of HRQL and its methods for 
deriving optimal weights. Most other utility-based indices do not incorporate a 
single-item global scale [9, 39, 90]. Incorporation of the single-item global scale has 
two potential advantages. First, it provides a unified reflection of how the patient 
rates their health status that enables incorporation of aspects of HRQL that are 
important but are not directly captured by multi-item subscales [32]. Second, it 
allows the scoring algorithm to be optimised in different treatment contexts by 
adjusting the weights assigned to the multi-item subscales [32]. The purpose of 
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optimising the algorithm is to reflect the differences in importance that patients with 
different types and stages of cancer, and treatments assign to various dimensions of 
HRQL [32, 63]. The implications of optimising the algorithm for different treatment 
contexts are addressed by application and discussion in a companion paper [146] 
(Chapter 6). 
 
This work enables HRQL data obtained with a simple cancer-specific questionnaire 
to be converted into a utility index that reflects the perspective of cancer patients. 
The approach is best-suited to generating estimates of mean utilities for groups, and 
our work so far supports this application. It can be applied in clinical trials to 
compare the effect of cancer treatments on HRQL using utility measures, and to 
generate QALYs for informing clinical decisions and as an alternate viewpoint for 
economic analyses. The approach provides a general method for converting HRQL 
ratings to valid utility-based measures that could be applied in other trial settings for 
analysis of HRQL data collected with different questionnaires. 
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5.6 Supplementary section 
Here we describe how we derived an equation to convert the overall HRQL index to 
the utility index. The scores on the overall HRQL index are expressed with a ‘value-
based’ scaling method, and the scores on the utility index are expressed with a 
‘utility-based’ scaling method. We define these terms in the following paragraphs 
based on descriptions by McDowell et al [5]. 
 
We refer to a measure expressed with a value-based scaling method as one that 
measures a respondent’s perceptions about the presence and severity of symptoms or 
disabilities [5]. The value-based scaling method is sometimes referred to as the 
psychometric scaling method because the numerical scores are assigned to the 
responses in a way that is derived from the psychometric tradition. The psychometric 
tradition focuses on perceptions or feelings and usually refers to current health status 
rather than future outcomes [5]. The responses to the individual items on the Utility-
Based Questionnaire-Cancer (UBQ-C) and the scores on the overall HRQL index 
that are derived from them are expressed with a value-based scaling method, as is the 
‘health status thermometer’ that assigns a perception of full health a score of 100 and 
death 0. 
 
In contrast, we refer to a measure expressed with a utility-based scaling method as 
one that measures a respondent’s strength of preference for particular outcomes when 
faced with uncertainty such as the possibility of a future gain [5, 9, 16]. The utility-
based scaling method is sometimes referred to as the econometric scaling method 
because the numerical scores are assigned to the responses in a way that is derived 
from the econometric tradition. The econometric tradition focuses on strength of 
preference for alternate outcomes that will occur in the future. The responses to a 
time trade-off interview are expressed with a utility-based scaling method, as is a 
utility index that is derived from a utility-based instrument. 
 
The value-based scaling method records values and the utility-based scaling method 
records utilities. The distinction between utilities and values is important because 
utilities have scaling properties that are designed for generating quality-adjusted life-
years (QALYs). This is because utilities capture both the person’s preference and 
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their attitude towards risk, which is relevant for studies of choices between 
alternative therapies for which the outcome lies in the future and remains uncertain 
[5]. The utility-based scaling method was chosen as the basis for expressing quality 
of life because it offers a way to integrate morbidity and mortality into a single scale 
called quality-adjusted life-years (QALYs) [5]. 
 
Because of the complexity of the utility-based scaling method, methods have been 
developed to convert measures expressed with a value-based scaling method 
(referred to in this section as ‘Q’) to measures expressed with a utility-based scaling 
method (referred to in this section as ‘U’). Several functions have been used in other 
studies to transform Q into U (see [37] for an overview). The functions vary in their 
form, complexity, and rationale; and include simple linear [152-155], quadratic [156-
157], cubic [156-157], plateau models [154], and power transformations [51, 93, 106, 
158-162]. Some directly transform Q to U, others transform impairment in quality 
(1-Q) to disutility (1-U). There is no consensus on the best functional form [37, 157], 
but there are two main criteria. One is that the functional form has an underlying 
conceptual rationale. The other is that it has predictive precision, which tests if the 
function predicts a value of U from Q that is similar to the true value of U.  
 
The power transformation is the best studied function. The utility power 
transformation is of the form U = Qk, and the disutility power transformation is of the 
form (1-U)=(1-Q)k [92]. An advantage of the power transformation is that the value 
of U will be between zero and one for any value of Q that is between zero and one, 
which satisfies one requirement of the utility-based scaling method [16]. The 
rationale for a power transformation is that Q is expressed with a value-based scaling 
method under conditions of certainty and lack of choice, and U is expressed with a 
utility-based scaling method under conditions of uncertainty and choice, so the 
difference between Q and U is due to the degree of risk aversion that subjects have 
about making choices with uncertain outcomes [163]. The exponent k adjusts Q for 
the degree of risk aversion, and its value varies between studies [92]. The predictive 
precision of the power transformation varies in different contexts. It appears better 
when three criteria are satisfied: U and Q are elicited from lay people rather than 
patients; the aggregate (mean or median) values for U and Q are calculated for each 
health state; and the test of predictive precision is based on the relationship between 
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values of U and Q at the aggregate level rather than at the individual respondent 
level. The predictive precision of the power transformation appears lower when these 
three criteria are not satisfied [37]. 
 
Four other functions have been used to convert Q into U. The most parsimonious is a 
simple linear model: U = b0 + b1 Q. A limitation of the simple linear model is that 
values of U are not bound between zero and one. More complex functions are 
disutility functions with no intercept: 1 – U = b1 (1 - Q); quadratic functions with no 
intercept: U = Q2 + b1 (Q – Q2); and cubic functions with no intercept: U = Q3 + b1 
(Q – Q3) + b2 (Q2 – Q3) [157, 164]. A problem with these functions is the lack of an 
underlying conceptual rationale [37]. The more complex cubic and quadratic models 
have better predictive precision than the linear models. The cubic and quadratic 
models have better predictive precision than the power transformation in some 
studies [157] but not in others [156]. 
 
We selected the function that best described the relationship between the overall 
HRQL index and the TTO utility in the valuation survey. As described previously, 
the measures were moderately correlated (Spearman correlation 0.38), however the 
overall HRQL index was typically substantially lower than the TTO utility (mean 
difference 0.17, 95% CI 0.14 to 0.19, p < 0.0001) (table 5.5, figure 5.2). 
 
A limitation of each of the six tested functional forms is that each ignored the half of 
respondents who assigned a utility of 1. The power transformation assigned a utility 
of less than 1 to any respondent with any impairment in HRQL at all. Future work 
could compare the power transformation to a plateau model. This would model a 
linear relationship where utilities greater than 1 are assigned a utility of 1 [154]. 
 
 We considered six potential functional forms which are outlined in table 5.5. 
Optimal parameters for each of the functional forms were estimated by least squares 
regression of the TTO utilities on the overall HRQL index. Our primary criterion for 
selecting a function was predictive precision, which was compared in terms of mean 
absolute error, root mean square error, and proportion of predicted values within 0.05 
of actual values. 
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Table 5.5 Functions to convert overall HRQL index to utility index 
  Parameters Predictive precision 
No Function Parameter 
estimates 
95% CI Root mean 
square error 
Mean 
absolute 
error 
Errors 
< 0.05 
(%) 
Errors 
< 0.1 
(%) 
1 Utility power 
transformation: 
U = Qk 
k=0.33 0.25, 0.41 0.16 0.11 36 65 
2 Disutility power 
transformation: 
(1-U) = (1-Q)k 
k=2.03 1.78, 2.28 0.16 0.10 52 68 
3 Utility linear function: 
U = b0 + b1 Q 
b0=0.59 
b1=0.43 
0.46, 0.71 
0.26, 0.59 
0.16 0.11 36 64 
4 Disutility linear function 
with no intercept: 
1 – U = b1 (1, Q) 
b1=0.38 
 
0.30, 0.47 0.16 0.11 33 65 
5 Quadratic function with 
no intercept: 
U = Q2 + b1 (Q – Q2) 
b1=1.98 1.85, 2.12 0.16 0.10 50 67 
6 Cubic function with no 
intercept: 
U = Q3 + b1 (Q – Q3) + b2 
(Q2 – Q3) 
b1= 2.59 
b2=-2.49 
1.88, 3.29 
-4.22, 0.76 
0.16 0.10 38 68 
 
Abbreviations, CI, confidence interval. ‘Errors < 0.05’ and ‘Errors < 0.1’, proportion of subjects 
where difference in value between utility predicted by function and directly elicited utility is < 0.05 or 
0.1. Q, overall HRQL index. U, utility index. 
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Figure 5.2 Valuation survey: relationship of overall HRQL index and time trade-off 
utility 
 
Scatter plot of time trade-off utility versus overall HRQL index. 
Superimposed is box and whiskers of time trade-off utility (Mean, 95% CI) grouped by overall HRQL 
index categories (cutpoints: 0.5, 0.6, 0.7, 0.8, 0.9). 
Superimposed is regression line of power transformation ie. utility index = 1 - (1 – overall HRQL 
index)2.03. 
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 We also checked for violations of the statistical assumptions underlying these 
functions by testing for bias of the mean error. Analyses were performed using the 
PROC REG and PROC NLIN functions of SAS System for Windows Release 8.02 
[145]. 
 
The predictive precision of the six tested functional forms is compared in table 5.5 
above. The disutility power transformation was selected because it had the best 
predictive precision on all criteria. The exponent for the power transformation was 
similar to that found in other studies [92]. The power transformation performed 
better in our dataset than more complex quadratic and cubic functions that others 
have advocated [157, 164] when we used similar selection criteria [93, 164]. We 
converted the overall HRQL index to the utility index with this disutility power 
transformation. There was no systematic bias in errors within its regression model 
(mean -0.01, 95% CI -0.03 to 0.01, p=0.3). When patients were grouped by their 
general health, mean scores on the utility index and TTO utilities were similar (table 
5.6). The proportion of scores on the utility index within 0.1 and 0.05 of TTO 
utilities was better for subjects with general health that was excellent or good 
compared to fair or poor (table 5.6). 
 
In conclusion, a disutility power transformation was used to convert the overall 
HRQL index to the utility index. This is a standard method to convert a measure 
from a value scale to a utility scale. The equation has adequate predictive precision to 
compare utility scores between groups in clinical trials. 
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Table 5.6 Valuation survey: comparison of utility index and TTO by general health 
status 
Group % Utility index  Time trade-off utility Errors < 0.05 
  Mean 95% CI  Mean 95% CI % 
All subjects 100 0.92 0.90, 0.93  0.91 0.89, 0.94 52 
SF-36 general health 
Excellent 
Good 
Fair 
Poor 
 
10 
48 
35 
7 
 
0.99 
0.95 
0.89 
0.81 
 
0.98, 1.0 
0.94, 0.96 
0.87, 0.91 
0.74, 0.87 
  
0.99 
0.95 
0.88 
0.73 
 
0.98, 1.0 
0.92, 0.97 
0.83, 0.92 
0.57, 0.89 
 
100 
65 
31 
8 
SF-36 General health, response to Short-Form-36 general health item; Errors < 0.05 (%), proportion 
of patients where absolute difference between utility index and directly elicited utility is < 0.05. 
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6.  Preliminary validation of an optimally-weighted 
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Abstract 
Objectives: To optimise, apply and validate a scoring algorithm that provides a 
utility index from a cancer-specific quality of life questionnaire called the Utility-
Based-Questionnaire-Cancer (UBQ-C) using datasets from randomised trials in 
breast cancer. The index is designed to reflect the perspective of cancer patients in a 
specific clinical context so as to best inform clinical decisions. 
 
Methods: We applied the UBQ-C scoring algorithm to trials of chemotherapy for 
advanced (n=325) and early (n=126) breast cancer. The algorithm converts UBQ-C 
subscales into a subset index, and combines it with a global health status item into an 
overall HRQL index, which is then converted to a utility index using a power 
transformation. The optimal subscale weights were determined by their correlations 
with the global scale in the relevant dataset. The validity of the utility index was 
tested against other patient characteristics. 
 
Results: Optimal weights (range 0-1) for the subset index in advanced (early) breast 
cancer were: physical function 0.20 (0.09), social/usual activities 0.23 (0.25), self-
care 0.04 (0.01), distresses 0.53 (0.64). Weights for the overall HRQL index were 
health status 0.66 (0.63) and subset index 0.34 (0.37). The utility index discriminated 
between breast cancer that was advanced rather than early (means 0.88 vs 0.94, 
p<0.0001) and was responsive to toxic effects of chemotherapy in early breast cancer 
(mean change 0.07, p<0.0001). 
 
Conclusions: The scoring algorithm for the UBQ-C utility index can be optimised in 
different clinical contexts to reflect the relative importance of different aspects of 
quality of life to the patients in a trial. It can be used to generate sensitive and 
responsive utility scores, and quality-adjusted life-years, that can be used within a 
trial to compare the net benefit of treatments and inform clinical decision-making. 
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6.2 Introduction 
The quality-adjusted life-year (QALY) approach is a useful way to compare cancer 
treatments, because it integrates the beneficial and harmful effects of treatment on 
health-related quality of life (HRQL), expressed as a utility, with the effects of 
treatment on survival [9, 61, 75]. Analyses of cancer trials in terms of utilities and 
QALYs are increasingly used to inform economic decisions about cancer treatments 
[76-81, 83], but can also be used to inform clinical decisions [60, 84-88]. 
 
A practical and feasible approach to obtain utility scores for generating QALYs in 
cancer trials is to use a utility-based instrument. A utility-based instrument uses a 
scoring algorithm to convert the responses from a questionnaire that elicits ratings 
about various dimensions of HRQL to a utility index [9, 16, 90]. The scoring 
algorithm is valued in a valuation survey, where a sample of people directly assign a 
utility score to the health states described by the questionnaire using a time trade-off 
interview or related technique [39]. A utility-based instrument may include generic 
or disease-specific questions, and the scoring algorithm may generate utilities that 
are based on the perspective of lay people or patients. Three of the most commonly 
used instruments are the EuroQol EQ-5D [103], Health Utilities Index (HUI3) [106] 
and SF-6D [107]. These instruments include generic questions applicable to any 
disease or population, and their scoring algorithms are based on the perspective of 
lay people. Utility-based instruments reported more recently have included disease-
specific questions and use scoring algorithms that are based on the perspective of 
patients rather than lay people [97-98, 165]. 
 
Ideally, the perspective from which a utility instrument is valued should reflect the 
views of the population that the researcher is trying to reflect in the decision-making 
[9, 16, 36, 99]. In a companion paper we emphasised that patients typically assign a 
higher utility to a health state than a lay person, which can have significant 
implications for health funding, policy and clinical decisions that incorporate utilities 
and QALYs [165]. Researchers using utilities to inform health funding and policy 
decisions will generally prefer the perspective of lay people [69-71], while 
researchers using utilities to inform clinical decisions will generally prefer the 
perspective of patients [9, 16, 36, 62, 73]. This is because the objective of clinical 
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decisions is to maximise health for an individual patient with that disease [165]. 
Recently, it has been recognised that the preferences and attitudes of lay people in 
different countries may differ, because of differences in demographic background, 
social and cultural values, and political and economic systems [66-67]. As a result, 
some scoring algorithms for utility-based instruments based on the perspective of lay 
people have been optimised for use in different countries to reflect these differences 
[66, 100-102]. It has also been recognised that the preferences and attitudes of cancer 
patients in different clinical contexts may differ, because patients with different 
cancer diagnoses, stages of disease and treatment may assign different importance to 
different aspects of HRQL [32, 63-65]. We posit that scoring algorithms for utility-
based instruments based on the perspective of patients should be optimised for 
different treatment contexts to reflect these differences. 
 
Lumley et al have developed a novel approach to optimising scoring algorithms for 
different clinical contexts using the HRQL data collected in that context [32]. 
Lumley’s approach requires a questionnaire including items about specific aspects of 
HRQL and a single-item global scale. We define a single-item global scale as one 
asking respondents directly for a unified assessment of their HRQL. Lumley’s 
approach gives extra weight to the responses about specific aspects of HRQL that are 
more highly correlated with the responses on the global scale. These weights are 
intended to reflect the relative importance that the subjects assign to different aspects 
of HRQL. The optimisation of the scoring algorithm requires weighting to be 
determined for each clinical context but does not require the valuation survey to be 
repeated. 
 
The aim of this work was to use Lumley’s approach to derive an optimised scoring 
algorithm for a cancer-specific HRQL instrument that is based on the perspective of 
cancer patients. In a companion paper we described the development and preliminary 
validation of the algorithm [165] (Chapter 5). This paper describes the application of 
the algorithm to trial datasets, and illustrates how it can be optimised in different 
treatment contexts. 
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6.3 Methods 
6.3.1 Sources of data 
The data used to optimise, apply and validate the scoring algorithm were collected in 
two randomised clinical trials of chemotherapy for breast cancer. Both studies were 
approved by the human research ethics committees at all participating institutions. 
All patients provided written informed consent.  
 
The first trial, referred to as the “advanced cancer trial”, was conducted by the 
Australian New Zealand Breast Cancer Trials Group. It included patients with 
advanced breast cancer who were randomly allocated to receive either daily oral 
capecitabine or standard CMF as first-line chemotherapy until disease progression 
[124]. The primary outcome measure of the trial was quality-adjusted time to 
progression. Secondary outcome measures were time to progression, response rates, 
HRQL, overall survival, safety and cost-effectiveness. Eligible subjects were 18 
years or older, and were about to start first-line chemotherapy for histologically 
confirmed advanced breast cancer. Subjects were excluded if they were totally 
confined to bed and completely disabled (ECOG performance status 4, as described 
in the next section). Enrolment was from June 2001 to July 2005 at 34 centres in 
Australia and New Zealand. Subjects completed the Utility-Based Questionnaire-
Cancer (UBQ-C) and other questionnaires about HRQL that are described below 
(unless they could not read English). The data described in this paper come from 
baseline questionnaires competed prior to randomisation. 
 
The second trial, referred to as the “early cancer trial”, was conducted by the 
Australian New Zealand Breast Cancer Trials Group in collaboration with the 
International Breast Cancer Study Group. It included patients with high-risk early 
stage breast cancer who were randomly allocated to receive either high-dose 
chemotherapy with stem cell support over 12 weeks or standard-dose chemotherapy 
over 24 weeks [136]. The primary outcome measure of the trial was overall survival. 
Secondary outcome measures were quality-adjusted survival, disease-free survival, 
toxicity, HRQL and cost-effectiveness. Eligible subjects were aged 16 to 65 years, 
and were about to start adjuvant chemotherapy for histologically confirmed early-
stage primary breast cancer with 5 or more involved axillary nodes. Subjects were 
 113
excluded if they were capable of only limited self-care and/or were confined to a bed 
or chair for more than 50% of waking hours (ECOG performance status 3 or 4). 
Enrolment was from March 1997 until March 2000 at multiple centres in Australia, 
New Zealand, Europe and Asia. Subjects living in Australia and New Zealand were 
eligible to participate in a substudy. Substudy participants were required to provide 
detailed information about HRQL and resource usage by completing the UBQ-C and 
other questionnaires described below. Questionnaires were completed prior to 
starting chemotherapy (baseline), 12 weeks after randomisation (during 
chemotherapy), and a few months after completing chemotherapy. 
6.3.2 Questionnaires and other characteristics of subjects 
The UBQ-C is a validated cancer-specific questionnaire that was designed as an 
outcome measure for clinical trials in the field of cancer. It includes 29 items about 
specific aspects of HRQL and a single-item global scale that asks respondents to rate 
their global health status (health status thermometer) [12-13, 165]. The 29 items 
about specific aspects of HRQL are grouped into subscales for physical function (3 
items), social/usual activities (4 items), self-care (1 item) and distresses (21 items) 
due to physical and psychological symptoms relevant to cancer and its treatment. The 
UBQ-C also includes the general health item from the Short-Form-36 health survey 
(SF-36) [132]. More details about the conceptual framework, development, 
composition and psychometric properties of the UBQ-C are given in a companion 
paper [165] (Chapter 5). 
 
Two additional questionnaires were completed. The Spitzer-Uniscale of global life 
quality was completed by all subjects as an additional global scale, but with the 
anchors of ‘highest quality’ and ‘lowest quality’ replaced by ‘best possible’ and 
‘worst possible’ [14-15]. The Priestman and Baum Linear Analog Self Assessment 
Scales (LASAS) were completed by subjects in the advanced trial as validated 
measures of cancer-specific HRQL that include five scales about physical well-
being, mood, pain, nausea and vomiting, and appetite [131, 134]. Clinicians 
completed the Eastern Cooperative Oncology Group (ECOG) performance status 
scale in the advanced trial. This rates patients’ physical functional status as ‘0’, fully 
active; ‘1’, restricted in physical activity but able to do light work; ‘2’, confined to a 
bed or chair for less than 50% of waking hours and capable of all self-care but unable 
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to do any work; ‘3’, confined to a bed or chair for more than 50% of waking hours 
but capable of limited self-care; ‘4’, totally confined to bed or chair, completely 
disabled, incapable of any self-care [135]. These questionnaires were described in 
chapter 3 (section 3.3) and are presented in appendix 2. 
6.3.3 Statistical methods 
We optimised the scoring algorithm described in detail in a companion paper [165] 
and applied it to the clinical trial datasets. The scoring algorithm was outlined in 
figure 4.1 of chapter 4. 
 
Firstly, we calculated subscale scores for physical function, social/usual activities, 
self-care and distresses as the simple average of the non-missing items, linearly 
transformed to a scale from 0 (worst) to 1 (best). 
 
Indices were then calculated by applying the following formulae: 
[1]  Subset index = [W1 * PF] + [W2 * SA] + [W3 * SC] + [W4 * DI] 
[2]  W = Var(T) * [ 1 – r(T) ] / MSE(R) 
[3]  Overall HRQL index = [ W * Subset index ] + [ (1 – W ) * HST ] 
[4]  Utility index = 1 – (1 – overall HRQL index)2.03 
W1-4 are the weights for the subscales, PF is physical function, SA is social/usual 
activities, SC is self-care, DI is distresses, HST is the health status thermometer. W is 
the weight allocated to the subset index, so 1 – W is the weight allocated to the 
health status thermometer. Var(T) is the variance of the health status thermometer 
obtained from the dataset. r(T) is the intraclass correlation coefficient of the health 
status thermometer, and was calculated with test-retest data from a previous 
validation study [13]. MSE(R) is the mean square for error from the linear regression 
of the health status thermometer on the four subscales, and was obtained from the 
dataset. 
 
Optimal weights for the subscales (W1-4), subset index (W) and health status 
thermometer (1-W) were derived for each trial using the ratings on the UBQ-C in the 
relevant dataset. Weights W1-4 were derived from and proportional to the 
coefficients obtained from multivariable, ordinary least squares regression of the 
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health status thermometer on the subscales. Weights W and (1-W) were derived 
using formula [2] above. 
 
The weights were then applied using formulae [1], [3] and [4] above to calculate 
scores for the subset index, overall HRQL index and utility index for each subject in 
each trial. 
 
We examined the validity of the utility index against other characteristics of subjects. 
We tested its convergent validity, discriminative validity, responsiveness and 
predictive validity by comparing it with other self-rated measures of HRQL and with 
measures of physical function, cancer stage, treatment phase and subsequent 
survival. 
 
Convergent validity tests how closely a measure is associated with related measures 
[2, 166]. The convergent validity of the utility index was tested by Spearman rank 
correlation (rS) with the Spitzer-Uniscale, the SF-36 general health item, and scales 
from the Priestman and Baum LASAS questionnaire referred to above. We expected 
substantial correlations with the Spitzer-Uniscale and the SF-36 general health item. 
Three clinical experts made a priori hypothesis about the expected values of rS with 
the LASAS scales as: insignificant (< 0.3), moderate (0.3-0.44), substantial (0.45-
0.59), or high (> 0.6). Hypotheses were considered supported by the data if the 
observed rS were at least as high as the median of the experts’ expected rS. 
 
Discriminative validity tests how well a measure can distinguish between groups 
defined by an alternate criterion [28, 166]. The discriminative validity of the utility 
index was tested by its ability to detect cross-sectional differences between subjects 
with differing physical function as rated by their clinicians on the ECOG 
performance status scale referred to above. We also compared the discriminative 
ability of the UBQ-C overall HRQL index with that of the health status thermometer 
and the Spitzer-Uniscale. Differences between groups were evaluated with students t- 
test. 
 
Responsiveness tests the ability of a measure to detect clinically important change 
over time [28, 144]. The responsiveness of the utility index was tested by comparing 
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scores in the early cancer trial before, during and after chemotherapy using paired t-
tests. 
 
Predictive validity tests how closely a measure is associated with a subsequent 
outcome [2, 166]. The predictive validity of the utility index was tested by its ability 
to predict survival duration in the advanced cancer trial, based on the hypothesis that 
overall survival in advanced cancer should be associated with baseline HRQL [167-
171]. The strength of association between the utility index and survival duration was 
tested with the logrank test, by dichotomising subjects into a ‘poor HRQL’ group 
(utility index less than or equal to the median) and a ‘good HRQL’ group (utility 
index greater than the median). 
 
The optimised scoring algorithm was applied to inform a specific treatment 
comparison of high-dose versus standard-dose chemotherapy for high-risk early-
stage breast cancer using the data collected during chemotherapy from the early 
cancer trial. First, we compared scores on the utility index for participants allocated 
to each treatment arm using unpaired t-tests. Second, we used the index to reflect the 
relative importance of the effects of chemotherapy on different aspects of HRQL by 
comparing the weights allocated to each subscale. Third, we tested the hypothesis 
that the overall HRQL index compared with the health status thermometer would 
give an estimate of the difference in mean scores between treatment groups that was 
more precise but unbiased. The relative precisions of the related measures were 
compared using a measure called the relative efficiency statistic [138, 144]. The 
reciprocal of the relative efficiency statistic is the factor by which the sample size 
can be reduced when a more precise and therefore more efficient scale is used. The 
relative efficiency statistic was calculated as the squared ratio of the t-score for the 
index when comparing groups divided by the t-score for the related global measure 
when comparing groups. 
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6.4 Results 
6.4.1 Study profiles and patient characteristics 
The study profiles describing the subjects in each trial are shown in figures 3.3 and 
3.4 of chapter 3. For the advanced cancer trial, compliance was excellent with 
questionnaires completed by 95% of subjects who were expected to complete them. 
For the early cancer trial, compliance was not as good with questionnaires completed 
by 72% prior to chemotherapy, 40% during chemotherapy, and 88% after completing 
it. All items on each UBQ-C questionnaire except for ‘Sex life’ and ‘Other problems’ 
were completed by over 90% of subjects in both trials. Characteristics of the 421 
patients are shown in table 6.1. Data was obtained from patients with breast cancer of 
both early and advanced stages. All subjects were female and most age groups were 
represented. For the advanced cancer trial, most had good performance status (ECOG 
0 in 34% and ECOG 1 in 54%), and fewer had poor performance status (ECOG 2 in 
11% and ECOG 3 in 2%). Ratings of general health ranged from ‘Excellent’ to 
‘Poor’. 
 
Subjects’ ratings on the UBQ-C are summarised in table 6.2. At baseline, patients 
with advanced cancer reported worse health status than patients with early cancer as 
expected (means of 0.69 vs 0.81, difference 0.13 [with rounding], 95% CI 0.08 to 
0.17, p<0.0001). Patients with early cancer reported worse health status during 
chemotherapy than before starting it (means 0.68 vs 0.81, mean deterioration 0.13, 
95% CI 0.08 to 0.19, p<0.0001); or after finishing it (means 0.68 vs 0.84, mean 
improvement 0.15 [with rounding], 95% CI 0.10 to 0.21, p<0.0001). Similar 
differences were reported for ratings on UBQ-C subscales (table 6.2). 
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Table 6.1 Breast cancer trials: patient characteristics 
Dataset  Advanced cancer trial 
(n=325) 
 Early cancer trial 
(n=126) 
 
Cancer stage  Advanced   High-risk early-stage 
Cancer type (%) 
  Breast 
  
100 
  
100 
 
Gender (%) 
  Female 
  
100 
  
100 
 
Age (Years) (%) 
  < 40 
  40-49 
  50-59 
  60-69 
  ≥ 70 
  
2 
12 
29 
36 
21 
  
14 
47 
35 
3 
- 
 
Dataset  Advanced cancer trial  Early cancer trial  
Treatment phase  Before 
treatment 
(n=295) 
 Before 
treatment 
(n=91) 
During 
treatment 
(n=51) 
After 
treatment 
(n=111) 
General health (%) 
  Excellent 
  Very good* 
  Good 
  Fair 
  Poor 
  
6 
18 
30 
32 
13 
  
22 
- 
54 
19 
4 
 
6 
- 
40 
42 
12 
 
22 
- 
66 
9 
3 
       
* Response category ‘Very good’ not included in some versions of ‘General health’ item of UBQ-C 
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Table 6.2 Breast cancer trials: ratings on UBQ-C, overall HRQL index, and utility 
index 
Dataset Advanced cancer trial Early cancer trial 
Treatment phase Before 
treatment 
Before 
treatment 
During 
treatment 
After 
treatment 
 Mean SD Mean SD Mean SD Mean SD 
Health status thermometer 0.69 0.20 0.81 0.15 0.68 0.21 0.84 0.13 
UBQ-C subscales  
Physical function 
Social/usual activities 
Self-care 
Distresses 
 
0.53 
0.66 
0.89 
0.78 
 
0.32 
0.29 
0.20 
0.15 
 
0.77 
0.74 
0.89 
0.77 
 
0.21 
0.23 
0.15 
0.15 
 
0.63 
0.69 
0.97 
0.69 
 
0.24 
0.22 
0.10 
0.18 
 
0.80 
0.88 
0.99 
0.83 
 
0.20 
0.17 
0.06 
0.13 
Overall HRQL index 0.69 0.18 0.80 0.13 0.68 0.18 0.84 0.12 
Utility index 0.88 0.13 0.94 0.07 0.87 0.15 0.96 0.06 
 
SD, standard deviation. UBQ-C, Utility-Based Questionnaire-Cancer. HRQL, health-related quality of 
life. All ratings on scale from best (one) to worst (zero). 
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6.4.2 Optimised scoring algorithms 
The optimised index weights for the subset index (W), health status thermometer (1-
W), and subscales (W1-4) for each trial are shown in table 6.3. The weight assigned 
to the health status thermometer was similar for each trial and accounts for about 
two-thirds of the overall HRQL index. Of the subscales, greatest weight was given to 
distresses and least to self-care. The ordering of the weights assigned to the advanced 
cancer trial and early cancer trial were similar. Distresses were assigned the greatest 
weight, followed by social/usual activities, physical function, and self-care. However 
greater weight was assigned to distresses, and less weight to physical function and 
self-care, in women with early breast cancer than in women with advanced cancer. 
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Table 6.3 Breast cancer trials: weights for scoring algorithm 
  Weights 
  Advanced cancer trial Early cancer trial 
W1 
W2 
W3 
W4 
Physical function 
Social/usual activities 
Self-care 
Distresses 
0.20 
0.23 
0.04 
0.53 
0.09 
0.25 
0.01 
0.64 
1-W 
W 
Health status thermometer 
Subset index 
0.66 
0.34 
0.63 
0.37 
1-W, W, W1-4 refer to the weights assigned to the health status thermometer, subset index, and 
subscales in formulae [1] and [2] (see text, and figure 4.2 of chapter 4) 
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6.4.3 Validation 
Comparisons of the utility index with other characteristics of subjects supported its 
validity. 
 
The convergent validity of the utility index was supported by its substantial 
correlation with the SF-36 general health item in both trials (rS 0.74 in advanced and 
0.64 in early) and the Spitzer-Uniscale in advanced cancer (rS 0.71). There was also 
complete concordance of all expected and observed correlations of the utility index 
with the Priestman and Baum LASAS in the advanced cancer trial (data not shown). 
 
The discriminative validity of the utility index was supported by strong evidence that 
subjects with early breast cancer prior to starting chemotherapy had higher utilities 
than those with advanced breast cancer (mean difference 0.07 [with rounding], 95% 
CI 0.04 to 0.10, p<0.0001) (table 6.2). The discriminative validity of the utility index 
was also supported by its ability to distinguish subjects with differing performance 
status (PS) as rated by their clinicians in the advanced cancer trial (good performance 
status: mean 0.90, 95% CI 0.88 to 0.91; poor performance status: mean 0.73, 95% CI 
0.67 to 0.79; mean difference 0.17, 95% CI 0.12 to 0.21; p < 0.0001). 
 
The responsiveness of the utility index was supported by strong evidence that 
subjects with early breast cancer had higher utilities before starting chemotherapy 
than during it (mean difference 0.07, 95% CI 0.04 to 0.10; p<0.0001) (table 6.2). 
 
The predictive validity of the utility index was supported by its ability to predict 
survival duration in the advanced cancer trial when patients were divided into 
roughly equal-sized groups above and below the median score on the utility index 
(figure 6.1). There was strong evidence that subjects with worse scores on the utility 
index at baseline (< 0.92) had shorter survival than those with higher scores (median 
17 versus 23 months, log-rank p=0.005). 
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Figure 6.1 Advanced cancer trial: Kaplan-Meier plots for survival duration of 
subjects grouped by utility index 
 
osMonths, survival in months. Good HRQL, score on utility index < 0.92. Poor HRQL, score on 
utility index ≥ 0.92. 
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6.4.4 Treatment comparison 
The scoring algorithm was applied to the treatment comparison of high-dose 
chemotherapy versus standard-dose chemotherapy for early-stage breast cancer. 
Subjects receiving high-dose chemotherapy reported worse impairment of most 
specific aspects of HRQL (figure 6.2), which was expected because high-dose 
chemotherapy is more toxic in this setting [136]. There was a trend to better mean 
scores on the utility index for patients allocated to standard-dose chemotherapy 
(mean 0.95) compared to high-dose chemotherapy (mean 0.92) with mean difference 
of -0.03 (95% CI -0.07 to 0.01, p = 0.10). The overall HRQL index gave stronger 
evidence of this effect (mean difference -0.07, 95% CI -0.13 to -0.01, t=2.36, p = 
0.02) than the health status thermometer (mean difference -0.06, 95% CI -0.12 to 
0.01, t=1.72, p = 0.09) (figure 6.2). The relative efficiency of the overall HRQL 
index compared with the health status thermometer was 1.9. In this practical 
illustration, the improvement in precision by using the overall HRQL index 
compared to the health status thermometer was sufficient to conclude that the more 
toxic regimen causes significantly worse effects on overall HRQL. 
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Figure 6.2 Early cancer trial: differences in HRQL between treatment groups, based 
on: (i) UBQ-C items, (ii) UBQ-C subscales, (iii) health status thermometer, (iv) 
overall HRQL index, (v) utility index 
 
HRQL, Health-related quality of life. All ratings on scale from 0 to 1. 
Overall HRQL index
Health status 
thermometer
Distresses
Self-care
Social/usual activities
Physical function
UBQ-C SUBSCALES 
Sleeping problems
Nausea
Fatigue
Pain
Concern about 
appearance
Dependence on others
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Lack of concentration
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OVERALL HRQL 
Utility index
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6.5 Discussion 
We have applied a scoring algorithm for a cancer-specific utility-based instrument to 
clinical trial datasets and illustrated how it can be optimised in different clinical 
contexts. The algorithm converts ratings from a cancer-specific questionnaire for 
HRQL into a utility index that is based on the perspective of cancer patients. First, 
we optimised the scoring algorithm in two different clinical contexts for breast 
cancer by adjusting the index weights using data from two clinical trials. Second, we 
applied the algorithm to generate utility scores. Third, we showed that the utility 
index had convergent validity with related scales from other instruments, 
discriminative validity between participants with differing performance status, 
responsiveness to toxic effects of chemotherapy in early cancer, and predictive 
validity about subsequent survival duration. Fourth, we used the utility index to 
inform a treatment comparison of high-dose chemotherapy with stem cell support 
versus standard-dose chemotherapy for high-risk early-stage breast cancer. It can be 
used to generate sensitive and responsive utility scores, and quality-adjusted life-
years, that can be used within a trial to compare the net benefit of treatments and 
inform clinical decision-making. 
 
The novelty of the approach described in this paper is that the scoring algorithm can 
be optimised for different clinical contexts. In contrast, most scoring algorithms for 
utility-based instruments use the same scoring algorithm across different diseases 
and treatments [9, 16] [103, 106-107]. The algorithm is optimised by giving 
additional weight to the subscales about specific aspects of HRQL that are most 
closely associated with a single-item global scale (the health status thermometer) in 
the relevant dataset. The reason to optimise the algorithm in different contexts is to 
reflect variations in patients’ attitudes, preferences and priorities across different 
cancer types, stages, and treatments [32, 63]. 
 
The primary benefit of optimising the scoring algorithm for each clinical context is 
that it should better reflect the perspective of the individuals in that situation. For 
example, in the comparison of high-dose versus standard-dose chemotherapy for 
early-stage breast cancer (figure 6.2), there were large differences in distresses and 
physical function but little or no difference in self-care. Combinations of the 
 127
subscales giving greater weight to self-care would yield little difference between 
high-dose and standard-dose chemotherapy, whereas those giving greater weight to 
distresses and physical function would favour standard-dose chemotherapy. We 
assigned weight according to correlations with the health status thermometer, 
resulting in significant differences between treatments on the indices for overall 
HRQL and utility which should reflect the preferences and attitudes of the women in 
the trial. 
 
Optimising the scoring algorithm could give more precise estimates of clinically 
important differences in utility between patient groups, because the index is focussed 
on those aspects of HRQL that are most relevant to those patients. A more precise 
utility index will reduce the uncertainty around the incremental effectiveness of 
treatments in sensitivity analyses, because it is more responsive to small but 
meaningful effects of cancer treatments [172]. A more precise utility index will also 
reduce the sample size required to detect a given difference with a given level of 
precision [172]. 
 
Another benefit of optimising the scoring algorithm for each clinical context is that 
the ordering of the weights can inform clinicians and researchers about the 
importance of various symptoms, side effects and dysfunctions that patients in 
different clinical contexts most wish to avoid. For example, in both datasets we 
found that greatest weight was given to distresses, followed by social/usual activities, 
physical function and self-care (table 6.3). The ordering of the weights assigned to 
each subscale may be related to several factors. The large weight assigned to 
distresses may reflect the emotional distress that most patients experienced due to 
having cancer, the physical symptoms of advanced cancer, and the side effects of 
toxic chemotherapy for early-stage cancer. The low weight assigned to self-care may 
reflect the lack of problems with self-care that most patients reported in each trial. 
The ordering of the weights may also reflect the number of items within each 
subscale, with distresses (21 items) assigned greater weight than physical function (3 
items), social/usual activities (4 items) or self-care (1 item). There were some 
differences in weights between datasets. Greater weight was assigned to distresses 
and less weight was assigned to physical function for early cancer compared with 
advanced cancer (table 3). The greater weight assigned to distresses for patients with 
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early cancer may reflect their greater emotional distress due to a recent diagnosis of 
cancer, and their experience of side effects from chemotherapy which had not yet 
been administered to the patients with advanced cancer. The lower weight assigned 
to physical function for patients with early cancer is probably explained by the 
absence of the deterioration in physical function that occurs with advanced cancer. 
This information can be used by researchers to design more targeted interventions to 
improve HRQL in the dimensions of greatest importance to patients, and by all 
health care workers to improve counselling of patients [63]. 
 
We recommend that the scoring algorithm is optimised for each clinical context in 
which it is used. This is a potential limitation in that it requires additional analyses, 
and familiarity with Lumley’s method. Another limitation is that the utility scores 
may not be comparable from one disease or treatment context to another, because the 
scoring algorithm and its index weights cannot be standardised across trials [32]. 
Consequently we recommend that our approach is used to compare treatments in the 
context of a trial in a well-defined population for a specific clinical condition, 
because the attitudes of patients are likely to be more similar. It is less suited to 
studies that include diverse populations, or for comparing utilities and quality-
adjusted life-years from one study or context to another, because the attitudes of 
patients will be more diverse. Comparability of utility scores is a key requirement 
when utilities are used to inform economic decisions, because health funders and 
policy makers make decisions across diseases and contexts [9, 108]. However 
comparability of utility scores is less important when utilities are used to inform 
clinical decisions, because a clinical decision is always limited to a single disease 
type and stage. The requirements of utility scores used to inform clinical decisions 
are that they reflect the experiences of the patients under study, and are valid, 
sensitive and reliable.  
 
The measurement properties of the utility index reported in this paper support its 
validity as a measure of HRQL for the clinical context of chemotherapy for early and 
advanced breast cancer. The utility index had convergent validity with independent 
scales of general health and global quality of life, was able to discriminate patients 
with different stages of cancer, and was responsive to changes attributable to having 
chemotherapy. Another way to validate a utility index is to compare the scores 
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derived by the utility index with utilities elicited directly from the same patients with 
a time trade-off interview. This could be performed in future studies. 
  
Future research is also needed to determine whether optimisation of the scoring 
algorithm for each context makes a meaningful difference to the utility scores and 
QALYs generated from the utility index, their sensitivity and responsiveness to 
detect differences between treatment groups, and most importantly to the outcome of 
clinical decisions in specific clinical contexts. 
 
Finally, it is important to comment on the strengths and limitations of the datasets 
used in this study. Patients participating in a clinical trial of treatments are the ideal 
source of information about the effects of those treatments on HRQL. The datasets 
included patients with early and advanced cancer, before, during and after 
chemotherapy. Compliance was good with questionnaire completion, particularly for 
the advanced cancer trial. We used validated cancer-specific questionnaires that 
included a broad range of items about specific aspects of HRQL that are commonly 
affected by cancer and side-effects of treatment. A limitation of the datasets is that 
they only included women in Australia and New Zealand with breast cancer 
receiving chemotherapy, so the results may not be applicable to other cancer types or 
treatments, other countries and men. Further application and validation of the utility 
index is ongoing in other clinical contexts including chemotherapy for advanced 
colorectal cancer and hormonal therapy for the prevention of breast cancer [126, 
150]. The colorectal study includes British and male subjects. Compliance with 
completing questionnaires in the early cancer trial was poor during chemotherapy. 
Patients who do not complete questionnaires tend to have worse HRQL [137], so the 
analyses may underestimate the detrimental effects of treatment on HRQL. Finally, 
the early cancer trial is relatively old so the effects of chemotherapy may be different 
to that with more modern treatments. However the primary purpose of generating 
utility scores in this study was to illustrate the approach, rather than to inform clinical 
or health policy decisions. 
 
Our approach enables HRQL data obtained with a simple questionnaire to be 
converted into utility scores by using an optimised scoring algorithm that reflects the 
perspective of the cancer patients under study. The approach is flexible and 
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applicable to other trials and other HRQL instruments. Generation of utility scores 
based on HRQL data collected within a clinical trial provides an ideal source of 
information to inform clinical decisions, and to add a useful additional perspective to 
inform health policy and economic decisions. 
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7.  Comparing treatments in a randomised trial 
7.1 Overview 
This chapter further develops the scoring algorithm that was derived in chapter 5, 
applies it to data from a randomised controlled trial of chemotherapy for advanced 
breast cancer, and uses the results to evaluate the differences in overall HRQL and 
utility between subjects allocated to each treatment group in the trial. The analyses 
required two extensions to the previously described scoring algorithm. First, 
additional information about HRQL relevant to the treatment comparison was 
incorporated in the indices. Second, a method for deriving index weights for the 
scoring algorithm from longitudinal data was developed. The approach developed in 
this thesis was shown to be feasible for use in clinical trial evaluation, and adaptable 
to the incorporation of additional information about HRQL. The index gave a more 
precise estimate of differences between groups compared to a single-item global 
scale. Trends in scores for overall HRQL during treatment favoured the oral 
chemotherapy regimen tested in the trial, but the differences were not statistically 
significant. The scores on the utility index are being used to evaluate quality-adjusted 
time to progression, which is the primary endpoint for the trial. 
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7.2 Introduction 
The previous three chapters described the development and validation of a scoring 
algorithm that converts responses to a cancer-specific HRQL questionnaire called the 
Utility-Based Questionnaire-Cancer (UBQ-C) into valid and precise indices of 
overall HRQL and utility. The indices are optimally weighted to reflect the relative 
importance of differing aspects of HRQL to patients, and express the desirability of 
cancer health states from the perspective of cancer patients. The scoring algorithm 
facilitates the evaluation and comparison of the net effect of cancer treatments tested 
in clinical trials in terms of overall HRQL and utility, and in terms of quality-
adjusted survival by combining utilities and survival data. 
 
The scoring algorithm developed in chapter 5 needed further development before it 
could be applied to the evaluation of a clinical trial. One limitation of the current 
scoring algorithm is that the indices of overall HRQL and utility may not incorporate 
relevant and potentially important information about particular aspects of HRQL that 
are likely to differ between specific study treatments. For example, it would be 
desirable to incorporate information about the convenience and acceptability of 
tablets versus injections in a trial of oral versus intravenous chemotherapy for 
advanced cancer. Another limitation of the current scoring algorithm is that the 
regression methods used to derive weights for the indices rely on the assumption that 
all the observations are independent of one another. It is valid to apply these 
regression methods to cross-sectional data (as in chapters 5 and 6), because the 
observations come from different patients so are independent. However the 
regression methods may give biased results when applied to longitudinal data that is 
obtained during a clinical trial, because successive measurements within a given 
patient are correlated but not independent. 
 
The primary aim of the work reported in this chapter was to further develop and 
apply the scoring algorithm derived in chapter 5, to facilitate evaluation of a 
randomised controlled trial of treatments for advanced breast cancer that was 
described in chapter 3 (section 3.5.2). The scoring algorithm was made more relevant 
for the specific treatment comparison by incorporating additional information about 
the expected side effects of the treatments in the indices of overall HRQL and utility. 
 133
The scoring algorithm was extended so that it could be applied to longitudinal 
datasets obtained during clinical trials. The secondary aim of this chapter was to 
compare the scores for overall HRQL and utility in each treatment group during 
treatment. This comparison would determine which treatment is preferable in terms 
of overall HRQL, and provide utility values for the planned evaluation of the trial 
using quality-adjusted survival analyses. 
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7.3 Methods 
7.3.1 Clinical trial design 
The specific clinical trial evaluated in this chapter was the advanced cancer trial that 
was described in chapter 3 (section 3.5.2), and for which baseline data was analysed 
in chapter 6. To recap, this was a randomised controlled trial conducted by the 
Australia New Zealand Breast Cancer Trials Group (ANZBCTG) that compared two 
types of chemotherapy for women with advanced breast cancer. Eligibility criteria 
were reported in chapter 3 (section 3.5.2). 
 
 The intervention group received chemotherapy with capecitabine, which is a newer 
drug that has the advantage of oral administration. Patients take 2000mg/m2 (about 6 
to 8 tablets) administered orally for the first 14 days of each 21-day treatment cycle, 
or 1300 mg/m2 (about 4 to 6 tablets) administered for all 21 days of each 21-day 
treatment cycle. Side effects are typically mild or moderate, but severe toxicity 
occurs in about 10% of patients. 
 
The control group received chemotherapy with ‘CMF’, which is a traditional 
combination of intravenous and oral drugs that has been in use since the 1970s. The 
use of CMF has declined over the last ten years, as its administration is more 
complex than competing newer regimens and requires intravenous administration. 
Patients receive intravenous chemotherapy with methotrexate 40 mg/m2 and 5-
fluouracil 600 mg/m2 on days 1 and 8, and oral cyclophosphamide 100mg/m2 (about 
3 to 4 tablets) for the first 14 days, of each 28-day treatment cycle. Side effects are 
different to capecitabine. They are also usually mild to moderate in severity, but 
severe in about 10% of patients. 
 
Treatment was continued until disease progression, unacceptable toxicity, or 
intolerance. Time to progression was measured by clinical assessments every three to 
four weeks and imaging (computed tomography and bone scan) every 12 weeks. The 
schedule for assessment of HRQL is outlined in the next section. 
 
The aim of the trial was to determine which chemotherapy regimen was preferable. It 
was hypothesised that capecitabine would be superior to CMF because of equivalent 
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or better tumour control, more convenient oral administration, and less troublesome 
side effects of treatment. The primary objective of the trial was to compare 
capecitabine with CMF in terms of quality-adjusted time to progression. This 
summary measure integrates improvements in HRQL due to relief of cancer 
symptoms, detriments in HRQL due to the side effects and inconvenience of 
treatment, and improvements in tumour control. It is potentially helpful as a measure 
of the net benefit of treatment that could assist patients and clinicians deciding 
between treatment options. Quality-adjusted time to progression is expressed in 
quality-adjusted life-years. It is calculated by applying standard quality-adjusted 
survival methods to HRQL data (expressed as a utility) and time to progression data 
(expressed in years) [75, 173]. The need to obtain utility data for this trial motivated 
the development and application of the scoring algorithm described in this thesis. 
7.3.2 HRQL assessment 
Subjects completed HRQL questionnaires prior to randomisation, then every three to 
four weeks until disease progression. This was done on day one of each treatment 
cycle (or up to seven days before) for subjects who were receiving study 
chemotherapy, and every four weeks for subjects who were no longer receiving study 
chemotherapy. HRQL questionnaires were not completed after disease progression. 
‘During treatment’ was defined as from the day after randomisation until 30 days 
after disease progression. 
 
The questionnaires that subjects completed were the UBQ-C, Chemotherapy 
Acceptability Questionnaire, and other questionnaires that were described in detail in 
chapter 3 (sections 3.2 and 3.3) and replicated in appendices 1 and 2. Only ratings on 
the UBQ-C and Chemotherapy Acceptability Questionnaire were used for analyses 
in this chapter. To recap, the UBQ-C is a validated, disease-specific HRQL 
questionnaire that includes 29 items grouped into four multi-item subscales about 
specific aspects of HRQL, and a global scale called the health status thermometer 
which is a single item that asks respondents for a unified assessment of their health 
status. The scores for the subscales are the simple average of the items, linearly 
transformed to a scale from 0 (worst) to 1 (best). The Chemotherapy Acceptability 
Questionnaire is a study-specific subscale that was designed to supplement the UBQ-
C for this trial. It includes 15 items about the inconvenience and additional specific 
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side effects that were not assessed by existing instruments but were expected to occur 
with capecitabine or CMF. The score for the Chemotherapy Acceptability 
Questionnaire subscale, which will be referred to as ‘chemotherapy acceptability’, is 
the simple average of the items, linearly transformed to a scale from 0 (worst) to 1 
(best). 
7.3.3 Further development of the scoring algorithm 
This section reports how the scoring algorithm based on Lumley’s approach [32] and 
derived in chapter 5 was extended to incorporate additional aspects of HRQL, and to 
be applied to longitudinal data. 
Extending the scoring algorithm 
The scoring algorithm was extended by incorporating the Chemotherapy 
Acceptability Questionnaire subscale, because it contributed additional information 
about aspects of HRQL that were expected to differ between treatment groups. The 
resultant indices were derived from a weighted combination of the health status 
thermometer, the four multi-item subscales of the UBQ-C, and the chemotherapy 
acceptability subscale (figure 7.1). The indices are referred to as the ‘UBQ-C/CAQ 
subset index’, ‘UBQ-C/CAQ overall HRQL index’ and ‘UBQ-C/CAQ utility index’ 
in the tables and figure of this chapter. 
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Figure 7.1 Deriving a utility index for the UBQ-C and CAQ questionnaires 
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UBQ-C, Utility-Based Questionnaire-Cancer. CAQ, Chemotherapy Acceptability Questionnaire. 
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Deriving subset index weights for longitudinal data 
A subset index was derived from a weighted combination of the subscales of the 
UBQ-C and Chemotherapy Acceptability Questionnaire. Optimal weights (W1-5) 
were derived using ratings on the relevant subscales and the health status 
thermometer from the advanced cancer trial (figure 7.1). Analogous to the approach 
presented in chapters 5 and 6, the weights for the subscales of the UBQ-C and 
Chemotherapy Acceptability Questionnaire (W1 to W5 in figure 7.1) are designed to 
reflect the relative contribution of each subscale to overall HRQL, and were derived 
by giving additional weight to subscales that are more closely associated with the 
health status thermometer. 
 
For the cross-sectional data analysed in chapters 5 and 6, there was one set of 
observations for each individual, and the weights reflected differences in the 
associations between people at one point in time. For the longitudinal data analysed 
in this chapter, there were multiple sets of observations for each individual, at 
multiple time points; so the weights should reflect the differences in the associations 
both between people and within each person over time. 
 
Weights for cross-sectional data can be determined with simple multivariable linear 
regression methods, because the observations in different patients are independent. 
Weights for longitudinal data cannot be determined with simple multivariable linear 
regression, because successive observations within a given individual are correlated, 
not independent. Specifically, the observation on one occasion will give information 
about the observations on subsequent occasions. To analyse a series of such 
observations with simple linear regression as if they were independent may bias the 
magnitude and variance of the regression coefficients used to derive the weights 
[138]. 
 
There is no standard method to derive weights for longitudinal data using Lumley’s 
approach [32], so the weights were derived using three different methods with 
varying levels of complexity: an ‘optimal method’, an ‘uncorrelated method’ and a 
‘baseline method’. The optimal method that will be described is valid for the analysis 
of longitudinal data because it avoids the problem of correlations between successive 
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measurements on a given individual. Because the optimal method is complex, in 
sensitivity analyses the weights were derived with two alternate methods: a simpler 
uncorrelated method that ignored the links between successive observations on a 
patient; and a baseline method that only used the cross-sectional data obtained at 
baseline. If the simpler methods gave similar weights, then they may be an 
appropriate alternative for future applications. 
 
The optimal method is an adaptation of validated methods outlined by Sheppard and 
colleagues for the analysis of longitudinal data in an epidemiological context [174-
175]. It avoids the problem of the correlation between successive measurements on a 
given individual by partitioning the association between the subscales and the health 
status thermometer into two components: First, the extent to which the differences 
between people in their subscale scores are reflected in the differences between 
people in their health status thermometer scores (as in chapter 5 and 6). Second, the 
extent to which the changes over time within each person in their subscale scores are 
reflected in the changes over time within each person in the health status 
thermometer scores (not in chapter 5 or 6). 
 
The between-people and within-person associations were partitioned using Sheppard 
et al’s approach. For each subscale, if we express the subscale score for the ith person 
at the tth timepoint as Xit, then the average personal subscale score for the ith person 
over all timepoints is iX , and the within-person deviation from the average personal 
subscale score over time for the ith person at the tth timepoint is ( )iit XX − . iX is 
used to determine the associations between people, and ( )iit XX −  is used to 
determine the associations within each person over time. 
 
Multivariable ordinary least squares regression was performed. The dependent 
variable was the health status thermometer. The ten independent variables were 
iX for each subscale, and ( )iit XX −  for each subscale. The between-people weight 
for each subscale was proportional to the regression coefficient of iX for the 
corresponding subscale. The within-person weight for each subscale was 
proportional to the regression coefficient of ( )iit XX −  for the corresponding 
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subscale. The weight (W1 to W5) for each subscale was proportional to the sum of 
the within-person weight and between-person weight for the corresponding subscale. 
The subset index scores were then calculated by applying these weights to the 
subscale scores as follows: 
 
[1] Subset index = [W1 * PF] + [W2 * SA] + [W3 * SC] + [W4 * DI] + [W5 * CAQ] 
W1-5 are the weights for the subscales, PF is physical function, SA 
is social/usual activities, SC is self-care, DI is distresses, CAQ is 
chemotherapy acceptability. 
 
In sensitivity analysis, the subset index weights that were derived with the optimal 
method were compared to weights derived with the two alternate methods that are 
simpler but potentially biased. The first was the uncorrelated method which ignored 
the link between successive measurements on a given individual. Multivariable 
ordinary least squares regression was performed using all data at baseline and during 
treatment. The dependent variable was the health status thermometer. The five 
independent variables were the five subscales. The weight for each subscale (W1-5) 
was proportional to the regression coefficient for the corresponding subscale. The 
advantage of the ‘uncorrelated’ method is that it is much simpler. The disadvantage 
is that the weights may be incorrect because the magnitude and variance of the 
regression coefficients may be biased. 
 
The second alternate method was the baseline method that only analysed the cross-
sectional data that was collected at baseline. The method described in chapter 5 was 
applied. Data collected during treatment was not used for this analysis. The 
advantage of this approach is that it is simple and statistically valid. The 
disadvantage is that the weights may be incorrect if the associations within subjects 
over time differ from the associations between subjects at baseline. This could 
conceivably occur if side effects that occur during treatment but are absent at 
baseline but adversely affect overall HRQL. 
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Deriving overall HRQL index weights 
An overall HRQL index was derived by combining the subset index with the health 
status thermometer. The weights and the index were calculated using the formula [2] 
below, and the weights were applied to calculate an overall HRQL index for each 
participant at each time point using formula [3] below, as described in chapter 5: 
 
[2] W = Var(T) * [ 1 – r(T) ] / MSE(R). 
[3] Overall HRQL index = [ W * Subset index ] + [ (1 – W ) * HST ] 
W is the weight allocated to the subset index, so 1 – W is the 
weight allocated to the health status thermometer. Var(T) is the 
variance of the health status thermometer in the dataset. r(T) is the 
intraclass correlation coefficient of the health status thermometer, 
and was calculated with test-retest data from a previous validation 
study [13]. MSE(R) is the mean square for error from the 
multivariable ordinary least squares regression referred to above.  
Transforming the overall HRQL index to the utility index 
The transformation function derived in chapter 5 was applied to calculate a utility 
index from the overall HRQL index for each participant at each time point, as 
follows: 
[4] Utility index = 1 – (1-overall HRQL index)2.03.  
7.3.4 Comparing ratings between treatment groups 
Baseline 
The comparison of baseline HRQL ratings between treatment groups was important 
in this clinical trial. Because of random allocation, baseline ratings on the health 
status thermometer, subscales, and indices of overall HRQL and utility were 
expected to be similar in each treatment group. However any clinically important 
imbalances between treatment groups at baseline suggest that they are dissimilar, and 
could confound the interpretation of the results [176]. Differences were considered to 
be potentially clinically important when the absolute difference in mean scores was 
greater than 0.05 on a scale from 0 to 1, consistent with recommendations from 
others as to the magnitude of a clinically meaningful difference [176]. Because any 
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imbalances can be attributed to chance, it was not appropriate to compare ratings 
using statistical tests. 
During treatment 
To compare HRQL between treatment groups during treatment, the mean ratings 
during treatment of subjects allocated to capecitabine and CMF on the health status 
thermometer, subscales, and indices of overall HRQL and utility were compared 
using generalised estimating equations that took into account the correlation between 
the successive observations for each participant [138, 177]. Differences were 
considered to be statistically significant when the p-value was < 0.05. In the primary 
analysis, the mean ratings during treatment were adjusted for baseline data where it 
was available, because this accounts for chance imbalances in HRQL between 
treatment groups at baseline. Because there is uncertainty about the desirability of 
adjusting for baseline data in HRQL evaluation of clinical trials [178-179], the effect 
of not adjusting for baseline data was tested in a sensitivity analysis. 
7.3.5 Evaluating the precision of the overall HRQL index 
A feature of the scoring algorithm described in this thesis is that the overall HRQL 
index compared with the health status thermometer should give an estimate of the 
differences in mean scores between subjects in each treatment group that is more 
precise (narrower confidence intervals) but unbiased (similar point estimates). This 
hypothesis was tested in two related ways. First, the magnitudes of the standard 
errors of the health status thermometer and of the overall HRQL index for the 
differences between treatment groups during treatment were compared. A more 
precise scale will have a smaller standard error, and correspondingly narrower 
confidence intervals [138]. Second, the relative precision of each measure was 
compared using the relative efficiency statistic. As described in chapter 5, the 
relative efficiency statistic is the factor by which the sample size can be reduced 
when the more precise and efficient scale is used [138, 144]. The relative efficiency 
statistic was calculated as the squared ratio of the z-score of the overall HRQL index 
and the z-score of the health status thermometer for the difference between treatment 
groups during treatment. 
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7.4 Results 
7.4.1 Study profile and patient characteristics 
The study profile and patient characteristics were presented in detail in chapter 3 
(sections 3.5.2 and 3.6). Of the 325 patients that were enrolled, 216 subjects were 
allocated to capecitabine, and 109 subjects were allocated to CMF. Two subjects 
were excluded from the primary analysis reported elsewhere [124], because one did 
not have breast cancer and one received a precluded study drug, but all subjects were 
included in the analyses reported in this chapter. 
 
Compliance with completion of forms was excellent (figure 3.3 of chapter 3). The 
UBQ-C was completed at baseline (prior to randomisation) by 295 of 311 subjects 
who were expected to complete it (96%). The UBQ-C was completed 3227 times 
during treatment by 299 of 311 subjects who were expected to complete it (96%). 16 
completed it once, 66 completed it two to four times, 95 completed it five to nine 
times, and 122 competed it ten or more times. Compliance with form completion was 
similar for subjects allocated to capecitabine or CMF.  
7.4.2 Ratings on the UBQ-C and Chemotherapy Acceptability 
Questionnaire 
Subjects’ mean ratings on the UBQ-C and Chemotherapy Acceptability 
Questionnaire for each treatment group at baseline are shown in table 7.1. Mean 
scores at baseline were similar between treatment groups for physical function, 
social/usual activities, and chemotherapy acceptability. This was expected because of 
randomisation. Mean scores at baseline were marginally better for subjects allocated 
to CMF than those allocated to capecitabine for the health status thermometer and 
distresses. The effect of this small chance imbalance on ratings during treatment was 
tested in the next section. 
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Table 7.1 Advanced cancer trial at baseline: ratings by treatment group 
Treatment arm Capecitabine  CMF     
 Mean SD  Mean SD  Mean difference  95% CI 
Health status thermometer 0.68 0.20  0.71 0.18  0.03  -0.02, 0.07 
UBQ-C, CAQ subscales 
Physical function 
Social/usual activities 
Self-care 
Distresses 
Chemotherapy acceptability 
 
0.53 
0.66 
0.89 
0.78 
0.90 
 
0.32 
0.28 
0.20 
0.16 
0.10 
  
0.54 
0.66 
0.88 
0.80 
0.91 
 
0.34 
0.31 
0.22 
0.14 
0.10 
  
0.01 
-0.01 
-0.01 
0.02 
0.01 
  
-0.07, 0.09 
-0.08, 0.06 
-0.06, 0.04 
-0.02, 0.06 
-0.02, 0.03 
Derived indices 
UBQ-C/CAQ subset index 
UBQ-C/CAQ overall HRQL index 
UBQ-C/CAQ utility index 
 
0.78 
0.72 
0.89 
 
0.15 
0.17 
0.12 
  
0.79 
0.74 
0.91 
 
0.15 
0.16 
0.09 
  
0.01 
0.02 
0.02 
  
-0.03, 0.05 
-0.02, 0.06 
-0.01, 0.04 
CMF, cyclophosphamide, methotrexate and 5-fluorouracil. SD, Standard deviation. 95% CI, 95% 
confidence intervals. UBQ-C, Utility-Based Questionnaire-Cancer. CAQ, Chemotherapy 
Acceptability Questionnaire. HRQL, heath-related quality of life. All ratings on scale from best (one) 
to worst (zero). 
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Subjects’ mean ratings on the UBQ-C and Chemotherapy Acceptability 
Questionnaire for each treatment group during treatment, adjusted for baseline, are 
shown in table 7.2. Subjects in both treatment groups reported worst impairment for 
physical function, and least impairment for self-care compared with other subscales. 
Mean ratings were significantly better for capecitabine than CMF for the distresses 
subscale (p=0.0003). Mean ratings were similar for capecitabine and CMF for 
subscales about physical function, social and usual activities, and chemotherapy 
acceptability (p > 0.2). 
 
The results of a sensitivity analysis, whereby subjects’ mean ratings on the UBQ-C 
and Chemotherapy Acceptability Questionnaire for each treatment group during 
treatment were not adjusted for baseline values, are shown in table 7.3. The 
unadjusted mean ratings on each subscale and index were generally about 0.04 lower 
than the adjusted mean ratings. The point estimate of the differences in mean ratings 
between treatment groups on each subscale and index was shifted by about 0.02 in 
favour of CMF. As a result, the differences for distresses were no longer statistically 
significant (p=0.12), and the trend to better mean ratings on capecitabine for other 
subscales were no longer apparent. 
 
 146 
Table 7.2 Advanced cancer trial during treatment: ratings by treatment group (adjusted for baseline) 
Figure shows mean difference between treatment groups and 95% confidence intervals. Abbreviations overleaf. 
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Table 7.3 Advanced cancer trial during treatment: ratings by treatment group (without adjustment for baseline) 
Figure shows mean difference between treatment groups and 95% confidence intervals. Abbreviations overleaf. 
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Legend for tables 7.2 and 7.3  
CMF, cyclophosphamide, methotrexate and 5-fluorouracil. Cap, capecitabine. UBQ-
C, Utility-Based Questionnaire-Cancer. CAQ, Chemotherapy Acceptability 
Questionnaire. HRQL, heath-related quality of life. All ratings on scale from best 
(one) to worst (zero). 
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7.4.3 Weights for health status thermometer, subscales and subset index 
The weights assigned to the health status thermometer, subscales and subset index 
with the optimal, uncorrelated and baseline methods are shown in table 7.4. For the 
optimal method, greatest weight was given to the distresses subscale, and least 
weight was given to the self-care subscale. Therefore distresses were most strongly 
associated with health status, and self-care was least strongly associated with health 
status. The between-people weights (sum 56%) were slightly greater than the within-
person weights (sum 44%). Therefore the differences in subscale ratings between 
people explained slightly more of the variation in health status than the differences in 
subscale ratings within each individual over time. The weights derived with the 
‘optimal’ and ‘uncorrelated’ methods were almost identical. The ‘baseline’ method 
assigned slightly higher weights to the health status thermometer and subscale for 
physical function, and lower weights to self-care and distresses. This means that self-
care and distresses were more strongly associated with the health status thermometer 
during the treatment phase than at baseline. 
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Table 7.4 Advanced cancer trial during treatment: weights for scoring algorithm 
   Optimal 
method 
  Uncorrelated 
method 
 Baseline 
method 
  Between-
people 
weights 
Within-
person 
weights 
Weight  Weight  Weight 
W1 
W2 
W3 
W4 
W5 
Physical function 
Social/usual activities 
Self-care 
Distresses 
Chemotherapy acceptability 
0.06 
0.08 
0.04 
0.18 
0.19 
0.03 
0.06 
0.02 
0.24 
0.08 
0.10 
0.15 
0.07 
0.42 
0.27 
 0.11 
0.15 
0.07 
0.44 
0.24 
 0.18 
0.15 
0.02 
0.39 
0.26 
W 
1-W 
Health status thermometer 
Subset Index 
  0.61 
0.39 
 0.61 
0.39 
 0.66 
0.34 
1-W, W, W1-5 refer to the weights assigned to the health status thermometer, subset index, and 
subscales in formulae [1] and [2] (see text of section 7.3.3, and figure 7.1) 
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7.4.4 Treatment comparison 
Subjects’ mean scores on the overall HRQL index and utility index for each 
treatment group at baseline were shown in table 7.1 above. Mean scores at baseline 
were marginally better for both indices amongst subjects allocated to CMF than 
those allocated to capecitabine. The effect of this small chance imbalance on ratings 
during treatment was tested in the next section. 
 
Mean scores on the overall HRQL index and utility index for each treatment group 
during treatment, adjusted for baseline, were shown in table 7.2 above. There was 
only a weak trend to better ratings for those allocated capecitabine than those 
allocated CMF for the overall HRQL index (p = 0.2) and the utility index (p=0.22). 
The mean rating for the utility index for those allocated capecitabine was 0.93 (95% 
CI 0.92 to 0.94), and for those allocated CMF was 0.92 (95% CI 0.91 to 0.93).  
 
The results of a sensitivity analysis, where subjects’ scores during treatment were not 
adjusted for baseline values, were shown in table 7.3 above. The point estimate of the 
differences between treatment groups on each index were shifted slightly in favour of 
CMF. As a result, the trend to better mean scores on capecitabine for the overall 
HRQL index was no longer apparent. 
 
7.4.5 Comparing precisions of the overall HRQL index and health status 
thermometer 
The overall HRQL index estimated the difference in mean scores more precisely than 
the health status thermometer by two measures. First, the standard error was smaller: 
0.012 versus 0.015. This is illustrated by the narrower confidence intervals for the 
overall HRQL index than the health status thermometer in tables 7.2 and 7.3. Second, 
the relative efficiency statistic derived from the z-scores for the health status 
thermometer (of 0.65) and the overall HRQL index (of 1.28) was 3.9. As outlined in 
chapter 5, a relative efficiency statistic of 3.9 corresponds to a 74% reduction in the 
sample size needed to detect a significant difference between treatment groups by 
using the overall HRQL index, rather than the health status thermometer. 
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7.5 Discussion 
In this chapter, the scoring algorithm that was developed in chapter 5 was extended 
by incorporating relevant information about the acceptability and convenience of 
treatment to subjects in a randomised trial comparing oral and intravenous 
chemotherapy for advanced breast cancer, and further developed so that it could be 
applied to the longitudinal data obtained during the trial. Average overall HRQL and 
utility of subjects allocated to the two chemotherapy regimens was compared. 
Differences between treatment groups were found in some aspects of HRQL but not 
others, which were reflected in the small differences between treatment groups for 
the indices of overall HRQL and utility. This was consistent with other global 
measures that found no statistically significant difference between treatment groups 
[124]. Consistent with findings in chapter 5, the derived overall HRQL index 
compared to the single-item health status thermometer gave an estimate of 
differences between treatment groups that was more precise but unbiased. 
 
The key development of the scoring algorithm in this chapter was the derivation of a 
method to derive optimal index weights from longitudinal data. The indices of 
overall HRQL and utility give additional weight to subscales that are more closely 
associated with the health status thermometer. They reflect differences between 
people at baseline, differences between people during treatment, and changes within 
each person over time. It can be argued that the associations within each person over 
time are the most relevant and important, because this variation reflects the effects of 
cancer and its treatment on the HRQL of each patient. It was uncertain if the 
associations within each person over time would be similar or different to the 
associations between people at baseline and between people during treatment. 
Application of the optimal method demonstrated that each of these associations were 
quite similar. The uncorrelated method of deriving index weights is not statistically 
valid, but is simpler and gave similar weights. If the weights are similar in future 
applications then the uncorrelated approach could be recommended as the standard 
approach in preference to the more complex optimal method. The baseline method 
gave slightly different weights, which implies that the aspects of HRQL that were 
most important to health status were not the same at baseline as during treatment. 
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Therefore we recommend at this time that weights should be derived using the 
optimal method from all data that will be analysed. 
 
A key extension of the scoring algorithm in this chapter was to incorporate additional 
information that was relevant for a specific treatment comparison. The indices of 
overall HRQL and utility incorporated a subscale for chemotherapy acceptability, in 
addition to the UBQ-C subscales for physical function, social and usual activities, 
self-care and distresses. Information about the convenience and acceptability of 
chemotherapy was relevant for the trial, which compared oral versus intravenous 
chemotherapy, and was also found to be important as reflected by the weight given to 
it. 
 
Ratings for distresses were significantly better for capecitabine than CMF. The 
distresses subscale is comprised of symptoms relating to the side effects of treatment 
and the symptoms of metastatic cancer. Better ratings for distresses indicate that on 
balance these symptoms were better controlled on capecitabine. Ratings for physical 
function, social and usual activities, and self-care were similar for each treatment 
group, which indicates that these aspects were equally affected on each regimen. 
Ratings for chemotherapy acceptability were also similar for each treatment group. 
This was an unexpected finding, because capecitabine has more convenient oral 
administration and was expected to be more acceptable to patients. The lack of 
difference suggests that the convenience of oral administration is less important than 
anticipated. 
 
There was a reasonable expectation that overall HRQL and utility would differ 
between treatments because of their different side effect profile, methods of 
administration and anti-cancer effects. This expectation was supported by better 
ratings for distresses for capecitabine, but was not supported by ratings for the health 
status thermometer, which were similar in each treatment group. It was hypothesised 
that the lack of a significant difference was due to the imprecision of the health status 
thermometer. The analyses found a trend to better overall HRQL on capecitabine, 
which was not statistically significant (mean difference 0.015 on a scale from 0 to 1, 
p=0.2). This implies that the side effects and inconvenience of therapy, and the 
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control of cancer-related symptoms, were similar or better for capecitabine versus 
CMF, but that the differences were not beyond the play of chance. 
 
The mean scores on the utility index in this study were 0.92 for the CMF group and 
0.93 for the capecitabine group. These scores equate to the subjects in the trial, who 
were suffering from metastatic breast cancer, being willing to trade-off less than 10% 
of their life-expectancy in order to return to full health. The validity of these scores 
has not been validated by direct comparisons with time trade-off interviews with trial 
subjects, but have face validity in that they are consistent with utilities reported in the 
few other studies that were valued by patients with metastatic breast cancer using 
direct utility interviews (table 7.5). Perez repeatedly interviewed 38 New Zealand 
patients with metastatic breast cancer over a 12 month period, using a time trade-off 
interview with an unusual 30 day horizon, and found a similar mean utility over time 
of 0.95 for those receiving chemotherapy [180]. Lidgren interviewed 61 Swedish 
patients with metastatic breast cancer using a time trade-off interview with 10 year 
horizon, and obtained a mean utility of 0.78 for those on chemotherapy [181].  
 
The mean scores on the utility index in this study were higher than utilities for 
metastatic breast cancer reported in studies when assigned by lay people using a 
direct utility-based scaling method, or by a utility-based instrument valued from the 
lay people perspective (table 7.5). The mean utilities in this study were also generally 
higher than utilities for metastatic breast cancer reported in studies when valued by 
experts by direct utility interview (table 7.5). This is expected because patients 
consistently assign higher utilities to cancer heath states than members of the general 
population and experts, as was described in chapter 2 (sections 2.4.3 and 2.5.4). 
Another explanation is the use of a time trade-off with a horizon of two years rather 
than five years, which tends to give higher values (section 2.4.2, table 7.5). A two-
year horizon was used because it is consistent with the expected median survival of 
the group (section 3.4). 
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Table 7.5 Comparison of utilities for advanced breast cancer 
Perspective 
Author, Year 
Reference Elicitation 
method 
Comments Specific to 
chemotherapy? 
Utility 
value 
Patient      
Perez 2001 [180] TTO 30-day horizon N 0.95 
Grimison This 
paper 
UBQ-C  Y 0.90 
Lidgren 2007 [181] TTO 10-year horizon Y 0.78 
Lay people      
Lloyd 2006 [182] SG  Y 0.72 
Lidgren 2007 [181] EQ-5D By patients/UK lay 
people tariff 
Y 0.69 
Dranitsar 2000 [183-185] TTO By lay people & 
experts 
Y 0.67 
Grann 1999 [186-188] TTO  N 0.52 
Milne 2006 [189] EQ-5D By lay people Y 0.51 
Milne 2006 [189] TTO  Y 0.49 
Milne 2006 [189] VAS  Y 0.46 
van den Hout 
2003 
[190-192] EQ-5D By patients/UK lay 
people tariff 
Y 0.40 
Cykert 2004 [193] SG  N 0.30 
Expert      
Hillner, 2000 [194] Estimate  N 1.00 
Launois 1996 [195-196] SG By nurses Y 0.75 
Brown 1998 [196-201] SG By nurses Y 0.70 
Hillner 1991 [202-205] Estimate  Y 0.70 
Dranitsar 2000* [183-185] TTO By lay people & 
experts 
Y 0.67 
Hutton 1996 [196, 206] SG By nurses Y 0.62 
Lonning 2006 [207] Estimate  N 0.50 
Perspective, perspective from which utility is elicited. Author, first author of reference study. Year, 
year of publication of reference study. ‘Specific to chemotherapy?,’ did study elicited values 
specifically for patients with metastatic breast cancer receiving chemotherapy? Y, yes. N, no. TTO, 
time trade-off. UBQ-C, Utility-Based Questionnaire-Cancer. SG, Standard gamble. VAS, visual 
analogue scale. EQ-5D, EuroQol EQ-5D. *, record listed under ‘lay people’ and ‘expert’ as utilities 
elicited from both. 
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The utility scores derived in this chapter will be used to inform important 
forthcoming trial analyses of quality-adjusted time to progression and quality-
adjusted survival. There is a reasonable expectation that quality-adjusted PFS and 
quality-adjusted overall survival will be better on capecitabine compared to CMF, 
because utility, determined in this chapter, and PFS and overall survival, reported 
previously [124], are at least as good or better on capecitabine. 
 
In summary, the scoring algorithm developed in this thesis has been shown to be 
feasible for the evaluation of a clinical trial, and the resultant utility scores have face 
validity. Ongoing work will use the results to inform quality-adjusted PFS and 
survival analyses of the trial. The next chapter summarises the work presented in this 
thesis, considers its strengths and limitations, and discusses its implications for 
practice and future research. 
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8.  Discussion 
8.1 Overview 
This chapter begins in section 8.2 by revisiting the rationale for, aims of, and general 
approach taken to the work reported in the thesis. Section 8.3 summarises the 
principal findings. Section 8.4 considers the strengths and limitations of the general 
approach taken compared with alternatives. Section 8.5 postulates the likely 
implications of a utility-based instrument that is based on the perspective of cancer 
patients, optimally weighted for specific clinical contexts, and feasible for use in 
clinical trials. Section 8.6 identifies priorities for future research. The chapter ends 
with concluding remarks. 
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8.2 Revisiting the rationale for, aims of, and approach taken to the 
thesis 
The background chapter (chapter 2) presented the rationale for using utilities to 
evaluate cancer treatments in terms of the potential trade-offs between benefits and 
harms. First, utilities provide a stand-alone assessment of the net effect of a treatment 
on overall health-related quality of life (HRQL) that can be used to quantitatively 
value relief of cancer symptoms and improvements in physical and psychological 
function, versus the impact of treatment-related side effects. Second, utilities can be 
combined with survival data to simultaneously value effects on survival and HRQL, 
in terms of quality-adjusted life years (QALYs). Third, utilities can be combined 
with survival and cost data to simultaneously value effects on survival, HRQL, and 
the costs of treatment, in terms of cost per additional QALY. 
 
The background chapter also emphasised that the source of utilities used to evaluate 
cancer treatments is important, because variations can influence the outcome of 
decision-making in two important ways [208]. One important source of variation in 
utilities is the perspective from which they are valued. Patients generally assign a 
higher utility to a given health state than lay people. The utility assigned to a health 
state influences the magnitude of the incremental effectiveness and cost-effectiveness 
of a treatment in QALYs and cost per additional QALY. Another important source of 
variation in utilities is the approach taken to derive the utility. Disease-specific, 
utility-based instruments may give more precise estimates than generic utility-based 
instruments or direct utility-based scaling methods such as the standard gamble or 
time trade-off, if they are more sensitive to changes in health status due to the effects 
of that disease and its treatment. The precision of a utility estimate influences the 
uncertainty around estimates of incremental effectiveness and cost-effectiveness. 
 
It was argued in chapter 2 that cancer treatments compared in clinical trials should be 
evaluated using utilities that are obtained from trial participants, because they have 
experienced the relevant health states. A utility measure in a clinical trial needs to be 
sufficiently responsive to detect small but meaningful changes in HRQL due to the 
effects of cancer treatments, and to be feasible for completion on a repeated basis by 
trial participants who are often unwell. 
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The work presented in this thesis was motivated by the need to determine the 
differences in utilities and QALYs between chemotherapy regimens being compared 
in clinical trials for early and advanced breast cancer that were described in chapter 
3. 
 
The general aim of the thesis, as presented in chapter 1 (section 1.2), was to develop 
a scoring algorithm that converts the responses to a cancer-specific questionnaire into 
an optimally-weighted utility index. The index was intended to: 
i) reflect the perspective of patients with cancer; 
ii) be optimally weighted for comparisons in a specific clinical context, and 
iii) be feasible for use in cancer clinical trials. 
 
The main approaches of the thesis, as outlined in chapter 4 (section 4.3), were to: 
1. Select the items of the Utility-Based Questionnaire-Cancer (UBQ-C) from which 
to derive the utility index  
2. Use data from a valuation survey of cancer patients to value the health states 
described by the UBQ-C 
3. Produce a scoring algorithm that assigns a utility index score to health states 
described by the UBQ-C  
4. Optimise the scoring algorithm in specific clinical contexts using data from 
randomised trials 
5. Validate the utility index using related measures of HRQL and other factors 
6. Apply the utility index to treatment comparisons using data from two randomised 
trials 
 
The next section summarises the findings of the thesis in relation to the approach 
taken and general aims. 
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8.3 Summary of principal findings 
This section summarises the principal findings of the thesis. 
 
A utility index was derived from the health status thermometer, and the multi-item 
subscales for physical function, social/usual activities, self-care and distresses from 
the UBQ-C. Each subscale is the simple average of its one to 21 component items. 
The UBQ-C is a validated cancer-specific HRQL questionnaire that was designed to 
be feasible for use in clinical trials of cancer treatments. 
 
204 patients with advanced cancer rated their current health status and HRQL by 
completing the UBQ-C, and assigning time trade-off utilities, in a valuation survey 
(chapter 3). The mean time trade-off utility was 0.91 and the median was 0.995. Half 
of the patients assigned a utility of 1.0 to their current health state. The valuation 
survey involved patients with cancer because the resultant utility index was intended 
to reflect the perspective of patients with cancer. 
 
A scoring algorithm was derived that assigned scores on the utility index to health 
states described by the UBQ-C (chapter 5), using data from the valuation survey and 
adapting a methodological approach developed by Lumley et al [32]. First, a subset 
index was derived from a weighted combination of the UBQ-C subscales for 
physical function, social/usual activities, self-care and distresses. The weight 
assigned to each subscale was proportional to its correlation with the health status 
thermometer. Second, an overall HRQL index was derived from a weighted 
combination of the health status thermometer and the subset index. The weights 
assigned were proportional to the statistical precision of each measure. Third, a 
utility index was derived by applying a power transformation to the overall HRQL 
index. The formulae were as follows: 
 Subset index = [W1 * PF] + [W2 * SA] + [W3 * SC] + [W4 * DI] 
 Overall HRQL index = [ W * Subset index ] + [ (1 – W ) * HST ] 
 Utility index = 1 – (1 – overall HRQL index)2.03 
W1-4 are the weights for the subscales, PF is physical function, SA is social/usual activities, SC is 
self-care, DI is distresses, HST is the health status thermometer. W is the weight allocated to the 
subset index, so 1 – W is the weight allocated to the health status thermometer. 
 
Formulae to calculate W and 1-W were presented in chapter 5 (section 5.3.3).  
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In the valuation survey, the mean of the utility index scores was similar to the mean 
of the TTO utilities (0.92 versus 0.91, p=0.6). The mean absolute error was 0.10, and 
half of the predicted utilities were within 0.05 of assigned time trade-off utilities. The 
utility index was substantially correlated with other measures of HRQL. 
 
The scoring algorithm for the utility index was optimised to reflect the attitudes of 
subjects in specific clinical contexts in chapter 6. The contexts were advanced breast 
cancer before chemotherapy; and early breast cancer before, during and after 
chemotherapy. The algorithm was optimised by adjusting the weights assigned to the 
subscales to reflect the correlations with the health status thermometer in each 
dataset. The weight assigned to the subset index and health status thermometer were 
also adjusted to reflect the precision of each measure in each dataset. Optimal 
weights for each trial are shown again in table 8.1. 
 
 
 162
Table 8.1 Included studies: comparison of weights for scoring algorithm 
 Study Valuation 
survey 
Early cancer 
trial 
Advanced cancer 
trial 
Advanced cancer 
trial 
 Clinical context Advanced 
cancer 
(chapter 5) 
Chemotherapy 
for early 
breast 
cancer 
(chapter 6) 
Before 
chemotherapy 
for advanced 
breast cancer 
(chapter 6) 
During 
chemotherapy 
for advanced 
breast cancer 
(chapter 7) 
Weights for subset index     
W1 Physical function 0.28 0.20 0.09 0.10 
W2 Social/usual activities 0.06 0.23 0.25 0.15 
W3 Self-care 0.01 0.04 0.01 0.07 
W4 Distresses 0.64 0.53 0.64 0.42 
W5* Chemotherapy acceptability - - - 0.27 
Weights for overall HRQL index     
1-W Health status thermometer 0.65 0.66 0.63 0.61 
W Subset index 0.35 0.34 0.37 0.35 
 
W1-5, 1-W, W refer to the weights assigned to the health status thermometer, subset index, and 
subscales in formulae in section 8.3. * Only included in one context. 
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 The utility index was validated by application to the early and advanced cancer trials 
using related measures of HRQL and other factors in chapter 6. The utility index 
discriminated between breast cancer that was advanced rather than early (means 0.88 
versus 0.94, p < 0.0001), and was responsive to toxic effects of chemotherapy in 
early breast cancer (mean change 0.07, p<0.0001). It also had convergent validity 
with related scales from other instruments, discriminative validity between 
participants with differing performance status, and predictive validity about 
subsequent survival duration. 
 
The indices were applied to inform a treatment comparison of high-dose 
chemotherapy with stem cell support versus standard-dose chemotherapy for high-
risk early-stage breast cancer in chapter 6. The utility index showed a trend towards 
better mean scores for standard-dose chemotherapy (means 0.95 versus 0.92, p=0.1). 
The indices were also applied to inform a treatment comparison of chemotherapy 
with oral capecitabine versus intravenous CMF for advanced breast cancer in chapter 
7. This required two modifications to the scoring algorithm. The utility index was 
extended by incorporating additional information about the specific side effects of 
chemotherapy for advanced breast cancer, and the algorithm was optimised using 
regression methods that accounted for the correlations between repeated measures 
from individual subjects. Optimal weights are shown in the last column of table 8.1. 
The utility index showed no significant difference between treatment groups. The 
mean utility scores were 0.927 for capecitabine and 0.918 for CMF (mean difference 
0.10, 95% CI -0.01 to 0.03, p=0.22). 
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8.4 Strengths and limitations of approach compared with alternatives 
8.4.1 Determining the items and response options 
The utility index was derived from the subscales of the UBQ-C, which is a cancer-
specific HRQL questionnaire. The UBQ-C has several strengths as the basis for a 
utility-based instrument. It includes items about a broad range of aspects of HRQL 
that are relevant to cancer patients, as well as a single-item global scale of health 
status. The items have established evidence of feasibility, reliability and validity as 
reported in chapter 3 (section 3.3). It focuses on cancer-specific aspects of HRQL 
likely to be affected by cancer and its treatment, which should increase the ability of 
the utility index to detect small but meaningful differences in HRQL between 
treatment groups, and subtle changes over time, as discussed in chapter 2 (section 
2.5.3). It has been shown to be feasible for use in clinical trials in other contexts 
including chemoprevention for breast cancer [126], and chemotherapy for testicular 
and colorectal cancer [123, 150]. Its use in these trials enables the use of data already 
collected to further establish the validity of the utility index, as was done in chapters 
6 and 7, and to derive utilities and QALYs to inform decisions about cancer 
treatments. 
 
An alternative approach would be to derive the utility index from one of the other 
cancer-specific HRQL instruments such as the EORTC QLQ-C30 or FACT-G that 
were described in chapter 2 (table 2.1). Because these instruments have been used 
more extensively, the scoring algorithm could be applied to data from a larger 
number of trials to generate utility scores for more clinical contexts. Another 
approach would be to derive the utility index from a generic instrument. This would 
improve the comparability of the scores across diseases, but would reduce the 
descriptive richness of the instrument and may limit the ability of the utility index to 
detect cancer-related effects. 
 
The utility index was derived from the subscales of the UBQ-C, rather than from 
individual items as done by others who have adapted a profile-based HRQL 
instrument [95, 98, 107]. Producing a scoring algorithm from four subscales rather 
than from a larger number of individual items minimised problems with collinearity. 
One disadvantage of using subscales rather than items is that they provide less 
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information about the relative importance of different aspects of HRQL. For 
example, trade-offs between cancer symptoms and treatment side-effects that could 
be understood by examining the weight assigned to each individual item were 
concealed because those items are all contained within the distresses subscale. 
8.4.2 The valuation survey 
The data used to value the health states described by the UBQ-C, and to produce the 
scoring algorithm, were taken from a valuation survey of patients with cancer. These 
respondents are the ideal source of patient-based valuations about cancer health 
states because they have direct experience of those health states. The valuation 
survey was restricted to patients with advanced cancer, so the scoring algorithm may 
be less applicable to those with cancer that is early, or in remission, or those who are 
at increased risk of developing cancer. An alternative approach to increase 
generalisability would have been to obtain utilities from people in all these situations. 
The disadvantage of this approach is that the attitudes of people in different 
situations may differ. Another approach would have been to conduct a separate 
valuation survey and produce separate scoring algorithms in other contexts, which 
would have required substantial additional resources. Instead, the scoring algorithm 
was optimised in different contexts by adjusting the weights based on correlations 
with the health status thermometer. 
 
The ratings assigned by subjects in the valuation survey were skewed towards full 
health, as reported in chapter 3 (section 3.8 and table 3.3). More data for subjects 
with poorer HRQL would have strengthened the robustness of the scoring algorithm 
across the full spectrum of health and disease, but selecting a greater proportion of 
patients with poorer HRQL would have required interviews with patients in hospital 
or in the terminal phase of their illness. Hospitalised patients may be too unwell for 
cognitively demanding interviews. Patients in the terminal phase of their illness may 
find that questions about life and death are too confronting. Another approach would 
have directed patients to assign utilities to hypothetical health states across the full 
range, rather than their current health state. The disadvantage of eliciting utilities for 
hypothetical health states is that the valuations may differ from those for experienced 
health states [59]. 
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The utilities assigned in the valuation survey were highly skewed towards full health, 
and half of the subjects assigned a utility of one (section 3.9 in chapter 3). This 
implies that many were unwilling to trade any survival time for an improvement in 
HRQL. One explanation for this finding is that the subjects truly valued survival 
more highly than HRQL. This is supported by 58% of subjects reporting their health 
as being ‘excellent’ or ‘good’, despite being recruited to the study because they had 
advanced cancer and impaired HRQL (table 3.2 of chapter 3). Another explanation is 
that many failed to comprehend the task, or objected to it. Assigning utilities by time 
trade-off interview may be too demanding for some patients with advanced cancer. 
Patients may have as much difficulty remembering full health as lay people have 
imagining severely impaired health [59]. Another is that they may adjust their 
valuations because of adaptation and response shift (section 2.4.3 of chapter 2). 
However the strength of using experienced patients rather than lay people to assign 
utilities is that they have a proper understanding of what it is like to live in that health 
state. 
 
A number of direct utility-based scaling methods could have been used to assign 
utilities in the valuation survey. The strengths and limitations of each were described 
in chapter 2 (section 2.4.3). In summary, the time trade-off method was used because 
it is practical, reliable and has empirical validity. One alternative is the standard 
gamble, which was used to derive scoring algorithms for the utility indices of the 
Health Utilities Index and SF-6D (table 2.2 of chapter 2). The standard gamble is the 
criterion method for direct utility-based scaling because it elicits utilities under 
conditions of uncertainty, but the time trade-off is generally accepted as having 
similar empirical properties to the standard gamble, and may be easier to complete. 
Martin et al. developed methods to convert time trade-off utilities to standard gamble 
utilities where they differed. In this study, this would further increase the utility 
scores [49]. This conversion was not used in this study because utilities were already 
strongly skewed towards full health. Another alternative to the time trade-off is the 
rating scale. This is an inferior method for eliciting utilities on both theoretical and 
empirical grounds. Data presented in chapter 3 confirmed that values elicited from 
patients about their current health status were significantly lower when elicited with 
a rating scale than with a time trade-off interview (table 3.3 versus section 3.9). 
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The data in the valuation survey was used to produce the scoring algorithm for the 
utility index. The next section describes the merits of the approach taken. 
8.4.3 Producing the scoring algorithm 
A statistical inference approach was used to produce the scoring algorithm for the 
utility index. The alternatives presented in chapter 2 (section 2.6.3) were the holistic 
approach, and the multi-attribute utility theory approach. The strength of the 
statistical inference approach over these alternatives derives from the type of health 
states that need to be valued. The holistic approach requires valuation of every 
conceivable health state, and the multi-attribute utility theory approach requires 
valuation of ‘corner health states’ with impairment of only one attribute. It would be 
difficult to recruit subjects with experience across the full spectrum of health states 
required. The statistical inference approach required only a representative sample of 
health states to be valued. 
 
Two standard statistical inference approaches were described in chapter 2 (sections 
2.5.1 and 2.6.3). The global health preference approach uses a single-item global 
scale, and the multi-attribute health preference approach uses multiple items. The 
strength of a single-item global scale is that it provides a single unified assessment of 
global HRQL; the strength of multiple items is that they improve responsiveness and 
the descriptive richness of the index, as discussed in chapter 2 (section 2.5.2). The 
scoring algorithm for the utility index used a novel statistical approach that combined 
a single-item global scale with multi-item subscales, incorporating the strengths of 
each approach. This enabled the index to be optimised to better reflect the attitudes 
of patients in specific clinical contexts, as discussed in the next section. 
 
There are a number of limitations of our approach. First, it is more complex to 
understand and implement. Second, the weight that is applied to the multi-item scales 
(subset index) was low and remarkably constant (about 0.33), such that they 
contribute little to the utility index. Third, the greater precision of the HRQL index 
compared to the health status thermometer could potentially reflect ignorance of 
uncertainty in its development. Fourth, the scores derived by the utility index in 
different contexts may be less comparable if the optimal algorithms differ across 
different contexts. All these issues warrant future research. 
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The utility index scores derived by the resultant scoring algorithm were sufficiently 
similar to directly assigned, time trade-off utilities for group comparisons, as 
reported in chapter 5, but the algorithm did not accurately predict utilities for 
individuals. An alternative approach could have incorporated other factors that 
influence utilities for individuals into the scoring algorithm, such as attitudes to risk, 
social and demographic factors that were outlined in chapter 2 (section 2.4). 
However, incorporating these factors is unlikely to yield precise estimates for 
individuals, because of the inherent variability of utilities. Another alternative 
approach would have compared the power transformation to a plateau model that 
took into account the large number of respondents with a utility of 1, as discussed in 
chapter 5 (section 5.6). 
8.4.4 Optimising the scoring algorithm in specific clinical contexts 
The scoring algorithm was optimised for trials of chemotherapy in early and 
advanced breast cancer. The limitation of the approach taken to optimising the 
weights is that it is data-driven, with weights assigned to each subscale based on their 
correlations with the health status thermometer. An alternative approach would be to 
optimise the algorithm by adjusting subscale weights based on their correlations with 
direct time trade-off utilities. This may better reflect the attitudes of respondents but 
requires substantial additional work. Another alternative or complementary approach 
would establish that the weights truly reflect the relative importance that patients 
attach to aspects of HRQL by qualitative interviews or questionnaires, again 
necessitating substantial additional effort. 
8.4.5 Validation using related measures of HRQL 
The utility index was validated by application to data from clinical trials of cancer 
treatments. The strength of this approach is that it used the type of data that the index 
was designed to analyse. It was validated as a measure of HRQL by comparison with 
related measures, with strong preliminary evidence of validity, sensitivity and 
responsiveness. An alternative or complementary approach would have focussed on 
establishing the validity of the utility index by comparison with directly elicited 
utilities in additional valuation surveys, or by dividing a larger valuation survey into 
a ‘development’ dataset where the algorithm was produced, and a ‘validation’ dataset 
where its predictive ability was tested. The responsiveness and sensitivity of the 
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utility index compared with those from other utility-based instruments could have 
also been tested. 
8.4.6 Application to treatment comparisons in randomised trials 
The utility index was applied to treatment comparisons of chemotherapy regimens 
for early and advanced breast cancer. These treatment comparisons were ideal 
because they are clinically relevant, and the utility scores that were generated are 
being used to inform decisions about these treatments in terms of QALYs in ongoing 
analyses. One limitation is that little difference in utility was found between 
treatment groups, as reported in section 8.3. This probably reflects the genuine 
similarities in overall HRQL between treatment groups, but could reflect the limited 
sensitivity of the utility index. A complementary approach would have applied the 
index in other types of cancer, and other treatment modalities such as surgery or 
supportive care, and compared it to scores from other utility indices, to better 
understand its applicability and sensitivity. 
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8.5 Practical implications of research for future trials 
The general aim of this thesis (section 8.1) proposed the ideal characteristics of a 
utility index for use in clinical trials to inform clinical decision-making about cancer 
treatments. Such a utility index would reflect the perspective of patients with cancer, 
be optimally weighted for comparisons within a specific disease and treatment 
context, and be feasible for use in clinical trials. The previous sections of this chapter 
reported how the work reported in this thesis successfully achieved these ideal 
characteristics. This section considers the practical implications of such a utility 
index for the conduct and evaluation of future clinical trials. 
8.5.1 Reflecting the perspective of patients with cancer 
The utility index was intended to reflect the perspective of patients, whereas indices 
for most utility-based instruments are designed to reflect the perspective of lay 
people. Because patient-based utilities are typically higher than community-based 
utilities, their use is likely to redirect priorities away from treatments that improve 
HRQL and towards treatments that extend life [59]. The effects are described in table 
8.2, and are explained in the following paragraphs. 
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Table 8.2 Effects of patient-based utilities on incremental benefit of interventions 
Treatment effect Examples of intervention and 
comparator 
Effect of patient-based 
utilities on incremental 
benefit 
Extend survival 1. Curative surgery versus nil 
2. Life-extending chemotherapy 
versus nil 
More favourable 
Reduce adverse effects of 
treatment 
1. Surgery that avoids 
colostomy versus surgery with 
colostomy 
2. Mastectomy with breast 
reconstruction versus 
mastectomy 
3. Adjuvant hormonal therapy 
without side effects versus toxic 
adjuvant hormonal therapy 
Less favourable 
Relieve cancer symptoms Palliative chemotherapy versus 
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Figure 8.1 Effects of patient-based utilities on incremental benefit of interventions 
Utilitycomparator
and
Utilitynew treatment
1.0
0
Utility
Survival
Incremental QALYs
Treatment that extends survival
with lay-person utilitiesA
 
Utilitycomparator
and
utilitynew treatment
will increase
1.0
0
Utility
Survival
Incremental QALYs
will increase
Treatment that extends survival 
with patient utilities
 
1.0
0
Survival
Utilitycomparator
Treatment that reduces adverse effects
with lay-person utilities
Incremental QALYs
Utilitynew treatment
Utility
B
 
1.0
0
Survival
Utilitycomparator
will increase
Treatment that reduces adverse effects
with patient utilities
Incremental QALYs will decreaseUtilitynew treat,mentremains at 1
Utility
 
1.0
0
Survival
Treatment relieves cancer symptoms
with lay-person utilities
Incremental QALYs
Utility
Utilitycomparator
Utilitynew treatment
C
 
1.0
0
Survival
Utilitynew treatment
and
utilitycomparator
increase
Treatment relieves cancer symptoms with
patient utilities - smaller absolute difference
Incremental QALYs decreases
Utility
Difference between utilities is smaller
 
1.0
0
Survival
Treatment relieves cancer symptoms 
with lay-person utilities
Incremental QALYs
Utility
Utilitycomparator
Utilitynew treatment
D
 
1.0
0
Survival
Utilitynew treatment
and
utilitycomparator
increase
Treatment relieves cancer symptoms with
patient utilities  - greater absolute difference
Incremental QALYs increases
Utility
Difference between utilities is larger
 
 173
Utilities valued by patients, rather than by lay people, are likely to make the 
incremental benefit of an intervention over a comparator that extends survival but 
does not alter HRQL seem more favourable. In this context, patient-based utilities 
assign higher utilities and more QALYs to both the intervention and the comparator. 
Because the utility of the intervention and the comparator is the same but the survival 
differs, the effect is greater incremental QALYs. The effect is illustrated in figure 8.1 
(A). This explains why cancer treatments that extend survival, such as life-
prolonging chemotherapy or curative surgery, seem more effective and cost-effective 
when patient-based utilities are used. 
 
In contrast, utilities valued by patients, rather than by lay people are likely to make 
the incremental benefit of an intervention over a comparator that restores perfect 
health but does not alter survival seem less favourable. In this context, patient-based 
utilities assign a higher utility and more QALYs to the comparator, but the utility of 
the intervention is fixed at one and its QALY is unchanged. Because the survival of 
the intervention and the comparator is the same, the effect is smaller incremental 
gains in QALYs between the intervention and the comparator [59, 71]. The effect is 
illustrated in figure 8.1 (B). This explains why treatments that reduce adverse effects 
of treatments but do not alter survival, such as breast reconstruction following 
mastectomy, or avoidance of colostomy, seem less effective and less cost-effective 
when patient-based utilities are used. 
 
Utilities valued by patients, rather than by lay people, can have variable 
consequences on the effectiveness and cost-effectiveness on interventions that 
incrementally improve HRQL, but do not restore HRQL to full health or extend 
survival. Patient-based utilities assign higher utilities to both the intervention and the 
comparator. Because survival of the intervention and the comparator is the same, the 
gain in QALYs is determined only by the absolute difference in utilities between 
them. If the absolute difference in utilities is smaller, then the effect is less gains in 
QALYs and diminished effectiveness and cost-effectiveness, as illustrated in figure 
8.2 (C) [209-210]. This tends to occur for less severe health states, because of a 
phenomenon called valuation compression where the valuations for less severe 
health states are all compressed near the top of the scale [59]. Conversely, if the 
absolute difference is greater then the effect is more gains in QALY and enhanced 
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effectiveness and cost-effectiveness, as illustrated in figure 8.2 (D). This tends to 
occur for more severe health states, because patients are better than lay people at 
distinguishing between them [59]. If the absolute difference in utilities is the same 
then the effectiveness and cost-effectiveness are unchanged. 
 
In summary, the use of utilities valued by patients compared to lay people in analyses 
of quality-adjusted survival and cost-effectiveness will favour treatments that 
prolong survival over treatments that improve HRQL. This finding requires 
validation by correlation with actual decision-making by patients. The implication is 
that many patients with cancer are unwilling to trade reductions in survival times for 
improvements in HRQL. It should be noted that utilities valued by patients rather 
than lay people may not always have a significant impact on decisions in specific 
contexts. Chapman et al reported that varying utilities substantially does not alter 
decisions in a sizeable proportion of cost-utility analyses [211]. 
 
The next section considers the implications of another characteristic of the utility 
index: its optimal weighting. 
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8.5.2 Optimal weighting 
The utility index was designed to be optimally weighted for comparisons within a 
specific disease and treatment context. This section considers the implications of 
using an optimally-weighted index in clinical trials in terms of the comparability of 
scores across trials, precision of estimates, information about trade-offs, and 
expertise required for analyses. 
 
The optimally-weighted scores on the utility index should better reflect the 
perspective of the respondents, because it gives additional weight to the aspects of 
HRQL that are more strongly correlated with global HRQL. The main disadvantage 
is that the utility scores may be less comparable in different contexts, because the 
weights may differ. This is not a limitation for evaluations of treatments within a 
specific clinical trial to inform clinical decision-making, because the comparisons are 
restricted to a single clinical context. However it does limit application of the method 
to studies that include diverse populations, or for comparing utilities and QALYs 
from one study to another. 
 
Optimal weighting could give more precise estimates of clinically important 
differences in utility between patient groups, because the index is focussed on those 
aspects of HRQL that are most relevant to those patients. A more precise utility 
index has implications for decision-making about cancer treatments. It will reduce 
the uncertainty around the incremental effectiveness and cost-effectiveness of 
treatments in sensitivity analyses, because it is more responsive to small but 
meaningful effects of cancer treatments [172]. It will reduce the sample size required 
to detect a given difference with a given level of precision [172]. A more precise 
utility index may also make an intervention versus a comparator seem more 
favourable if it detects greater differences in utilities between treatment groups. As 
discussed in the previous section and figure 8.1 (D), a larger absolute difference in 
utilities and QALYs between an intervention and its comparator will enhance its 
incremental effectiveness and cost-effectiveness, but a smaller absolute difference 
will diminish it. 
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Optimal weighting may help researchers and clinicians better understand the relative 
importance of different aspects of HRQL in a specific clinical context. The 
implications are illustrated by table 8.1. For example, distresses were assigned the 
greatest weight and self-care the least weight in our studies. The implication is that 
clinicians and researchers should pay greater attention to relieving distresses due to 
physical and psychological symptoms in these contexts, rather than focussing on 
self-care, because self-care wasn’t as severely impaired in the studies. The effects of 
optimising the weights to reflect the preferences of individual patients on trial results 
can also be tested in sensitivity analyses. 
 
The approach to optimal weighting requires familiarity with the methods developed 
in this thesis. The work reported in this thesis has shown the feasibility and 
advantages of optimal weighting. However, implementation of this approach requires 
additional work for statisticians. 
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8.5.3 Feasibility of use in clinical trials 
The feasibility of the utility index for use in clinical trials of cancer treatments was 
supported by the high completion rate of the UBQ-C in the clinical trials evaluated in 
this thesis, as reported in chapter 3, and the ability to derive utility scores from the 
UBQ-C in each trial, as reported in chapters 6 and 7. 
 
A utility index that is feasible for use in clinical trials should increase the pool of 
utility scores available for treatment comparisons. A current limitation of evaluating 
clinical trials in terms of utilities and QALYs is the limited number of specific health 
states for which utility data is available. The utility index developed in this thesis 
should promote the use of these analyses to evaluate treatments in randomised trials. 
The analyses can be used to inform clinical decision-making, and provide an 
alternate perspective to lay person-based utilities to inform evaluation of the 
incremental cost-effectiveness of treatments to inform funding and policy decisions. 
 
Deriving utility scores with the utility index developed in this thesis is more feasible 
than eliciting utilities directly with a standard gamble or time trade-off interview. 
The direct approach is not practical for cancer patients participating in clinical trials 
because the procedure is resource-intensive for researchers, difficult for patients, and 
potentially distressing for those with severe symptoms or side effects, or at the end of 
life [59], as described in chapter 2 (section 2.4.4). The utility index developed in this 
thesis is also more efficient in clinical trials of cancer treatments than standard 
generic utility-based instruments such as the EuroQol EQ-5D or Health Utilities 
Index (HUI3), because demands on patients and trial staff are reduced by using a 
single instrument that gives both a cancer-specific, profile-based, description of 
HRQL, and a utility score. 
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8.6 Priorities for ongoing and future research 
Current work is further establishing the validity of this utility index as a HRQL 
measure by testing its sensitivity and responsiveness in other contexts such as 
chemotherapy for advanced colorectal cancer [150] and chemoprevention for breast 
cancer [126]. Current work is also comparing its measurement properties with those 
of the EuroQol EQ-5D, which is one of the most commonly used generic utility-
based instruments [150]. Publications relating to this work are in progress. 
 
Future work could further establish the validity of the utility index by comparing its 
scores with utilities directly elicited by time trade-off interview about patients’ 
current health in new samples. Sensitivity analyses should test if optimisation of the 
scoring algorithm in different clinical contexts makes a meaningful difference to the 
utility scores, and to their sensitivity and responsiveness. 
 
Application of the utility index to inform decision-making will be an important 
extension of this work. Comparison of treatments in terms of incremental QALYs 
and incremental cost per QALYs is planned in four clinical contexts where data 
about survival, HRQL and costs have been collected: the early and advanced cancer 
trials presented in this thesis, chemotherapy for advanced colorectal cancer [150], 
and chemoprevention for breast cancer [126]. Publications relating to analyses of 
these randomised controlled trials in terms of utilities and QALYs are planned or in 
progress. 
 
Planned sensitivity analyses comparing patient-based utilities derived from the UBQ-
C with lay person-based utilities derived from the EQ-5D will determine whether 
differences in utilities make a meaningful difference to the outcomes of decisions in 
each context. Sensitivity analyses will also explore the effect on treatment 
recommendations of optimising the scoring algorithm in different clinical contexts. 
 
Future work should look at adaptations of the methods used to derive the utility 
index. One adaptation would be to derive the utility index from a weighted 
combination of items rather than subscales. This would provide additional 
information about the trade-offs between different aspects of HRQL (section 8.4.1). 
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Another adaptation would be to derive a utility index for the UBQ-C based on the 
perspective of lay people, by repeating the valuation survey in a general population. 
This would facilitate the comparison of patient-based and lay-people based utilities 
with a single instrument. Finally, the methodological approach could be applied to 
derive a utility index for other HRQL instruments that are relevant to cancer or other 
diseases. 
8.7 Contribution to knowledge and practical significance 
The work presented in this thesis has developed a scoring algorithm that converts the 
responses from a simple, self-rated cancer-specific questionnaire about health-related 
quality of life to a utility index. The index can be used to generate utility scores and 
quality-adjusted life-years in clinical trials. It enables the evaluation of the net effect 
of treatments on health-related quality of life (accounting for trade-offs between 
disparate aspects); the evaluation of the net benefit of treatments (accounting for 
trade-offs between quality of life and survival); and an alternate perspective for 
comparing the incremental cost-effectiveness of treatments (accounting for trade-offs 
between net benefit and costs). 
 
The practical significance of this work is to facilitate the integration of data about 
health-related quality of life with traditional trial endpoints such as survival and 
tumour response. This will better inform interpretation of clinical trials that are used 
to inform clinical decision-making, and provide an alternate viewpoint for economic 
decision-making. Broadly, it will help patients, clinicians and health funders make 
better decisions about cancer treatments by considering effects on both length and 
quality of life. 
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Appendix 1 Utility-Based Questionnaire-Cancer (UBQ-C) 
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UBQ-C Questionnaire (Page 1 of 3) 
Randomisation number:  Patient’s initials  
Today’s Date:   // Institution/Hospital:__________________ 
Place of completion (;): Clinic  Home   
 
1. How would you describe your general health over the past 3-4 weeks? 
 Please tick (;) the one most appropriate answer. 
 Excellent .............................. 
 Very good ............................ 
 Good  .............................. 
 Fair  .............................. 
 Poor  .............................. 
 
 
2.   Has your health affected your ability to perform any of the following activities over the 
past 3-4 weeks? Please tick (;) the one most appropriate answer for each activity. 
 
   Not   Slightly Severely Unable to  
   affected affected activities do activities 
      at all 
Usual daily activities  
(eg.  paid work, house chores, etc.)...      
 
Your social life..................................      
 
Your hobbies or leisure activities......      
 
Your sex life ....................................      
 
Walking several blocks (500 metres)      
 
Climbing one flight of stairs .............      
 
Vigorous activities such as running  
or strenuous sports ............................      
 
Self-care (washing, dressing etc.) .....  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UBQ-C Questionnaire (Page 2 of 3) 
Randomisation number:  Patient’s initials  
Today’s Date:   // Institution/Hospital:__________________ 
Place of completion (;): Clinic  Home   
 
3. Over the past 3-4 weeks have you experienced any of the following problems? If no, 
please circle (NONE). If yes, circle on a scale from 1 to 10 how much distress this has 
caused you. 
      AMOUNT OF DISTRESS 
 NONE MILD MODERATE SEVERE EXTREME 
Shortness of breath .............................. 0 1 2 3 4 5 6 7 8 9 10 
Difficulty sleeping ............................... 0 1 2 3 4 5 6 7 8 9 10 
Feeling sick (nausea/vomiting)............ 0 1 2 3 4 5 6 7 8 9 10 
Lack of energy..................................... 0 1 2 3 4 5 6 7 8 9 10 
Aches and pain .................................... 0 1 2 3 4 5 6 7 8 9 10 
Feeling sad or depressed...................... 0 1 2 3 4 5 6 7 8 9 10 
Feeling anxious or worried .................. 0 1 2 3 4 5 6 7 8 9 10 
Loss of appetite.................................... 0 1 2 3 4 5 6 7 8 9 10 
Dissatisfaction with your weight or 
appearance 
0 1 2 3 4 5 6 7 8 9 10 
Uncertainty about the future ................ 0 1 2 3 4 5 6 7 8 9 10 
Numbness or pins & needles ............... 0 1 2 3 4 5 6 7 8 9 10 
Anger or resentment ............................ 0 1 2 3 4 5 6 7 8 9 10 
Loneliness  0 1 2 3 4 5 6 7 8 9 10 
Loss of hair 0 1 2 3 4 5 6 7 8 9 10 
Diarrhoea  0 1 2 3 4 5 6 7 8 9 10 
Constipation......................................... 0 1 2 3 4 5 6 7 8 9 10 
Loss of self confidence ........................ 0 1 2 3 4 5 6 7 8 9 10 
Feeling dependent on others ................ 0 1 2 3 4 5 6 7 8 9 10 
Thought of chemotherapy.................... 0 1 2 3 4 5 6 7 8 9 10 
Inability to concentrate ........................ 0 1 2 3 4 5 6 7 8 9 10 
Any other problems that cause you 
distress  
(if none circle ‘0’) 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Please list: _________________________________________________________________________________  
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UBQ-C Questionnaire (Page 3 of 3) 
Randomisation number:  Patient’s initials  
Today’s Date:   // Institution/Hospital:__________________ 
Place of completion (;): Clinic  Home   
 
4. To help people say exactly how good or bad their health is, we have drawn a scale 
(rather like a thermometer) on which full health is marked by 100 and death is marked by 0.  
We would like you to indicate on this scale how good or bad your own health is today, in 
your opinion.  Please do this by drawing a line from the box below to whichever point on the 
scale indicates how good or bad your current health state is. 
 
   
 Your own health 
state today 
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Appendix 2 Other questionnaires 
 
1. Priestman and Baum Linear Analog Self Assessment Scales (LASAS) 
2. Spitzer-Uniscale 
3. Chemotherapy Acceptability Questionnaire 
4. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 
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Priestman and Baum Linear Analog Self Assessment Scales (LASAS): 
1st five scales 
Spitzer-Uniscale: 
Labelled ‘Overall life quality’ 
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Chemotherapy Acceptability Questionnaire: 
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ECOG Performance Status Scale 
 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g. light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
 
As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: 
Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 
5:649-655, 1982
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RESEARCH STUDY INTO THE DEVELOPMENT OF A UTILITY BASED 
QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH CANCER 
INFORMATION FOR PARTICIPANTS 
You are invited to take part in a research study into the development of a Quality of 
Life Questionnaire in patients with cancer. The objective is to develop a short health 
questionnaire for cancer patients. Such a questionnaire could be used to monitor 
patients well-being over time and could be used to evaluate new treatments. The 
study is being conducted by Professor John Simes, Elaine Beller, Andrew Martin, of 
the Clinical Trials Centre part of the National Health and Medical Research Council, 
in association with the New South Wales Cancer Council. 
If you agree to participate in this study, you will be given a short questionnaire which 
should take you about 15 minutes to complete. Shortly after you will receive another 
questionnaire of a similar length. After completing the second questionnaire you will 
be asked to take part in an interview at your outpatient clinic at a time which is 
convenient for you. In the interview you will be presented with descriptions of 
different health conditions and you will be asked to choose which you think sounds 
best. Although no physical risks are involved it is possible that some people may be 
upset by interview questions relating to their illness. 
All aspects of the study, including results, will be strictly confidential and not 
revealed to any medical staff looking after you. A report of the study may be 
submitted for publication, but individual participants will not be identifiable in such a 
report. 
While we intend that this research study furthers medical knowledge and may help 
identify better treatments, it may not be of direct benefit to you. 
Participation in this study is entirely voluntary: you are not obliged to participate and 
- if you do participate - you can withdraw at any time. Whatever your decision it will 
not affect your medical treatment or your relationship with medical staff. 
When you have read this information, Vicki Greatorex, will discuss it with you 
further and answer any questions you may have. If you would like to know more at 
any stage, please feel free to contact Vicki Greatorex (Research Assistant) on (02) 
692 4561. This information sheet is for you to keep. 
Any person with concerns or complaints about the conduct of a research study can 
contact the Secretary of the Ethics Review Committee of the Central Sydney Area 
Health Service on (02) 516 6766. 
 216
RESEARCH STUDY INTO THE DEVELOPMENT OF A UTILITY BASED 
QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH CANCER 
PARTICIPANT CONSENT FORM 
I, ............................................................... [name] of 
.........................................................[address] have read and 
understood the Information for Participants on the above named research study and have 
discussed the study with ............................. 
I am aware of the procedures involved in the study, including any inconvenience, risk, 
discomfort or side effect, and of their implications. 
I freely choose to participate in this study and understand that I can withdraw at any 
time. 
I also understand that the research study is strictly confidential. 
I hereby agree to participate in this research study. 
NAME:    ............................. 
SIGNATURE:   ............................. 
DATE:    ............................. 
NAME OF WITNESS:  ............................. 
SIGNATURE OF WITNESS: ............................. 
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INFORMATION FOR PARTICIPANTS & SAMPLE CONSENT FORM 
To be printed on the local institutions letterhead 
 
ANZ BCTG Protocol 0001 
Capecitabine vs CMF in Advanced Breast Cancer 
A phase III trial to evaluate oral chemotherapy with capecitabine versus  
standard chemotherapy with CMF in advanced breast cancer. 
Principal Investigator:  Principal Investigator Name 
Associate Investigators:  Co-investigator Name 
     Co-investigator Name 
INFORMATION FOR PARTICIPANTS 
You are invited to take part in a research project.  The next few pages describe the 
project in detail.  Its purpose is to explain to you as openly and clearly as possible 
what being in this project involves, before you decide whether to take part. 
Please read this Participant Information carefully.  Feel free to ask questions about 
any information in the document.  You may also wish to discuss the project with a 
relative or friend or your local health worker.  Feel free to do this. 
Once you understand what the project is about, and if you agree to take part in it, you 
will be asked to sign the Consent Form.  By signing the Consent Form, you indicate 
that you understand the information and that you give your consent to participate in 
the research project. 
You will be given a copy of the Participant Information and Consent Form to keep as 
a record. 
The purpose of this study is to compare a new form of chemotherapy given daily by 
mouth (capecitabine) to the standard form of chemotherapy given as a combination 
of tablets and injections given intermittently (CMF).  The study also tests whether it 
is better to give capecitabine daily over 21 days, or to give the same dose spread over 
14 out of every 21 days. 
Who is conducting the study? 
This study is being carried out in hospitals around Australia and New Zealand, and is 
being coordinated by the Australian and New Zealand Breast Cancer Trials Group.  
At this hospital, the study is being carried out by Principal Investigator and 
colleagues from the Department, Centre. The pharmaceutical company Roche is 
supplying some of the study medication. 
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How many people will take part? 
465 people like you will take part in this study. 
What is involved? 
If you are interested in taking part in this study, then some tests need to be done to 
make sure that it is suitable for you.  These will include:  
- a full medical history (it is important that we know if you have any other 
medical conditions or are taking any medications) 
- a physical examination by your doctor  
- routine blood tests (about one tablespoon) 
- imaging tests (for example X-rays, CT scans, and a bone scan) to check the 
extent of your disease   
While receiving treatment, you will have check-ups with your doctor and have blood 
taken for routine blood tests (about one tablespoon) every 3 to 4 weeks. Scans and x-
rays will be done every 12 weeks to check how your disease is responding to the 
treatment.  You will also be asked to fill in forms with simple questions about how 
you are feeling and getting on (‘quality of life questionnaires’). 
If you agree to take part in this study you will get one of the three treatments 
described below.  The treatment you get will be chosen by a computer using a 
process known as randomisation.  This means that your treatment will be selected at 
random (like drawing a card from a pack) and that you have an equal chance of 
getting any one of the three treatments.  This is necessary to make sure that the 
people getting each treatment are comparable.  Neither you nor your doctor can 
choose which treatment you will receive.  In this study, everyone gets an active 
treatment – there is NO placebo group in this study. 
Treatments 
If you take part in this study you will get one of the three following treatments: 
1.  CMF (cyclophosphamide, methotrexate, fluorouracil) 
2 drugs (M&F) are given by injection into a vein on the 1st and 8th day of each 28 day 
treatment cycle, and 1 drug (C) is given as pills for the first 14 days of each 28 day 
treatment cycle.  The treatment is given as an outpatient without need for hospital 
admission and is repeated every 28 days if there are no troublesome side effects. 
2.  Intermittent capecitabine 
Capecitabine is given as pills taken by mouth morning and night for the first 14 days.  
There are no injections.  The treatment is given as an outpatient without need for 
hospital admission and is repeated every 21 days if there are no troublesome side 
effects. 
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3.  Continuous capecitabine 
Capecitabine is given as pills taken by mouth morning and night for 21 days.  There 
are no injections.  The treatment is given as an outpatient without need for hospital 
admission and is repeated every 21 days if there are no troublesome side effects. 
How long will I be in the study? 
The chemotherapy will continue so long as it seems to be working, it is not causing 
troublesome side effects, and both you and your doctor think it should continue.  On 
average, this means treatment for about 6 months, but it may be for as little as a few 
weeks or as much as a few years.  You can choose to stop the treatment at any time 
without penalty.  Once the study treatment is stopped, the choice of further treatment 
is up to you and your doctor.  If you have further treatment we will continue to 
follow your progress, but you will not need to have any extra visits or tests and you 
will not be asked to complete any more forms.   
What are the possible problems or side effects? 
Cancer treatments are often associated with unwanted side effects.  You may 
experience none, some, or all of the effects listed below, and they maybe of mild, 
moderate or severe intensity.   In addition there is always the risk of a previously 
unknown side effect occurring.  If a severe side effect or reaction occurs, your doctor 
may need to stop your treatment.  You should inform your doctor of any problems.  
In addition to the side effects of treatment, there is a small risk of discomfort or 
bruising when having blood and imaging tests.    
Problems or side effects with CMF 
Treatment with CMF includes pills taken by mouth and injections.  Some people find 
it difficult to swallow pills.  The injections require placement of a thin tube into a 
vein (cannula or ‘drip’) on the 1st and 8th day of each 28 day treatment cycle.  
Placement of the cannula usually causes a little discomfort but usually no serious 
problems.  It may cause bleeding, bruising, discomfort, pain and rarely infection at or 
near the insertion point.  The possible side effects of CMF include fatigue; altered 
taste and appetite; nausea and/or vomiting; sore mouth, eyes or abdomen; diarrhoea; 
hair loss; skin rashes and nail changes; irritation of the bladder; decrease in blood 
cell counts with the possibility of fever, infection and bleeding.  These side effects 
generally disappear once treatment is stopped. 
Problems or side effects with capecitabine 
Treatment with capecitabine includes only pills taken by mouth, there are no 
injections.  Some people find it difficult to swallow pills.  The possible side effects of 
capecitabine include fatigue; altered taste and appetite; nausea and/or vomiting; sore 
mouth, eyes or abdomen; diarrhoea; pins and needles, swelling or rashes of the hands 
and/or feet; skin rashes and nail changes; hair loss.  Decreases in blood cell counts 
are less common with capecitabine than with CMF.  These side effects generally 
disappear once treatment is stopped.   
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Other less common problems or side effects with CMF or Capecitabine 
Angina (chest pain) and deep vein thrombosis (blood clots in the legs) have been 
reported in people having CMF, capecitabine and other types of chemotherapy.  
These problems are uncommon (less than 1% of people having chemotherapy) and 
are more likely to affect those who have had them before.  These problems can be 
severe, but usually improve with standard treatments.   
Pregnancy and contraception 
The effects of chemotherapy drugs on the unborn child and on the newborn baby are 
not known.  Because of this, it is important that the study participants are not 
pregnant or breast feeding and do not become pregnant during the course of the 
study.  You must not participate in the study if you are pregnant or trying to become 
pregnant, or breast feeding.   
If you are female and child bearing is a possibility, you will be required to undergo a 
pregnancy test prior to commencing the study.  Female participants are strongly 
advised to use effective contraception during the course of the study.  If you do 
become pregnant whilst participating in the study, you should advise your treating 
doctor immediately.  He/she will withdraw you from the study and advise you on 
further medical attention, should this be necessary.  You must not continue in the 
study if you become pregnant. 
Other treatment whilst on study 
It is important that you tell your doctor about any treatments or medications you 
start, stop or change while you are taking part in the study. This includes non-
prescription medications, vitamins and herbal remedies. 
Do I have to take part in this study? 
Participation in this study is voluntary -- you do not have to take part, and if you do 
take part, you can decide to stop the study treatment at any time. Whatever your 
decision, it will not affect your treatment or your relationship with the medical or 
other staff.  
If you decide to stop the trial treatment or wish to withdraw from participating in the 
study, please first notify a member of the research team.  This notice will allow that 
person or the research supervisor to inform you if there are any health risks or special 
requirements linked to withdrawing.  We would also like, with your permission, to 
continue collecting information about your health status. 
What happens if I don’t participate? 
If you do not wish to participate in this study, there are other treatments available to 
you. Your doctor will discuss other treatment options available to patients with your 
type of cancer and explain the risks and benefits of these treatments to you.  
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Are there any benefits to taking part in this study? 
The aim of this research study is to improve medical knowledge and improve the 
treatment of breast cancer in the future, however taking part in the trial may not be of 
direct benefit to you.  All of the drugs in the study are known to work in breast 
cancer, and each has potential advantages and disadvantages.  It is not clear which is 
the best treatment. 
How will information about me be kept private? 
Any information obtained in connection with this study and that can identify you will 
be stored in strict confidence, as required by law, on computer disk and/or paper file 
in locked offices in the hospital Medical Oncology Department. Only staff associated 
with this trial will have access to it and it will only be disclosed with your 
permission, except as required by law. Once the study is completed, records will be 
retained in a locked storage facility indefinitely. However, your medical records and 
any information obtained during the study are subject to inspection (for the purpose 
of verifying the procedures and the data) by the Australian Government’s 
Therapeutic Goods Administration (TGA) or a New Zealand equivalent, other 
national drug regulatory authorities (where this is applicable) such as the Food and 
Drug Administration (FDA) of the United States of America, authorised 
representatives of ANZ BCTG, and of the pharmaceutical company supplying or 
distributing the study drugs, Roche Products Pty Ltd and subcontractors.  This will 
be done only under the formal agreement that confidentiality will be respected in all 
cases. 
By signing the consent form, you authorise release of, or access to, this confidential 
information to the relevant study personnel and regulatory authorities, as noted 
above. 
Data on the treatment you receive, tests done and your progress will be reported in 
confidence to the ANZ BCTG, who will put this together with data from other 
patients in the study, without identifying anyone individually. Data about you will 
not have your name on it. It will have a unique patient identification number that has 
been assigned when you entered the study. 
Under Australian Privacy and other relevant laws, you have the right to access 
information that is collected and stored about you. You should contact the 
persons named in the ‘Who can I call if I have questions or problems?’ section 
of this document, if you wish to access your information. 
What if new information comes to light during the study? 
You will be informed of any significant new findings about the trial treatments which 
occur during the study and which may lead you to change your willingness to 
participate. 
What will happen with the results of the study? 
It will take several years for this study to be finished and for its results to become 
available. The results will be published in medical journals that are available to the 
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public. If you would like to see these reports, then you should ask your doctor. No 
report will include information that allows you to be identified. 
What are the costs of the study? 
Chemotherapy and other medications will be prescribed and paid for as usual in this 
cancer centre outside of this study.  You may have to pay a small amount for some 
prescriptions (approximately $3.60 for pensioners, $22.40 for others). You will not be 
paid for taking part in this study. 
In the unlikely event of a physical injury as a result of your participation in this 
study, the parties involved in this study agree to be bound by the Guidelines for 
Compensation for Injury Resulting from Participation in an Industry-Sponsored 
Clinical Trial of the Medicines Australia or New Zealand equivalent.  A copy of 
these guidelines is available from the Secretary of the Ethics Review Committee. 
The cancer centre responsible for your treatment will receive some payment from the 
ANZ Breast Cancer Trials Group to offset the costs of running the trial. 
Who can I call if I have questions or problems? 
When you have read this information, Dr_____________ will discuss it with you 
further and answer any questions you may have.  If you would like to know more 
about the study or treatment, please contact Principal investigator on phone number.  
This information sheet is for you to keep. 
This study has been approved by the Ethics Review Committee – Centre.  If you 
have any concerns or complaints about the conduct of this study, you may contact the 
Secretary of the Ethics Review Committee – Centre on phone number.  
Alternatively, if you wish to speak with an independent person within the Hospital 
about any problems or queries about the way in which the study was conducted, you 
may contact the Patient Representative on phone number. 
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ANZ BCTG Protocol 0001 
Capecitabine vs CMF in Advanced Breast Cancer 
A phase III trial to evaluate oral chemotherapy with capecitabine versus  
standard chemotherapy with CMF in advanced breast cancer. 
Principal Investigator:  Principal Investigator Name 
Associate Investigators:  Co-investigator Name 
     Co-investigator Name 
PARTICIPANT CONSENT FORM 
I, .......................................................................................................................  [name]  
Of...........................................................……………………………………[address] 
have read and understood the Information for Participants on the above named 
research study and have discussed the study with ............................................... 
I have been made aware of the procedures involved in the study, including any 
known or expected inconvenience, risk, discomfort or side effect, and of their 
implications as far as they are currently known by the researchers. 
I understand that the research project will be carried out according to the principles 
in the National Health & Medical Research Council National Statement on Ethical 
Conduct in Research Involving Humans (June 1999).   
I freely choose to participate in this study and understand that I can withdraw at any 
time. 
I also understand that the research study is strictly confidential. 
I hereby agree to participate in this research study. 
NAME: ......................................…  
SIGNATURE:  ......................................… DATE:  ...............................… 
 
NAME OF WITNESS: .....................................… 
SIGNATURE OF WITNESS: ......................................… DATE: ........................... 
 
NAME OF INVESTIGATOR:      ……………………… 
SIGNATURE OF INVESTIGATOR:  ………………… DATE: ...……………… 
Please note: all parties signing the consent form must date their own signature.
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INFORMED CONSENT FORM SAMPLE 1 
IBCSG Trial 15-95 
Randomized Trial of 3 Cycles of High-Dose Epirubicin + Cyclophosphamide versus 4 
Cycles of Epirubicin/Adriamycin + Cyclophosphamide and 3 Cycles of 
Cyclophosphamide + Methotrexate + Fluorouracil as Adjuvant Treatment for High 
Risk Operable Stage II and Stage III Breast Cancer in Premenopausal and Young 
Postmenopausal Patients 
Plain Language Statement 
Introduction and Aims of the Study 
As has already been explained to you, you have a cancer of your breast. This has been 
treated by surgery and the tissue removed from under your arm has shown that there is 
evidence of spread of the cancer to the lymph nodes under your arm. Unfortunately, the 
amount of tissue involved with tumour in your case implies a high risk of the tumor 
returning. 
Recent studies have shown that up to 90 per cent of women (a high risk group) with this 
problem have the cancer come back either in the breast or elsewhere. This is because some 
of the cancer cells have escaped into the body before the breast has been removed. 
Because of this risk, we are conducting a clinical trial to determine whether the addition of 
further treatment after surgery decreases the chance of the cancer recurring either in the 
breast or in the body generally. 
We know from previous clinical trials that the use of chemotherapy at standard doses after 
breast surgery reduces the chance for cancer recurrence and improves survival in patients at 
lower risk than yourself. In an effort to improve your chances of survival. we are assessing 
whether giving you higher doses of chemotherapy is a more effective in killing all remaining 
cancer cells. 
In this study, approximately 110 women with breast cancer will receive very high doses of 
chemotherapy and will be compared with the same number of women with breast cancer 
who receive standard doses of treatment. This is a randomized study, that is, your treatment 
will be decided by chance and you have a 50:50 chance of receiving either treatment. You 
and your treating doctor cannot choose your treatment. 
The Design of the Study 
HIGH-DOSE CHEMOTHERAPY 
If you are assigned to this treatment, you will receive 3 treatments with very high doses of 
the chemotherapy drugs epirubicin and cyclophosphamide. A problem with giving these 
doses of chemotherapy is that it lowers your resistance to infection. This lowering of 
resistance is due to the toxic effects of the chemotherapy drugs on normal cells, particularly 
the in bone marrow where the blood is made. This can lead to severe infections and 
prolonged hospital stays for treatment. When the anticancer drugs epirubicin and 
cyclophosphamide are used at high doses, they must be followed by “rescue” with 
previously collected blood cells. These cells improve the production of blood which is 
necessary because of damage to bone marrow cells. In order to collect sufficient numbers of 
cells from your blood, we give you a hormone called granulocyte colony stimulating factor 
(G-CSF) that controls the release of the bone marrow or “stem” cells into the blood. Without 
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the use of G-CSF, there are too few of these “stem” cells in the blood to allow collection of 
sufficient cells for high dose chemotherapy. 
To collect the stem cells from the blood, you will need a catheter (tube) to be inserted via 
your chest into the big vein that drains blood into your heart. This may be done under a local 
or general anesthetic. This catheter is used for collecting the stem cells, taking blood tests, 
and giving chemotherapy and antibiotics or blood or platelets (if needed). The catheter is left 
in place for the duration of the treatment, about 4 months. Complications can occasionally 
occur with insertion of the catheter, such as a punctured lung. The catheter may also become 
blocked or infected, and may need replacing before your treatment is finished. 
Prior to receiving chemotherapy, you will undergo collection of blood “stem” cells by a 
procedure called leukapheresis, performed using a cell separator machine. This equipment is 
the same as that used by the Red Cross and hospitals to collect plasma or other blood 
products from patients with normal bone marrow. This will require you to have a needle 
inserted into a vein in your arm. This procedure takes two to four hours to perform. You will 
be given G-CSF for 6 days and have the cell collection procedure performed on the 5th, 6th 
and 7th days. The hormone is given by continuous injection under the skin using a portable 
pump, which is worn on a belt. You will need to wear this pump for the 6 days. The hormone 
is given to you as an outpatient, and the cell collection procedures are performed in a day 
ward. You will only require one period of stem cell collection. 
You will then be given 3 treatments with high doses of epirubicin and cyclophosphamide. 
The drugs are given by injection into the catheter in your chest. Each will be given with the a 
portion of the blood stem cells that were collected, and further G-CSF treatment. The 
treatments will be given at 21 day intervals. You will be hospitalized for about 5 days to 
receive the chemotherapy, and for a variable period after that, depending if you develop an 
infection or severe complications from the treatment. 
Your doctors expect the G-CSF to stimulate the normal bone marrow cells and reduce the 
risk from infections. No other licensed alternative therapies are known to have this 
stimulating effect on bone marrow and blood cells. The treatment with the G-CSF allow us 
to use repeated courses of high dose chemotherapy and so have a better effect on your 
cancer. 
Possible Side Effects 
This approach has been tested in over 60 patients in a pilot study in Australia. The treatment 
was generally well tolerated, and all women recovered from the side-effects of therapy. 
Apart from the effects of the chemotherapy drugs on the white blood cells, the other 
problems encountered in the pilot study included: 
a) damage to the red blood cells and platelets, causing anaemia and possible increased risk of 
bleeding. - you may need a transfusion if this occurs. 
b) irritation of the bladder - this risk is reduced by giving you a specific antidote (a drug 
called MESNA) intravenous fluids before and after chemotherapy. 
c) nausea and vomiting - you will be given anti-sickness medications to reduce this. 
d) temporary hair loss. 
e) soreness in the mouth and throat, including mouth ulcers 
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f) at very high doses of epirubicin impaired function of the heart can occur, but this is 
preventable with routine monitoring of your heart function. 
g) if you are still having your periods, there is a strong possibility that these will cease after 
treatment (ie you will become menopausal). 
You will be carefully monitored for any side effects during the course of treatment. After 
receiving the chemotherapy, you will have a blood test daily until after the blood has 
recovered. 
There have been few side effects identified with the use of G-CSF, and the most frequent is 
mild to moderate aching the bones, which can be controlled with paracetamol, has been 
reported by about 10 to 20% of patients. 
If you or your doctor believe that any of the side-effects from G-CSF and/or chemotherapy 
become unacceptable you will be withdrawn from the study and treated for your cancer with 
conventional medications. 
STANDARD DOSE THERAPY 
If you are assigned the standard-dose treatment, you will receive 1 chemotherapy (drugs 
called adriamycin and cyclophosphamide, which are injected into a vein once every 3 weeks 
for four times, for a total of 12 weeks of treatment), followed immediately by the second 
chemotherapy (drugs called cyclophosphamide, methotrexate and fluorouracil, which are 
given as tablets daily for 14 days and by injection into the vein on 2 days, every 4 weeks for 
3 times, for a further 12 weeks of treatment). This treatment is associated with a similar 
spectrum of side-effects as the high-dose therapy, however they are likely to be much less 
severe. All treatment will be administered to you as an outpatient, unless you need to be 
admitted for a complication. You will be carefully monitored for any side effects during the 
course of treatment. 
BOTH TREATMENTS 
Prior to commencing treatment, you will need tests to assess the exact extent of your cancer 
as would normally be done prior to the start of any chemotherapy - these may include: xrays, 
CT scans, a bone scan and a heart scan. You will also have blood tests, urine tests, a tracing 
of your heart (ECG) and a full physical examination to give us a good understanding of your 
state of health before treatment commences. 
There have been 4 cases of cancer of the uterus reported with long term (2 years or more) 
use of tamoxifen. These women, however, received tamoxifen in double the doses used in 
this program. Moreover, 200,000 women have been given tamoxifen for more than 2 years in 
the standard doses used in this study without an apparent increase in the rate of uterine 
cancer. 
The chemotherapy drugs given in this study are associated with a risk of the later 
development of leukemia. The risk is thought to be < 0.2% when the drugs are given at the 
standard doses. A recent report form the USA suggests there might be an increased risk of 
leukemia in patients receiving increased doses of the drugs. In a study with 2548 patients 
with breast cancer treated with higher than normal doses of cyclophosphamide and normal 
doses of doxorubicin (a very similar drug to epirubicin) with G-CSF, 5 women developed 
acute leukemia with features indicating it was caused by the chemotherapy drugs. The risk of 
leukemia appears to be minor in patients receiving standard doses of chemotherapy, and any 
increase in this risk with higher doses must be balanced against the possible benefit in terms 
of improved survival. 
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In an effort to monitor your ability to cope with both the disease and the therapy, we will ask 
you to fill out a brief "quality of life" questionnaire at various times. This takes 5 to 10 
minutes to complete. 
In the first 2 years after therapy you will be seen every 3 months, then every 6 months for 3 
years (ie to 5 years), and every year thereafter. 
Authorization to Allow Inspection of Medical Reports 
It is important for representatives of the health authorities (the National Department of 
Health) and the hospital ethics committee to be able to inspect your medical records. Any 
such review will be performed in such a way so that your identity is not revealed. Therefore, 
you are requested to authorise your doctor to allow such representatives access to review 
your medical record. 
You should ask for any information you want 
If you would like more information about the study or if there is any matter about it that 
concerns you, either now or in the future, do not hesitate to ask one of the researchers or one 
of the doctors treating you. People you can ask include ____________________________. 
Before deciding whether or not to take part you may wish to discuss the matter with a 
relative or friend or with your local doctor. You should feel free to do this. 
Deciding Not to Participate or Withdrawing From the Study 
Your participation in this study must be voluntary 
It is important that you understand that your participation in this study must be voluntary. 
This is the case with all research projects in the hospital. 
If you do not wish to take part, you are under no obligation to do so. Also, if you decide not 
to take part, or to withdraw, it will not affect your routine medical treatment or your 
relationship with those treating you, or your relationship with the Hospital. 
Consent Form 
I have read the above information and I understand the purpose, benefits and risks of this 
clinical study and voluntarily agree to participate. My signature below also acknowledges 
that I have been given a copy of this form for my personal records. 
_________________________________  _______________  
Patient’s Signature Date 
_________________________________  _______________  
Doctor's Signature Date 
_________________________________  _______________  
Witness' Signature Date
 
 
